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ABSTRACT
Characterization of M-cadherin’s Role in Regulating Apoptosis and
Myogenic Differentiation of Myoblasts by Interacting with Key
Components of Canonical Wnt Signaling
Yan Wang
Activation, proliferation, and differentiation of satellite cells are the basic means for adult
muscle regeneration. Apoptosis is concurrent to differentiation of satellite cells and
dysregulated apoptosis contributes to the occurrence and progression of certain
muscular dystrophies. This study investigated the role of M-cadherin-mediated signaling
in regulating apoptosis versus survival of myoblasts during the process of myogenic
differentiation. Inhibition of M-cadherin expression by RNAi (RNA interference) in
confluent C2C12 myoblasts sensitized the cells to mitochondria-associated intrinsic
apoptosis induced by either cell confluence or serum starvation. Manipulation of Mcadherin signaling regulated the Glycogen Synthase Kinase-3β (GSK-3β) activity via
phosphoinositide-3 kinase (PI3K)/Akt pathway. Overexpession of wild-type (WT) GSK3β in confluent C2C12 myoblasts sensitized the cells to apoptotic insults, while GSK-3β
inhibition attenuated apoptosis and partially rescued the myogenic differentiation
impaired by M-cadherin RNAi in both C2C12 myoblasts and Syndecan-4-positive
primary myoblasts. These data suggest that M-cadherin-mediated signaling protects
myoblasts against mitochondria-associated intrinsic apoptosis during myogenic
differentiation via PI3K/Akt/GSK-3β pathway. We further examined the role of Mcadherin in regulating the N-terminal phosphorylation status of β-catenin and the effect
of this regulation on myoblast fate specification. M-cadherin RNAi enhanced the GSK3β-dependent phosphorylation of β-catenin at N-terminus which can be reversed by
GSK-3β inhibition via LiCl treatment. N-terminus unphosphorylated β-catenin was more
responsive to LiCl treatment. In addition, M-cadherin RNAi led to an increase in
TCF/LEF transcription activity but significantly abrogated the myogenic differentiation
induced by LiCl or Wnt-3a treatment. β-catenin RNAi also blocked the myogenic
induction by LiCl or Wnt-3a. Although forced expression of a phosphorylation-resistant
mutated β-catenin (S33Y-β-catenin) failed to increase myogenic differentiation, it
partially rescued the impaired myogenic differentiation and attenuated the apoptosis
caused by M-cadherin RNAi. These data indicate that M-cadherin-mediated signaling
plays a positive role in maintaining a cytosolic pool of signaling-active N-terminal
unphosphorylated β-catenin, which is critical for the TCF/LEF-independent myogenesispromoting effect of canonical Wnt signaling. Our findings in this research identify a
novel role of M-cadherin in regulating myoblasts survival and differentiation and provide
a potentially novel molecular mechanism for the regulation of adult muscle regeneration.
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SPECIFIC AIMS
Differentiation of satellite cells and fusion into myotubes is the basic means for
adult muscle regeneration (1; 2). Apoptosis is a concurrent event to myogenic
differentiation, that is, a substantial portion of cells die of apoptosis as the majority of
cells differentiate and fuse into myotubes (3; 4). The molecular mechanism by which the
myoblasts make the life versus the death decision remains unclear. Cadherins are
calcium-dependent homophilic cell adhesion molecules forming adherens junctions and
desmosomal junctions between cells. M-cadherin is a member of classical cadherins
that is specifically expressed in skeletal muscle and certain neural tissues (5; 6). It is
reported that M-cadherin mediates the cell-cell fusion and is required for myogenic
differentiation (7; 8). However, its role in regulating myoblast survival/apoptosis has
never been addressed.
β-catenin/canonical Wnt signaling plays a critical role in myogenesis and adult
muscle regeneration (9; 10). β-catenin is an essential mediator for canonical Wnt
signaling as well as a key adaptor protein that connects M-cadherin to α-catenin and the
actin cytoskeleton system (11). Cadherin has an established role as a β-catenin
signaling inhibitor by either mechanical sequestration or transcriptional suppression (1214). A recent study showed that E-cadherin in colon carcinoma cells could directly
suppress β-catenin activity by promoting its phosphorylation at the N-terminus by GSK3β (15). Sequential phosphorylation of β-catenin at the N-terminus by CKIα and GSK-3β
results in its recognition by β-TrCP and subsequent degradation in the proteasome (16).
However, the regulatory effect of M-cadherin on phosphorylation status of β-catenin N-

xiii

terminus and the impact of this regulation on myogenic differentiation remains to be
elucidated.
The central hypothesis of this project is that M-cadherin-mediated signaling
regulates the biological behavior and fate of myoblasts by (i) protecting
myoblasts against mitochondrial dysfunction-associated intrinsic apoptosis via
the PI3K/Akt/GSK-3β pathway and (ii) attenuating GSK-3β-dependent phosphorylation

of

β-catenin

at

N-terminus

and

maintaining

a

signaling-active

unphosphorylated β-catenin, which is critical to canonical Wnt signaling.
This hypothesis will be tested by the following specific aims.
Specific Aim 1: To determine if M-cadherin-mediated signaling may protect C2C12
myoblasts against apoptosis and if this protective effect is mediated by the
PI3K/Akt/GSK-3β pathway.
Hypothesis 1.1: Knockdown of M-cadherin expression by RNAi will sensitize
myoblasts to mitochondria-associated intrinsic apoptosis induced by either cell
confluence or serum starvation while activation of M-cadherin-mediated signaling
has the opposite effect, indicating that M-cadherin protects myoblast against
apoptosis.
Hypothesis 1.2: Knockdown of M-cadherin expression by RNAi will decrease Akt
activation and attenuate the Akt-dependent inhibitory phosphorylation of GSK-3β.
Conversely activation of M-cadherin-mediated signaling will have the opposite
effect. In addition, the GSK-3β inhibition by M-cadherin is PI3K dependent.

xiv

Hypothesis 1.3: Overexpression of GSK-3β will sensitize myoblasts to apoptosis
induced by either cell confluence or serum starvation while inhibition of GSK-3β has
the opposite effect, indicating activation of GSK-3β promotes apoptosis of
myoblasts.
Hypothesis 1.4: Inhibition of GSK-3β activity will rescue the apoptotic and
myogenic phenotype of myoblast caused by M-cadherin RNAi, indicating the
protective effect against apoptosis by M-cadherin is mediated by GSK-3β
suppression.

Specific Aim 2: To determine if M-cadherin-mediated signaling may protect
primary muscle progenitor cells against apoptosis and if this protective effect is
mediated by GSK-3β activity.
Hypothesis 2.1: Knockdown of M-cadherin expression by RNAi in primary
progenitor cells will exacerbate apoptosis and impair the myogenic differentiation in
specific population of primary progenitor cells.
Hypothesis 2.2: Inhibition of GSK-3β activity by certain chemical inhibitors will
rescue the apoptotic and myogenic phenotype caused by M-cadherin RNAi in
primary muscle progenitor cells;
Specific Aim 3: To determine if M-cadherin modulates phosphorylation status of
β-catenin N-terminus and the effect of this modulation on myoblast fate
specification.

xv

Hypothesis 3.1:

Knockdown of M-cadherin expression by RNAi will enhance

phosphorylation of β-catenin N-terminus by GSK-3β while inhibition of GSK-3β by a
chemical inhibitor will rescue this effect, indicating that M-cadherin regulates
phosphorylation status of β-catenin at N-terminus in a GSK-3β activity-dependent
manner.
Hypothesis 3.2: Chemical inhibition GSK-3β will promote myogenic differentiation
while M-cadherin RNAi will abrogate this effect, indicating M-cadherin is required for
GSK-3β inhibition-induced increase in myogenic differentiation.
Hypothesis 3.3: β-catenin RNAi or treatment with canonical Wnt inhibitor will
effectively reverse the myogenic induction caused by chemical inhibition of GSK-3β,
indicating the phenotype of myoblasts induced by GSK-3β inhibition is mediated by
β- catenin/canonical Wnt signaling.
Hypothesis 3.4:

Transfection of a phosphorylation-resistant mutant form of β-

catenin will rescue the myoblast phenotype caused by M-cadherin RNAi, indicating
that M-cadherin’s role in promoting myogenic differentiation is at least partially
mediated by the modulation of the phosphorylation status of β-catenin N-terminus.
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CHAPTER 1:
BACKGROUND AND SIGNIFICANCE

1

1.1.

Satellite cells and muscle regeneration

1.1.1.

Satellite cells: heterogeneity and molecular markers. Satellite cells

were first identified in 1961 by Mauro (1). They are named after their typical
position in muscles that is between the basal lamina and the sarcolemma of their
associated muscle fibers. Satellite cells are considered as the primary source of
stem cells for adult muscle regeneration and plays a crucial role in mediating the
postnatal growth of muscle (2). Satellite cells are heterogeneous in their
embryological origin, fiber association, and biological behavior when culture in vitro
(3-5). Several markers have been used to identify the majority of satellite cells,
including syndecan-3 and -4, integrin-α7, CD34, M-cadherin, c-met, Pax7, Myf5,
etc (4). Many groups have separated different subpopulations of satellite cells
using FACS (fluorescence-activated cell sorting) based on the expression of
surface markers. For example, the Olwin lab reported that syndecan-4 is a reliable
marker for muscle-derived stem cells (6). Wagers’ group showed that a population
of satellite cells that are CD45-Sca-Mac1-CXCR4+ 1integrin+ are more efficient in
engrafting into dystrophic muscles compared with control populations without this
marker combination when both transplanted into host muscles (7).
1.1.2.

Activation, proliferation and differentiation of satellite cells. In the

adult muscle, under normal physiological resting state, satellite cells are quiescent
both mitotically and metabolically. In response to stress stimuli such as muscle
injury or increased workload, the quiescent satellite cells can be activated and
move out of their niche to the basal lamina and re-enter the cell cycle with Pax7
and Myf5 expressed. The descendents of activated satellite cells are defined as
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myoblasts that will proliferate and undergo multiple divisions and differentiate and
fuse to form multinucleated myofibers, which is a critical process for post-injury
muscle regeneration (8; 9). The mechanism that explains how satellite cells are
activated in response to a range of stimuli remains largely unknown. Various
growth factors and secondary messengers, such as hepatocyte growth factor
(HGF) (10), fibroblast growth factor (FGF) (11; 12) and nitric oxide (NO) (13) are
thought to play important roles in the activation of satellite cells. After being
activated, muscle regulatory factors (MRFs) are expressed in satellite cells at
different stages of myogenesis (14): Myf5 is expressed in both quiescent and
activated satellite cells and proliferating myoblasts. MyoD expression start as the
satellite cell is activated. The expression of myogenin occurs in myoblasts that exit
cell cycle and marks the first commitment step for myogenic differentiation. As the
cell cycle inhibitor p21 accumulates in the nuclei, terminal differentiation is
accomplished with the expression of contractile and associated proteins such as
myosin heavy chain (MyHC) and Troponin T (15). The muscle cells fuse to each
other to form myotubes in vitro or myofibers in vivo (16; 17) (Figure 1).

Figure 1. Schematic process of satellite cell myogenesis (14).
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The C2C12 cell line is a subclone (produced by H. Blau, (18)) of the mouse
myoblast cell line established by D. Yaffe and O. Saxel (19). When being cultured
in vitro in growth medium at a low cell density, the C2C12 myoblasts are capable
of proliferating for self-renewal. When they obtain confluence or when they are
cultured in low-serum conditions, they differentiate spontaneously and rapidly, fuse
with each other, and form contractile myotubes and produce characteristic muscle
proteins. Thus, the C2C12 myoblast is an established and well-studied in vitro
model for activated myoblasts (18).
1.1.3.

Satellite cell dysfunction-related muscular dystrophic disorders. In

mouse, fast myofibers contain about 300 myonuclei and they are associated with
5-12 satellite cells per fiber. In a slow myofibers, there are about 450 myonuclei
associated with about 30 satellite cells (20). Studies have demonstrated that
satellite cells undergo an asymmetrical division, which generates a replacement
satellite cell and a daughter cell that is committed to a myogenic fate (21). Thus,
satellite cells may maintain a constant pool during the process of muscle
regeneration (22). The total number of satellite cells decreases in both fast and
slow muscle fibers with aging in rodents. At birth, satellite cells account for about
32% of total muscle nuclei, but the number drops to less than 5% in adult muscle
(23). A significant decline in the number of M-cadherin-positive satellite cells in
human muscle during aging was also reported (24). Interestingly the proliferation
and regenerative capacity of satellite cells in old skeletal muscle could be restored
when exposed to a young systemic environment by parabiotic pairings of young
and old animals, indicating that in addition to intrinsic potential of the cells, the
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extrinsic microenvironment, the niche where satellite cells reside is very important
in regulating the functional status of satellite cells (25; 26).
The impaired capability of proliferation and differentiation of satellite cells is
regarded as one of the major factors that contribute to the occurrence and
progression of certain muscle wasting conditions, such as sarcopenia and
Duchene Muscular Dystrophy. Sarcopenia is a Greek term that means lack of
flesh. This is an aging-associated decline of muscle mass, quality and performance
which leads to frailty in the elderly (27; 28). Sarcopenia begins in the fourth decade
of life and accelerates after the age of 70. The total cross section area of skeletal
muscle decreases by up to 40% at the age of 80s compared with that at the age of
20s (29).

Sarcopenia has multiple detrimental effects and leads to physical

disability, loss of independence, a variety of metabolic disorders and increased
morbidities. The estimated health care costs directly related to sarcopenia was
about 18.5 billion dollars in US in 2000 (30). Both number and functionality of
satellite cells decline in aged people with sarcopenia (31; 32). Another pathological
condition that is associated with decreased or even exhausted number and
functionality of satellite cells is Duchenne Muscular Dystrophy (DMD), which is a
lethal recessive x-linked muscular dystrophy. The mutation occurs in the gene
coding for dystrophin. Dystrophin is a cytoplasmic protein, a vital component of
dystroglycan complex (DGC) which connects the cytoskeleton of a muscle fiber to
the surrounding extracellular matrix (ECM) via cell membrane. Thus the DGC is
critical for cell integrity, signaling and muscle function. Without DGC, the muscles
undergo repeated injury and regeneration due to the mechanical stress during
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contraction, which results in rapid exhaustion of satellite cells and rapid
progression of muscle degeneration, eventually leads to loss of ambulation,
paralysis and death. DMD is one of the most prevalent muscular dystrophies and
affects one out of 3500 males in USA (33).

1.2.

β-catenin/canonical

Wnt

signaling

and

its

role

in

muscle

regeneration.
1.2.1.

β-catenin/canonical Wnt signaling and its regulation by GSK-3β.

Wnts are secreted extracellular proteins that trigger a wide range of cellular
responses upon receptor binding and activation (34). Wnt signaling can be broadly
categorized as canonical or noncanonical pathways. Both require the Wnt ligation
of Frizzled receptor (Figure 2). But the noncanonical Wnt pathway is β-cateninindependent, mediated by the intracellular calcium ion, JNK, and PKC, which leads
to signaling events such as activation of NFAT transcription and planar cell polarity
(35), which is not the focus of this review. Canonical Wnt pathway is initiated by
the binding of Wnts to two cell surface proteins, one is the Frizzled receptor, the
other is lipoprotein receptor-related protein-5 and 6 (LRP5/6). Ligation of Wnts
triggers phosphorylation of LRP5/6’s cytoplasmic tail and recruits Disheveled
protein to the plasma membrane, followed by recruitment of Axin and GSK-3β to
Disheveled, which inactivates the so-called destruction complex for β-catenin (36).
β-catenin belongs to the armadillo family of proteins, which have a central domain
consisting a repeating 42 amino acid motif termed as the “arm repeat” (37). X-ray
crystallographic analysis shows that the 12 arm repeats in the central domain of β-

6

catenin form a superhelix of helices. This creates a long, positively charged groove
(38) that is capable of interacting with many negatively charged ligands, such as
cadherin,

the

Axin/APC

destruction

complex,

and

the

TCF/LEF(T

cell

factor/lymphoid enhancer factor) transcription factors (Figure 3). In the absence of
Wnt ligands, cytosolic β-catenin is recruited to a destruction complex composed of
Axin, adenomatous polyposis coli (APC), and Glycogen Synthase Kinase-3β
(GSK-3β). The N-terminus of β-catenin is phosphorylated sequentially by axinbound casein kinase Iα (CK1α) at serine 45, and by GSK-3β at serine 33/37 and
threonine 41 (39) (Figure 2 and Figure 3). The N-terminal phosphorylated βcatenin is recognized by β-TrCP(β-transducin repeat-containing protein), a
component of the E3 ubiquitin ligase complex, which results its rapid degradation
in 26S proteasome (40). So without Wnt signaling, the level of β-catenin is kept low
by degradation of cytoplasmic β-catenin. Thus, the transcription factors LEF1 and
TCF interact with Grouchos in the nucleus to repress Wnt-specific transcription. In
the presence of Wnt ligands, LRP5/6 surface receptors are phosphorylated by
CKIγ and GSK-3β, Dishevelled is recruited to the plasma membrane which leads
to dissociation of the destruction complex, resulting in stabilization and
accumulation of cytosolic β-catenin.

β-catenin translocates into nucleus and

displaces Grouchos and forms a transcriptionally active complex. The TCF/LEF
transcription factors then induce Wnt-specific target gene expression (36) (Figure
2). Therefore, the key regulatory factor in β-catenin signaling is its stabilization and
accumulation in the cytosol (41-43).
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Figure 2. Dual role of β-catenin in cadherin and canonical
Wnt signaling pathways (erbiotek.erciyes.edu.tr/dosyalar/Molecular_
mechanisms_of_pluripotency.ppt)

Figure 3. Regulatory residues at N-terminus and binding
sites in β-catenin protein.
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1.2.2.

The role of β-catenin/canonical Wnt signaling in regulating muscle

regeneration. Canonical Wnt signaling regulates many cellular events including
proliferation, differentiation, and morphogenesis. Dysregulated Wnt signaling has
been associated with cancers especially colon cancers, tissue fibrosis,
osteoporosis, etc (34; 36). In skeletal muscle, it was demonstrated that in response
to muscle injury, the muscle resident CD45+ stem cells were mobilized to enter cell
cycle for self-expansion. Furthermore, activation of Wnt signaling effectively
induces the myogenic specification of these muscle resident CD45+ stem cells
(44). It was also shown that activation of β-catenin signaling induces myogenesis
and inhibits adipogenesis in mesenchymal stromal cells (MSC) (45). The
expression of β-catenin and activation of Wnt signaling in activated satellite cells
promotes their proliferation and self-renewal (46; 47).

More importantly, by

working collaboratively with Notch signaling, Wnt signaling is critical for myogenic
differentiation. Upon muscle injury, the expression of Notch signaling components
(Delta-1, Notch-1, and active Notch) is up-regulated in activated satellite cells.
Increased Notch signaling promotes the transition of activated satellite cells to
highly proliferative myoblasts. However, the elevated Notch signaling also prevents
the occurrence of myogenic differentiation (48). As the cells start to commit to
myogenic differentiation, there is a transition from Notch signaling to Wnt signaling
in myogenic precursor cells with an increase in both Wnt expression in tissue and
Wnt responsiveness in progenitor cells (49). On the other hand, hyperactivation of
Wnt signaling turns myogenic progenitor cells into a fibrotic lineage and results in
muscle fibrosis (50).
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Recent studies have added novel information to the mechanism of

β-

catenin signaling and they show more clearly how it regulates myogenesis. It was
reported that upon Wnt stimulation, the N-terminal unphosphorylated β-catenin is
more responsive, and accumulates in nuclei (51; 52), Additionally, the N-terminal
unphosphorylated β-catenin is more signaling-active and plays a major role in
mediating

canonical

Wnt

signaling

(53).

Thus

the

GSK-3β-dependent

phosphorylation of β-catenin at the N-terminus alone might be sufficient to inhibit
β-catenin

activity

by

preventing

its

nuclear

translocation

via

cytosolic

sequestration, without affecting its stability in certain types of cells and tissues.
Furthermore, in addition to its classical binding partner in nuclei, TCF/LEF, βcatenin was found to interact with I-mfa (an inhibitor of the MyoD family of muscle
MRFs) in muscle progenitor cells. This interaction relieved the transcription activity
suppression and cytosolic sequestration of MRFs caused by the binding of I-mfa
(54). In addition, β-catenin has been shown to directly bind to MyoD and this
binding enhances MyoD transcription activity that is necessary for myogenic
differentiation, whereas TCF/LEF activity is dispensable for this effect (55). These
findings suggest that β-catenin/canonical Wnt signaling may promote myogenesis
independent of TCF/LEF transcription activity.

1.3.

Apoptosis and its role in muscle remodeling and satellite cell

biology
1.3.1. Apoptosis and its molecular regulation. Apoptosis is a systemic process
of programmed cell death that is important for normal tissue morphogenesis and
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homeostasis during development. Apoptosis is a genetically predetermined
mechanism that may be initiated by three different molecular pathways. Firstly, the
extrinsic death receptor-mediated pathway of apoptosis is triggered by the ligand
binding-induced activation of death receptors at the cell surface. The death
receptors include the tumor necrosis factor (TNF) receptor-1, CD95/Fas (the
receptor of CD95L/FasL) and TNF-related apoptosis inducing ligand (TRAIL)
receptors-1 and 2. The ligation of death receptors leads to their homo-trimerization
and the recruitment and oligomerization of the cytoplasmic adapter molecule
FADD (Fas-associating death domain-containing protein) within the death-inducing
signaling complex (DISC). Oligomerized FADD binds to caspases-8 and 10,
resulting in their dimerization and activation (56). The second pathway is intrinsic
mitochondrial-associated pathway which is activated in response to extracellular or
intracellular insults such as DNA damage, and characterized by the occurrence of
mitochondrial outer membrane permeabilization (MOMP), which is marked by the
release of a number of proteins that normally exist within the intermembrane space
(IMS) into an extramitochondrial compartment (cytosol and nuclei). Many proteins
released from mitochondria including Cyt c (cytochrome c), AIF (apoptosis
inducing

factor),

EndoG

(endonuclease),

and

Smac/DIABLO

(second

mitochondria-derived activator of caspases/direct inhibitor of apoptosis-binding
protein with a low isolelectric point) are proapoptotic in the cytosol or nucleus (57).
Cyt c, a component of the mitochondrial respiratory chain, interacts with its adaptor
molecule Apaf-1 (apoptosis protease activating factor 1) in cytosol and triggers the
ATP/dATP-dependent oligomerization of Apaf-1. Oligomerized Apaf-1 binds to

11

procaspase-9, leading to the formation of the caspases-9 activation complex
named as apoptosome (58) that cleaves procaspase-9 into its active form. This in
turn cleaves and activates the executioner caspases, such as caspases-3 and -7,
leading to the cleavage of caspases substrate proteins and resulting in the
biological and morphological features of programmed cell death. The third pathway
is also intrinsic and associated with endoplasmic reticulum (ER) stress, which
includes disruption of ER calcium homeostasis and accumulation of excessive
proteins in ER. Caspase-12 is activated by ER stress as an initiator caspase that
is responsible to the cascade of executioner caspases activation (59). However,
the precise mechanism remains to be elucidated.
1.3.2. Apoptosis in muscle remodeling and satellite cell biology. Dysregulated
apoptosis contributes to the occurrence and progression of many pathological
conditions including autoimmune diseases, cancer, neurodegenerative diseases,
and certain cardiovascular diseases (56; 60). In skeletal muscle, accumulating
evidence suggests that apoptosis plays an important role in muscle remodeling.
Elevated apoptotic signaling has been detected in various muscle wasting
conditions caused by disuse, denervation, and aging (61-63). As for the satellite
cells, their number in aged muscle declines due to increased apoptotic depletion in
aged muscle

(64). Moreover, when cultured in vitro, muscle progenitor cells

isolated from aged muscle are more sensitive to apoptotic insults compared with
the cells isolated from young muscles (65). Elimination of muscle progenitor cells
by apoptosis also contributes to the low regeneration capability of dystrophic
muscles and the poor outcomes of stem-cell-based therapeutic strategies (66-69).
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In addition, in vitro culture of myoblasts has shown that apoptosis is concurrent
with myogenic differentiation (70).

1.4.

Cadherin and its role in apoptosis, β-catenin/canonical Wnt signaling

and muscle regeneration.
1.4.1. Cadherins and their roles in regulating cell survival. Cadherins are Ca2+dependent cell adhesion molecules that are the key components of several cell-cell
adhesion complexes including adherens junctions and desmosomes. The cadherin
superfamily consists of different subfamilies: classic cadherins (type I & type II),
desmosomal cadherins, protocadherins, and other related cadherins (71; 72). The
classical cadherins are composed of a highly conserved carboxy-terminal
cytodomain, a single-pass transmembrane domain, and five extracellular cadherinmotif subdomains (C1-C5) with a conserved His-Ala-Val (HAV) sequence in C1 of
type I classic cadherins. They mediate homophilic, Ca2+-dependent cell-cell
adhesion. In the absence of calcium, the cadherin structure is disorganized and
incapable of participating in adhesion. As calcium concentration increases, the
C1-C5 subdomains become organized (C1, which has the lowest affinity for
calcium, becomes organized last) and the cadherin ectodomains become rigid and
competent to participate in cis-dimerization and also trans-dimerization as the
calcium concentration increases (73; 74). In addition, to establishing strong
adhesion, classical cadherins need to link to the cytoskeleton. This is mediated by
binding of the cytoplasmic tail of classical cadherin to β-catenin, which in turn binds
to α-catenin. α-catenin bridges the cadherin-β-catenin complex to the actin
13

cytoskeleton either directly or indirectly via actin-binding proteins such as α-actinin
or profiling, thus coupling ectodomain interactions to dynamic intracellular tensile
forces (72).
The accumulating evidence shows that cadherin-mediated cell-cell adhesion
provides a survival signal in a variety of cell types, including neural cells (75),
endothelial cells (76; 77), ovarian cells (78; 79), granulosa cells (80), enterocytes
(81), vascular smooth muscle cells (82) and many tumor cells (83-87). Cadherins
mediate cell survival via several possible mechanisms as revealed by studies on
different cell types. One of the most important pathways that mediate cadherins’
survival-promoting effect is PI3K/Akt, which can be activated by different types of
cadherins, and results in the phosphorylation and inactivation of the pro-apoptotic
protein Bad, and the stabilization of the anti-apoptotic protein Bcl-2 (80; 85; 87;
88). This cadherin-dependent Akt activation appears to be ligand/growth-factor
independent (86-88). Another candidate pathway is fibroblast growth factor
receptor (FGF-R) which also has a HAV motif in its extracellular domain.
Cadherins like N-cadherin has an IDPVNGQ motif in ECD4 which can bind to the
HAV motif of FGF-R. Therefore, by forming heterodimers with FGF-R through the
binding of these two motives, cadherins can activate FGF-R and mediate cell
survival (76; 89). Cadherin may also regulate cell survival via β-catenin. However,
the role of β-catenin in cell survival/death is cell-type specific. β-catenin is survivalpromoting in some types of cells including epithelial cells cultured in suspension
(90), fibroblasts (91), and an embryonic liver culture system (92), but apoptosis-
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promoting in other types of cells, including COS7 and 293 cells (93), as well as
several cancer cell lines (94).
1.4.2. The role of cadherins in regulating myogenesis. Cadherins also play an
important role in regulating myogenesis. Gurdon et al reported that during
myogenesis, the “community effect”, occurs, whereby cells must contact a
sufficient number of like neighbors if they are undergoing coordinate differentiation
within a developing tissue (95; 96). N-cadherin is expressed throughout the
process of avian and murine myogenesis, and antibodies that neutralize Ncadherin inhibit differentiation of myogenic cells (97-99). Conversely, recombinant
cadherin ectodomains coupled to planar substrates or beads, which are able to
induce lateral clustering of cadherins at sites of attachment, facilitate the
recruitment of catenin to cadherin and induce the reorganization of actin
cytoskeleton system thus allow myoblasts to differentiate at low cell density, in a
similar way to that observed in cells cultured on plastic substrate at high cell
density (100; 101). As for the signaling events downstream to cadherins leading to
myogenic gene programming, it’s reported that cadherin ligation results in upregulation of p21 and p27 cyclin-dependent kinase inhibitors and cell cycle arrest,
and increases expression of myogenin, and muscle-specific sarcomeric proteins.
In addition, cadherin ligation can also regulate the reorganization of actin
cytoskeleton by altering the activation status of Rho GTPases (activating RhoA but
suppressing Rac1 and Cdc42), the established regulators of actin dynamics (99101).
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1.4.3. The role of cadherins in regulating β-catenin transcription activity.
Sadot reported that in Chinese hamster ovary (CHO) and SW480 colon carcinoma
cell lines, the binding of β-catenin to the cadherin cytoplasmic tail either in the
membrane, or in the nucleus, can inhibit β-catenin degradation and efficiently block
its transactivation (102). Gottardi reported that expression of wild-type E-cadherin
significantly inhibits the growth of colorectal tumor cell line via inhibiting βcatenin/TCF gene promoter activity in an adhesion-independent manner (103).
Similarly, Stockinger demonstrated that forced expression of E-cadherin in both
fibroblasts and epithelial cells induces cell cycle arrest by inhibiting β-catenin
transcriptional activity (104). Gauthier-Rouviere’s group reported that N-cadherindependent cell-cell contact activates muscle-specific promoters and RhoA in
C2C12 cells. RhoA activity is required for β-catenin recruitment to intercellular
adhesions sites (105). Kuphal and Behrens (106) reported that in DLD-1 colorectal
cancer cells, inhibition of E-cadherin expression by RNA interference led to nuclear
translocation of β-catenin and an enhancement of β-catenin/TCF-dependent
reporter activity. On the other hand, forced expression of E-cadherin in L929
fibroblasts which are deficient in both E-cadherin expression and Wnt signaling
induces the stabilization of β-catenin at the cell junctions and resulted in evident
changes in cell phenotype but no significant impact on the expression level of Wntrelated genes. Recent study from Gottardi lab demonstrated that in S2480 colon
carcinoma cell line, the forced expression of E-cadherin enhances the GSK-3βdependent phosphorylation of β-catenin N-terminus, leading to the inhibition of Wnt
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signaling. This observation provides a novel mechanism underlying cadherin’s
regulation on β-catenin activity (107).
1.4.4. M-cadherin and its role in myogenesis and apoptosis. M-cadherin is a
member of classic cadherins. It was first identified in differentiating muscle cells by
Donalies and colleagues (108) in 1991. They reported that M-cadherin mRNA was
present at low levels in myoblasts and up-regulated in myotube-forming cells but
not detectable in mouse fibroblasts. Its gene locus is linked to the E-cadherin (but
not N-cadherin) locus on chromosome 8 of mouse and the human homologue was
mapped to chromosome 16q24.1 (109). During the process of myogenesis, Mcadherin is specifically involved in secondary myogenesis and its expression is
down-regulated after birth (110-112). In mature skeletal muscle, M-cadherin is only
detectable on satellite cells and on the sarcolemma of myofibers underlying
satellite cells. At early stages of regeneration, M-cadherin was exclusively and
strongly expressed in myoblasts. After fusion of myoblasts into myotubes, Mcadherin was down-regulated and was barely detectable on more mature
myotubes surrounded by distinct basal lamina sheaths (113; 114). It’s reported that
there was a significant decline in the number of M-cadherin-positive satellite cells
in human muscle during aging (24).
During the past decade, the M-cadherin’s role in myoblast fusion has been
established attributed to the studies from various groups. Kuch et al (115) reported
that similar as E-cadherin and N-cadherin, M-cadherin formed two distinct
cytoplasmic complexes in myogenic cells, either with α-catenin/β-catenin or with αcatenin/plakoglobin, indicating that M-cadherin shares important features with the
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classical cadherins in spite of its phylogenetic divergence. Zeschnigk and
coworkers (116) treated myoblasts with antagonistic M-cadherin peptides and
found the fusion of myoblasts into myotubes was inhibited and the expression of
troponin T, an established marker of terminal myogenic differentiation, was
downregulated. The cell cycle withdrawal process was also impaired. Their data
strongly suggested that M-cadherin-mediated myoblast interaction plays an
important role in terminal differentiation of skeletal muscle cells. Charrasse and
coworkers demonstrated that M-cadherin may mediate myoblast fusion by
activating Rac1 GTPase and its function is regulated by RhoA which promotes Mcadherin’s degradation through lysosomal pathway (117; 118). In spite of the
above evidences that establish M-cadherin’s role in myogenesis and muscle
regeneration, there is another study questioning M-cadherin’s absolute necessity in
myogenesis and muscle regeneration. Hollnel and colleagues generated an Mcadherin-null mutation in mice. The mutant mice were viable and fertile and
showed no gross developmental defects. The skeletal muscle appeared normal.
Moreover, muscle lesions induced by cardiotoxin injection were efficiently repaired
in mutant mice, suggesting that satellite cells can be activated to form new
myofibers. Thus they concluded that M-cadherin in the mouse doesn’t serve
absolutely required function during muscle development and regeneration and the
lack of M-cadherin seems to be largely compensated by N-cadherin or other
cadherins. However, they failed to observe a compensatory increase in either the
expression or the function of any other cadherins such as N-cadherin, in Mcadherin-/- skeletal muscle. Furthermore, they didn’t demonstrate the status of
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regeneration capability of muscle in aged M-cadherin-null mice (119). Thus the
importance of M-cadherin in muscle regeneration, as well as the mechanism that
how M-cadherin regulates muscle regeneration, remains to be elucidated.
Although the role of other cadherins, (e.g. E-cadherin, N-cadherin, VEcadherin), in regulating cell survival and death are under extensively investigation,
there is no report published concerning M-cadherin’ role in regulating the apoptosis
of myoblasts or satellite cells. Furthermore, the role of M-cadherin in regulating βcatenin phosphorylation status and the impact of this regulation on canonical Wnt
signaling and myogenesis has not been addressed yet.
1.5.

PI3K/Akt/GSK-3β pathway and its role in apoptosis and muscle

remodeling
1.5.1. PI3K/Akt pathway and its role in cell survival and apoptosis.
Phosphatidylinositiol 3-kinase (PI3K) is a heterodimer composed of a regulatory
subunit (p85) and a catalytic (p110) subunit and possesses activities of both
phosphoinositide kinase and serine/threonine protein kinase (120; 121). P85
subunit negatively regulates the catalytic activity of the p110 subunit (121). The
trigger event for PI3K activation is the activation of receptor or non-receptor
tyrosine kinases in response to ligation of growth factors on the plasma membrane,
which

leads

to

the

autophosphorylation

on

tyrosine

residues

and

transphosphorylation of adaptor proteins, generating specific phosphotyrosine
sequences that bind to the SH2 domain of p85 and alleviates its inhibition on p110.
This results in the enzymatic activation of PI3K (122). On the other hand, GTPassociated Ras can induce the activation of PI3K by directly binding to the p110
19

subunit (123). Once activated, PI3K phosphorylates phosphatidylinositol at the 3’OH of the inositol ring and converts phosphatidylinositol (3,4,) biphosphate (PIP2)
to phosphatidylinositol (3,4,5) triphosphate (PIP3) (124; 125). This functions as a
lipid second messenger and has a high affinity to the pleckstrin (PH) domaincontaining proteins, including the serine/threonine kinase Akt. The binding to PIP3
recruits Akt to the inner surface of plasma membrane (126). Phosphoinositide
dependent kinase 1 (PDK1), another PH domain-containing protein, is also
recruited to plasma membrane by PIP3 (127). Full activation of Akt requires
phosphorylation of the Tyrosine308 and Serine473 residues by PDK1 and PDK2
respectively (127-129). Akt is the key downstream target of PI3K that transmits
most signals from PI3K. A large number of downstream effectors of Akt have been
identified, including mTOR, p70S6K1, Forkhead (FH) transcription factors, GSK3β, IRS-1, caspase-9, Bad, and eNOS (130). The PI3K/Akt pathway has been
established as one of the key signaling pathways that play a crucial role in
regulating various cellular processes, such as cell proliferation, survival,
differentiation, protein synthesis, glucose metabolism, and cell motility (129; 130).
Akt is also known as protein kinase B (PKB). It was originally identified as the
oncogene in the transforming retrovirus, AKT8, which was isolated from an AKR
mouse thymoma cell line (131). AKT plays a crucial role in cellular survival
pathways by phosphorylating a number of target proteins. Akt directly
phosphorylates human procaspase-9 at serine196 and inhibits its protease activity
(132). Akt also phosphorylates Bad, a proapoptotic member of Bcl-2 family, at the
residue of serine136. This phosphorylation releases Bad from the complex with
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Bcl-2/Bcl-XL localized on the mitochondrial membrane and promotes its binding to
14-3-3 proteins in the cytosol, leading to the inhibition of its proapoptotic activity
(133). In addition, Akt is able to phosphorylate Forkhead (FoxO) transcription
factors and this phosphorylation leads to their nuclear exclusion and the
suppression of FoxO-related proapoptotic transcription events (134-136). Akt also
activates IKKα (IκB kinase α) and promotes NF-κB-mediated survival signaling
(137). Furthermore, Akt phosphorylates Glycogen Synthase Kinase-3β (GSK-3β)
at the N-terminal regulatory residue of serine 9, and this phosphorylation
inactivates GSK-3β (138).
1.5.2. GSK-3β: function, regulation, and its role in apoptosis. GSK-3β is a
serine/threonine kinase that phosphorylates numerous substrates including
transcription factors, structural proteins, and signaling proteins. It is involved in
various physiological pathways such as glucose homeostasis and metabolism, cell
cycle control, cell morphogenesis, development, tumor transformation, and
neuroprotection. Thus it has been associated with many diseases including type II
diabetes, inflammation, cancer, Alzheimer’s disease, and bipolar disorder (139;
140). Since GSK-3β is constitutively active in cells under normal resting conditions,
the primary regulatory mode of GSK-3β activity is to inactivate it, which is achieved
by phosphorylation of an N-terminal residue of serine 9 which creates a
pseudosubstrate that occupies the active site of the enzyme, preventing its
interaction with real substrates (141). The kinases that are able to inactivate GSK3β include PKA (cyclic AMP-dependent protein kinase) (142), PKB/AKT (protein
kinase B)(138), PKC (protein kinase C) (143), and p90RSK (p90 ribosomal S6
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kinase) (144). In addition, there are more than 30 chemical compounds that has
been identified to be the GSK-3 inhibitors (145). Lithium chloride (LiCl) is one of
the earliest established inhibitor for GSK-3. LiCl inhibits GSK-3 activity by two
mechanisms: firstly, it competes with ATP in the ATP-binding site of the kinase via
directly competing with magnesium; secondly, it increases the inhibitory
phosphorylation of Serine 9 residue of GSK-3β and Serine 21 residue of GSK-3α
(146). The small heterocyclic thiadiazolidinones (TDZD) are the first group of
chemicals that inhibit GSK-3β activity in a non-APT-competitive pattern (147).
GSK-3β is an established negative regulator of canonical Wnt signaling by
phosphorylating β-catenin (39). GSK-3β also plays an important but paradoxical
role in regulating apoptosis. Firstly, it promotes intrinsic mitochondria-associated
apoptosis (148). GSK-3β can directly phosphorylate Bax at Serine163 which leads
to Bax activation (149). GSK-3β promotes p53-induced intrinsic apoptosis by both
upregulating its expression level and regulating its intracellular localization (150;
151). GSK-3β can also phosphorylate and inhibit a number of transcription factors
that favor the gene expression for anti-apoptotic proteins. For example, the βcatenin/canonical Wnt signaling pathway has been shown to promote growth and
survival. However, phosphorylation of β-catenin by GSK-3β results in its
degradation and the turnoff of canonical Wnt signaling (39). Another survivalpromoting transcription factor that is inhibited by GSK-3β is HSF-1 (Heat shock
factor-1), which induces the expression of several heat shock proteins that protects
cells against apoptosis (152-154). Overexpression of GSK-3β has been shown to
induce apoptosis in various types of cells, including PC12 cell and Rat1 fibroblasts
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(155), cortical neurons (156), vascular smooth muscle cells (157), endothelial cells
(158), and human umbilical vein endothelial cells (159). On the other hand, GSK3β antagonizes the death receptor-mediated extrinsic apoptosis (148). The mouse
GSK-3β knockout model results in embryonic lethality because of massive liver
apoptosis due to TNF hypersensitivity (160), indicating that GSK-3β inhibits TNFinduced apoptosis. Although the exact molecular mechanism that underlies the
anti-apoptotic effect of GSK-3β in extrinsic apoptosis remains to be elucidated,
accumulating evidences suggest that GSK-3β-dependent anti-apoptotic effect is
executed at a very early stage that precedes the initiating step of caspases-8
activation (148).
1.5.3. The role of GSK-3β in muscle wasting and satellite cell biology. Many
studies have suggested that GSK-3β negatively regulates cardiac hypertrophy and
inactivation of GSK-3β is an important mechanism in the development of cardiac
hypertrophy (161; 162). In skeletal muscles, association between GSK-3β and
various muscle wasting conditions has been reported in many studies. GSK-3β
activity is increased in aged (163) and burn-injured skeletal muscles (164). The
activity of GSK-3β is downregulated during myogenic differentiation induced by
IGF-1 (165). In addition, GSK-3β inhibition reduces protein degradation in wasting
muscles and promotes re-growth of atrophic muscle (166-168). A conditional
skeletal muscle knockout of GSK-3β shows an improved insulin tolerance and
glucose metabolism in muscle tissues (169), but there is no data that evaluate a
direct role of GSK-3β in regulating the muscle progenitor cell survival and
apoptosis during myogenic differentiation.
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Regulation of GSK-3β activity has been shown to be a key event in mediating
the switch between Notch and Wnt signaling as the muscle progenitor cells stop
proliferation and start to commit to myogenic differentiation (49), suggesting that
GSK-3β may play a crucial role in regulating the fate specification of satellite cells.

1.6.

Summary and relevance.
Number and functionality of satellite cells is crucial to adult muscle

regeneration. Understanding the molecular mechanism that underlies the
regulation of the survival and differentiation of satellite cells is critical to provide
applicable information to potential clinical intervention of certain muscular
dystrophic disorders. M-cadherin as a key component for cell-cell adhesions
between myoblasts, its function in regulating the survival/apoptosis of myoblasts
and the underlying pathways, as well as its role in regulating β-catenin/canonical
Wnt signaling have not be addressed. In this dissertation, we tried to seek answers
to the following questions: Does M-cadherin protects myoblasts against apoptosis
or makes the myoblasts more susceptible to apoptosis, and what is the signaling
pathway that mediates this effect? Does M-cadherin regulate phosphorylation
status of β-catenin N-terminus in myoblasts? What is the impact of this regulation
on canonical Wnt signaling and myoblast biological behavior? Our ultimate goal is
to determine whether M-cadherin plays a critical role in regulating myoblasts
biological behavior and fate specification and to get insights in novel molecular
mechanism of muscle regeneration and to provide clues for novel therapeutic
strategies for muscular dystrophic disorders.

24

REFERENCES

1.

MAURO A. Satellite cell of skeletal muscle fibers. J Biophys Biochem

Cytol 9: 493-495, 1961.
2.

Seale P and Rudnicki MA. A new look at the origin, function, and "stem-

cell" status of muscle satellite cells. Dev Biol 218: 115-124, 2000.
3.

Sherwood RI, Christensen JL, Conboy IM, Conboy MJ, Rando TA,

Weissman IL and Wagers AJ. Isolation of adult mouse myogenic progenitors:
functional heterogeneity of cells within and engrafting skeletal muscle. Cell 119:
543-554, 2004.
4.

Biressi S and Rando TA. Heterogeneity in the muscle satellite cell

population. Semin Cell Dev Biol 21: 845-854, 2010.
5.

Collins CA, Olsen I, Zammit PS, Heslop L, Petrie A, Partridge TA and

Morgan JE. Stem cell function, self-renewal, and behavioral heterogeneity of
cells from the adult muscle satellite cell niche. Cell 122: 289-301, 2005.
6.

Cornelison DD, Filla MS, Stanley HM, Rapraeger AC and Olwin BB.

Syndecan-3 and syndecan-4 specifically mark skeletal muscle satellite cells
and are implicated in satellite cell maintenance and muscle regeneration. Dev
Biol 239: 79-94, 2001.
7.

Cerletti M, Jurga S, Witczak CA, Hirshman MF, Shadrach JL,

Goodyear LJ and Wagers AJ. Highly efficient, functional engraftment of
skeletal muscle stem cells in dystrophic muscles. Cell 134: 37-47, 2008.
8.

Boldrin L and Morgan JE. Activating muscle stem cells: therapeutic

potential in muscle diseases. Curr Opin Neurol 20: 577-582, 2007.

25

9.

Le Grand F and Rudnicki MA. Skeletal muscle satellite cells and adult

myogenesis. Curr Opin Cell Biol 2007.
10. Tatsumi R, Anderson JE, Nevoret CJ, Halevy O and Allen RE. HGF/SF
is present in normal adult skeletal muscle and is capable of activating satellite
cells. Dev Biol 194: 114-128, 1998.
11. Johnson SE and Allen RE. Activation of skeletal muscle satellite cells
and the role of fibroblast growth factor receptors. Exp Cell Res 219: 449-453,
1995.
12. Yablonka-Reuveni Z, Seger R and Rivera AJ. Fibroblast growth factor
promotes recruitment of skeletal muscle satellite cells in young and old rats. J
Histochem Cytochem 47: 23-42, 1999.
13. Anderson JE. A role for nitric oxide in muscle repair: nitric oxide-mediated
activation of muscle satellite cells. Mol Biol Cell 11: 1859-1874, 2000.
14. Zammit PS, Partridge TA and Yablonka-Reuveni Z. The skeletal
muscle satellite cell: the stem cell that came in from the cold. J Histochem
Cytochem 54: 1177-1191, 2006.
15. Gomes AV, Barnes JA, Harada K and Potter JD. Role of troponin T in
disease. Mol Cell Biochem 263: 115-129, 2004.
16. Andres V and Walsh K. Myogenin expression, cell cycle withdrawal, and
phenotypic differentiation are temporally separable events that precede cell
fusion upon myogenesis. J Cell Biol 132: 657-666, 1996.
17. Guo K, Wang J, Andres V, Smith RC and Walsh K. MyoD-induced
expression of p21 inhibits cyclin-dependent kinase activity upon myocyte
terminal differentiation. Mol Cell Biol 15: 3823-3829, 1995.
26

18. Silberstein L, Webster SG, Travis M and Blau HM. Developmental
progression of myosin gene expression in cultured muscle cells. Cell 46: 10751081, 1986.
19. Yaffe D and Saxel O. Serial passaging and differentiation of myogenic
cells isolated from dystrophic mouse muscle. Nature 270: 725-727, 1977.
20. Zammit PS and Beauchamp JR. The skeletal muscle satellite cell: stem
cell or son of stem cell? Differentiation 68, 193-204. 2001.
Ref Type: Generic
21. Kuang S, Kuroda K, Le GF and Rudnicki MA. Asymmetric self-renewal
and commitment of satellite stem cells in muscle. Cell 129: 999-1010, 2007.
22. Moss FP and Leblond CP. Satellite cells as the source of nuclei in
muscles of growing rats. Anat Rec 170: 421-435, 1971.
23. Seale P and Rudnicki MA. A new look at the origin, function, and "stemcell" status of muscle satellite cells. Dev Biol 218: 115-124, 2000.
24. Sajko S, Kubinova L, Cvetko E, Kreft M, Wernig A and Erzen I.
Frequency of M-cadherin-stained satellite cells declines in human muscles
during aging. J Histochem Cytochem 52: 179-185, 2004.
25. Conboy IM and Rando TA. Aging, stem cells and tissue regeneration:
lessons from muscle. Cell Cycle 4: 407-410, 2005.
26. Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL and
Rando TA. Rejuvenation of aged progenitor cells by exposure to a young
systemic environment. Nature 433: 760-764, 2005.
27. Nair KS. Aging muscle. Am J Clin Nutr 81: 953-963, 2005.
27

28. Welle S. Cellular and molecular basis of age-related sarcopenia. Can J
Appl Physiol 27: 19-41, 2002.
29. Doherty TJ. Invited review: Aging and sarcopenia. J Appl Physiol 95:
1717-1727, 2003.
30. Janssen I, Shepard DS, Katzmarzyk PT and Roubenoff R. The
healthcare costs of sarcopenia in the United States. J Am Geriatr Soc 52: 8085, 2004.
31. Welle S. Cellular and molecular basis of age-related sarcopenia. Can J
Appl Physiol 27: 19-41, 2002.
32. Corbu A, Scaramozza A, Badiali-DeGiorgi L, Tarantino L, Papa V,
Rinaldi R, D'Alessandro R, Zavatta M, Laus M, Lattanzi G and Cenacchi G.
Satellite cell characterization from aging human muscle. Neurol Res 32: 63-72,
2010.
33. Emery AE. The muscular dystrophies. Lancet 359: 687-695, 2002.
34. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell
127: 469-480, 2006.
35. Sugimura R and Li L. Noncanonical Wnt signaling in vertebrate
development, stem cells, and diseases. Birth Defects Res C Embryo Today 90:
243-256, 2010.
36. Cadigan KM and Peifer M. Wnt signaling from development to disease:
insights from model systems. Cold Spring Harb Perspect Biol 1: a002881,
2009.

28

37. Riggleman B, Wieschaus E and Schedl P. Molecular analysis of the
armadillo locus: uniformly distributed transcripts and a protein with novel
internal repeats are associated with a Drosophila segment polarity gene. Genes
Dev 3: 96-113, 1989.
38. Huber AH, Nelson WJ and Weis WI. Three-dimensional structure of the
armadillo repeat region of beta-catenin. Cell 90: 871-882, 1997.
39. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X and
He X. Control of beta-catenin phosphorylation/degradation by a dual-kinase
mechanism. Cell 108: 837-847, 2002.
40. Liu C, Kato Y, Zhang Z, Do VM, Yankner BA and He X. beta-Trcp
couples beta-catenin phosphorylation-degradation and regulates Xenopus axis
formation. Proc Natl Acad Sci U S A 96: 6273-6278, 1999.
41. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S and Kikuchi A.
Axin, a negative regulator of the Wnt signaling pathway, forms a complex with
GSK-3beta and beta-catenin and promotes GSK-3beta-dependent
phosphorylation of beta-catenin. EMBO J 17: 1371-1384, 1998.
42. Aberle H, Bauer A, Stappert J, Kispert A and Kemler R. beta-catenin is
a target for the ubiquitin-proteasome pathway. EMBO J 16: 3797-3804, 1997.
43. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X and
He X. Control of beta-catenin phosphorylation/degradation by a dual-kinase
mechanism. Cell 108: 837-847, 2002.
44. Polesskaya A, Seale P and Rudnicki MA. Wnt signaling induces the
myogenic specification of resident CD45+ adult stem cells during muscle
regeneration. Cell 113: 841-852, 2003.

29

45. Shang YC, Zhang C, Wang SH, Xiong F, Zhao CP, Peng FN, Feng SW,
Yu MJ, Li MS and Zhang YN. Activated beta-catenin induces myogenesis and
inhibits adipogenesis in BM-derived mesenchymal stromal cells. Cytotherapy 9:
667-681, 2007.
46. Perez-Ruiz A, Ono Y, Gnocchi VF and Zammit PS. beta-Catenin
promotes self-renewal of skeletal-muscle satellite cells. J Cell Sci 121: 13731382, 2008.
47. Otto A, Schmidt C, Luke G, Allen S, Valasek P, Muntoni F, LawrenceWatt D and Patel K. Canonical Wnt signalling induces satellite-cell proliferation
during adult skeletal muscle regeneration. J Cell Sci 121: 2939-2950, 2008.
48. Conboy IM and Rando TA. The regulation of Notch signaling controls
satellite cell activation and cell fate determination in postnatal myogenesis. Dev
Cell 3: 397-409, 2002.
49. Brack AS, Conboy IM, Conboy MJ, Shen J and Rando TA. A temporal
switch from notch to Wnt signaling in muscle stem cells is necessary for normal
adult myogenesis. Cell Stem Cell 2: 50-59, 2008.
50. Brack AS, Conboy MJ, Roy S, Lee M, Kuo CJ, Keller C and Rando TA.
Increased Wnt signaling during aging alters muscle stem cell fate and
increases fibrosis. Science 317: 807-810, 2007.
51. Hendriksen J, Fagotto F, van d, V, van SM, Noordermeer J and
Fornerod M. RanBP3 enhances nuclear export of active (beta)-catenin
independently of CRM1. J Cell Biol 171: 785-797, 2005.
52. van NM, Meeldijk J, van der Zee R, Destree O and Clevers H. Wnt
signaling controls the phosphorylation status of beta-catenin. J Biol Chem 277:
17901-17905, 2002.
30

53. Staal FJ, Noort MM, Strous GJ and Clevers HC. Wnt signals are
transmitted through N-terminally dephosphorylated beta-catenin. EMBO Rep 3:
63-68, 2002.
54. Pan W, Jia Y, Wang J, Tao D, Gan X, Tsiokas L, Jing N, Wu D and Li
L. Beta-catenin regulates myogenesis by relieving I-mfa-mediated suppression
of myogenic regulatory factors in P19 cells. Proc Natl Acad Sci U S A 102:
17378-17383, 2005.
55. Kim CH, Neiswender H, Baik EJ, Xiong WC and Mei L. Beta-catenin
interacts with MyoD and regulates its transcription activity. Mol Cell Biol 28:
2941-2951, 2008.
56. Rastogi RP, Shinha R and Sinha RP. Apoptosis: molecular mechanisms
and pathogenicity. EXCLI Journal 8: 155-181, 2009.
57. Kroemer G, Galluzzi L and Brenner C. Mitochondrial membrane
permeabilization in cell death. Physiol Rev 87: 99-163, 2007.
58. Zou H, Li Y, Liu X and Wang X. An APAF-1.cytochrome c multimeric
complex is a functional apoptosome that activates procaspase-9. J Biol Chem
274: 11549-11556, 1999.
59. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA and Yuan J.
Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and
cytotoxicity by amyloid-beta. Nature 403: 98-103, 2000.
60. MacFarlane M and Williams AC. Apoptosis and disease: a life or death
decision. EMBO Rep 5: 674-678, 2004.

31

61. Siu PM, Pistilli EE and Alway SE. Apoptotic responses to hindlimb
suspension in gastrocnemius muscles from young adult and aged rats. Am J
Physiol Regul Integr Comp Physiol 289: R1015-R1026, 2005.
62. Siu PM, Pistilli EE, Ryan MJ and Alway SE. Aging sustains the
hypertrophy-associated elevation of apoptotic suppressor X-linked inhibitor of
apoptosis protein (XIAP) in skeletal muscle during unloading. J Gerontol A Biol
Sci Med Sci 60: 976-983, 2005.
63. Alway SE and Siu PM. Nuclear apoptosis contributes to sarcopenia.
Exerc Sport Sci Rev 36: 51-57, 2008.
64. Jejurikar SS and Kuzon WM, Jr. Satellite cell depletion in degenerative
skeletal muscle. Apoptosis 8: 573-578, 2003.
65. Jejurikar SS, Henkelman EA, Cederna PS, Marcelo CL, Urbanchek
MG and Kuzon WM, Jr. Aging increases the susceptibility of skeletal muscle
derived satellite cells to apoptosis. Exp Gerontol 41: 828-836, 2006.
66. Tews DS and Goebel HH. DNA-fragmentation and expression of
apoptosis-related proteins in muscular dystrophies. Neuropathol Appl Neurobiol
23: 331-338, 1997.
67. Tidball JG, Albrecht DE, Lokensgard BE and Spencer MJ. Apoptosis
precedes necrosis of dystrophin-deficient muscle. J Cell Sci 108 ( Pt 6): 21972204, 1995.
68. Gussoni E, Blau HM and Kunkel LM. The fate of individual myoblasts
after transplantation into muscles of DMD patients. Nat Med 3: 970-977, 1997.
69. Partridge T, Lu QL, Morris G and Hoffman E. Is myoblast
transplantation effective? Nat Med 4: 1208-1209, 1998.
32

70. Dee K, Freer M, Mei Y and Weyman CM. Apoptosis coincident with the
differentiation of skeletal myoblasts is delayed by caspase 3 inhibition and
abrogated by MEK-independent constitutive Ras signaling. Cell Death Differ 9:
209-218, 2002.
71. Angst BD, Marcozzi C and Magee AI. The cadherin superfamily:
diversity in form and function. J Cell Sci 114: 629-641, 2001.
72. Pokutta S and Weis WI. Structure and mechanism of cadherins and
catenins in cell-cell contacts. Annu Rev Cell Dev Biol 23: 237-261, 2007.
73. Pertz O, Bozic D, Koch AW, Fauser C, Brancaccio A and Engel J. A
new crystal structure, Ca2+ dependence and mutational analysis reveal
molecular details of E-cadherin homoassociation. EMBO J 18: 1738-1747,
1999.
74. Steinberg MS and McNutt PM. Cadherins and their connections:
adhesion junctions have broader functions. Curr Opin Cell Biol 11: 554-560,
1999.
75. Skaper SD, Facci L, Williams G, Williams EJ, Walsh FS and Doherty
P. A dimeric version of the short N-cadherin binding motif HAVDI promotes
neuronal cell survival by activating an N-cadherin/fibroblast growth factor
receptor signalling cascade. Mol Cell Neurosci 26: 17-23, 2004.
76. Erez N, Zamir E, Gour BJ, Blaschuk OW and Geiger B. Induction of
apoptosis in cultured endothelial cells by a cadherin antagonist peptide:
involvement of fibroblast growth factor receptor-mediated signalling. Exp Cell
Res 294: 366-378, 2004.

33

77. Joshi MB, Philippova M, Ivanov D, Allenspach R, Erne P and Resink
TJ. T-cadherin protects endothelial cells from oxidative stress-induced
apoptosis. FASEB J 19: 1737-1739, 2005.
78. Peluso JJ. N-cadherin-mediated cell contact regulates ovarian surface
epithelial cell survival. Biol Signals Recept 9: 115-121, 2000.
79. Pon YL, Auersperg N and Wong AS. Gonadotropins regulate Ncadherin-mediated human ovarian surface epithelial cell survival at both posttranslational and transcriptional levels through a cyclic AMP/protein kinase A
pathway. J Biol Chem 280: 15438-15448, 2005.
80. Peluso JJ, Pappalardo A and Fernandez G. E-cadherin-mediated cell
contact prevents apoptosis of spontaneously immortalized granulosa cells by
regulating Akt kinase activity. Biol Reprod 64: 1183-1190, 2001.
81. Fouquet S, Lugo-Martinez VH, Faussat AM, Renaud F, Cardot P,
Chambaz J, Pincon-Raymond M and Thenet S. Early loss of E-cadherin from
cell-cell contacts is involved in the onset of Anoikis in enterocytes. J Biol Chem
279: 43061-43069, 2004.
82. Koutsouki E, Beeching CA, Slater SC, Blaschuk OW, Sala-Newby GB
and George SJ. N-cadherin-dependent cell-cell contacts promote human
saphenous vein smooth muscle cell survival. Arterioscler Thromb Vasc Biol 25:
982-988, 2005.
83. Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Ng
T, Reynolds CP, Triche TJ and Sorensen PH. E-cadherin cell-cell adhesion
in ewing tumor cells mediates suppression of anoikis through activation of the
ErbB4 tyrosine kinase. Cancer Res 67: 3094-3105, 2007.

34

84. Kantak SS and Kramer RH. E-cadherin regulates anchorageindependent growth and survival in oral squamous cell carcinoma cells. J Biol
Chem 273: 16953-16961, 1998.
85. Li G, Satyamoorthy K and Herlyn M. N-cadherin-mediated intercellular
interactions promote survival and migration of melanoma cells. Cancer Res 61:
3819-3825, 2001.
86. Reddy P, Liu L, Ren C, Lindgren P, Boman K, Shen Y, Lundin E,
Ottander U, Rytinki M and Liu K. Formation of E-cadherin-mediated cell-cell
adhesion activates AKT and mitogen activated protein kinase via
phosphatidylinositol 3 kinase and ligand-independent activation of epidermal
growth factor receptor in ovarian cancer cells. Mol Endocrinol 19: 2564-2578,
2005.
87. Tran NL, Adams DG, Vaillancourt RR and Heimark RL. Signal
transduction from N-cadherin increases Bcl-2. Regulation of the
phosphatidylinositol 3-kinase/Akt pathway by homophilic adhesion and actin
cytoskeletal organization. J Biol Chem 277: 32905-32914, 2002.
88. Pece S, Chiariello M, Murga C and Gutkind JS. Activation of the protein
kinase Akt/PKB by the formation of E-cadherin-mediated cell-cell junctions.
Evidence for the association of phosphatidylinositol 3-kinase with the Ecadherin adhesion complex. J Biol Chem 274: 19347-19351, 1999.
89. Williams EJ, Williams G, Howell FV, Skaper SD, Walsh FS and
Doherty P. Identification of an N-cadherin motif that can interact with the
fibroblast growth factor receptor and is required for axonal growth. J Biol Chem
276: 43879-43886, 2001.

35

90. Orford K, Orford CC and Byers SW. Exogenous expression of betacatenin regulates contact inhibition, anchorage-independent growth, anoikis,
and radiation-induced cell cycle arrest. J Cell Biol 146: 855-868, 1999.
91. Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, Mayo MW,
Kitajewski J and Wang CY. Wnt-1 signaling inhibits apoptosis by activating
beta-catenin/T cell factor-mediated transcription. J Cell Biol 152: 87-96, 2001.
92. Monga SP, Monga HK, Tan X, Mule K, Pediaditakis P and
Michalopoulos GK. Beta-catenin antisense studies in embryonic liver cultures:
role in proliferation, apoptosis, and lineage specification. Gastroenterology 124:
202-216, 2003.
93. van Gijn ME, Snel F, Cleutjens JP, Smits JF and Blankesteijn WM.
Overexpression of components of the Frizzled-Dishevelled cascade results in
apoptotic cell death, mediated by beta-catenin. Exp Cell Res 265: 46-53, 2001.
94. Kim K, Pang KM, Evans M and Hay ED. Overexpression of beta-catenin
induces apoptosis independent of its transactivation function with LEF-1 or the
involvement of major G1 cell cycle regulators. Mol Biol Cell 11: 3509-3523,
2000.
95. Gurdon JB, Lemaire P and Kato K. Community effects and related
phenomena in development. Cell 75: 831-834, 1993.
96. Gurdon JB, Tiller E, Roberts J and Kato K. A community effect in
muscle development. Curr Biol 3: 1-11, 1993.
97. Knudsen KA, Myers L and McElwee SA. A role for the Ca2(+)dependent adhesion molecule, N-cadherin, in myoblast interaction during
myogenesis. Exp Cell Res 188: 175-184, 1990.

36

98. George-Weinstein M, Gerhart J, Blitz J, Simak E and Knudsen KA. Ncadherin promotes the commitment and differentiation of skeletal muscle
precursor cells. Dev Biol 185: 14-24, 1997.
99. Charrasse S, Meriane M, Comunale F, Blangy A and GauthierRouviere C. N-cadherin-dependent cell-cell contact regulates Rho GTPases
and beta-catenin localization in mouse C2C12 myoblasts. J Cell Biol 158: 953965, 2002.
100. Gavard J, Marthiens V, Monnet C, Lambert M and Mege RM. Ncadherin activation substitutes for the cell contact control in cell cycle arrest and
myogenic differentiation: involvement of p120 and beta-catenin. J Biol Chem
279: 36795-36802, 2004.
101. Goichberg P and Geiger B. Direct involvement of N-cadherin-mediated
signaling in muscle differentiation. Mol Biol Cell 9: 3119-3131, 1998.
102. Sadot E, Simcha I, Shtutman M, Ben Ze'ev A and Geiger B. Inhibition
of beta-catenin-mediated transactivation by cadherin derivatives. Proc Natl
Acad Sci U S A 95: 15339-15344, 1998.
103. Gottardi CJ, Wong E and Gumbiner BM. E-cadherin suppresses cellular
transformation by inhibiting beta-catenin signaling in an adhesion-independent
manner. J Cell Biol 153: 1049-1060, 2001.
104. Stockinger A, Eger A, Wolf J, Beug H and Foisner R. E-cadherin
regulates cell growth by modulating proliferation-dependent beta-catenin
transcriptional activity. J Cell Biol 154: 1185-1196, 2001.
105. Charrasse S, Meriane M, Comunale F, Blangy A and GauthierRouviere C. N-cadherin-dependent cell-cell contact regulates Rho GTPases

37

and beta-catenin localization in mouse C2C12 myoblasts. J Cell Biol 158: 953965, 2002.
106. Kuphal F and Behrens J. E-cadherin modulates Wnt-dependent
transcription in colorectal cancer cells but does not alter Wnt-independent gene
expression in fibroblasts. Exp Cell Res 312: 457-467, 2006.
107. Maher MT, Flozak AS, Stocker AM, Chenn A and Gottardi CJ. Activity
of the beta-catenin phosphodestruction complex at cell-cell contacts is
enhanced by cadherin-based adhesion. J Cell Biol 186: 219-228, 2009.
108. Donalies M, Cramer M, Ringwald M and Starzinski-Powitz A.
Expression of M-cadherin, a member of the cadherin multigene family,
correlates with differentiation of skeletal muscle cells. Proc Natl Acad Sci U S A
88: 8024-8028, 1991.
109. Kaupmann K, Becker-Follmann J, Scherer G, Jockusch H and
Starzinski-Powitz A. The gene for the cell adhesion molecule M-cadherin
maps to mouse chromosome 8 and human chromosome 16q24.1-qter and is
near the E-cadherin (uvomorulin) locus in both species. Genomics 14: 488-490,
1992.
110. Rose O, Rohwedel J, Reinhardt S, Bachmann M, Cramer M, Rotter M,
Wobus A and Starzinski-Powitz A. Expression of M-cadherin protein in
myogenic cells during prenatal mouse development and differentiation of
embryonic stem cells in culture. Dev Dyn 201: 245-259, 1994.
111. Pouliot Y, Gravel M and Holland PC. Developmental regulation of Mcadherin in the terminal differentiation of skeletal myoblasts. Dev Dyn 200: 305312, 1994.

38

112. Cifuentes-Diaz C, Nicolet M, Alameddine H, Goudou D, Dehaupas M,
Rieger F and Mege RM. M-cadherin localization in developing adult and
regenerating mouse skeletal muscle: possible involvement in secondary
myogenesis. Mech Dev 50: 85-97, 1995.
113. Bornemann A and Schmalbruch H. Immunocytochemistry of M-cadherin
in mature and regenerating rat muscle. Anat Rec 239: 119-125, 1994.
114. Irintchev A, Zeschnigk M, Starzinski-Powitz A and Wernig A.
Expression pattern of M-cadherin in normal, denervated, and regenerating
mouse muscles. Dev Dyn 199: 326-337, 1994.
115. Kuch C, Winnekendonk D, Butz S, Unvericht U, Kemler R and
Starzinski-Powitz A. M-cadherin-mediated cell adhesion and complex
formation with the catenins in myogenic mouse cells. Exp Cell Res 232: 331338, 1997.
116. Zeschnigk M, Kozian D, Kuch C, Schmoll M and Starzinski-Powitz A.
Involvement of M-cadherin in terminal differentiation of skeletal muscle cells. J
Cell Sci 108 ( Pt 9): 2973-2981, 1995.
117. Charrasse S, Comunale F, Grumbach Y, Poulat F, Blangy A and
Gauthier-Rouviere C. RhoA GTPase regulates M-cadherin activity and
myoblast fusion. Mol Biol Cell 17: 749-759, 2006.
118. Charrasse S, Comunale F, Fortier M, Portales-Casamar E, Debant A
and Gauthier-Rouviere C. M-cadherin activates Rac1 GTPase through the
Rho-GEF trio during myoblast fusion. Mol Biol Cell 18: 1734-1743, 2007.
119. Hollnagel A, Grund C, Franke WW and Arnold HH. The cell adhesion
molecule M-cadherin is not essential for muscle development and regeneration.
Mol Cell Biol 22: 4760-4770, 2002.
39

120. Carpenter CL, Duckworth BC, Auger KR, Cohen B, Schaffhausen BS
and Cantley LC. Purification and characterization of phosphoinositide 3-kinase
from rat liver. J Biol Chem 265: 19704-19711, 1990.
121. Dhand R, Hiles I, Panayotou G, Roche S, Fry MJ, Gout I, Totty NF,
Truong O, Vicendo P, Yonezawa K and . PI 3-kinase is a dual specificity
enzyme: autoregulation by an intrinsic protein-serine kinase activity. EMBO J
13: 522-533, 1994.
122. Cantrell DA. Phosphoinositide 3-kinase signalling pathways. J Cell Sci
114: 1439-1445, 2001.
123. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I,
Fry MJ, Waterfield MD and Downward J. Phosphatidylinositol-3-OH kinase
as a direct target of Ras. Nature 370: 527-532, 1994.
124. Whitman M, Downes CP, Keeler M, Keller T and Cantley L. Type I
phosphatidylinositol kinase makes a novel inositol phospholipid,
phosphatidylinositol-3-phosphate. Nature 332: 644-646, 1988.
125. Yamamoto K, Graziani A, Carpenter C, Cantley LC and Lapetina EG.
A novel pathway for the formation of phosphatidylinositol 3,4-bisphosphate.
Phosphorylation of phosphatidylinositol 3-monophosphate by
phosphatidylinositol-3-monophosphate 4-kinase. J Biol Chem 265: 2208622089, 1990.
126. Sable CL, Filippa N, Filloux C, Hemmings BA and Van OE.
Involvement of the pleckstrin homology domain in the insulin-stimulated
activation of protein kinase B. J Biol Chem 273: 29600-29606, 1998.

40

127. Anderson KE, Coadwell J, Stephens LR and Hawkins PT.
Translocation of PDK-1 to the plasma membrane is important in allowing PDK1 to activate protein kinase B. Curr Biol 8: 684-691, 1998.
128. Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter
GF, Holmes AB, McCormick F and Hawkins PT. Dual role of
phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B.
Science 277: 567-570, 1997.
129. Downward J. Mechanisms and consequences of activation of protein
kinase B/Akt. Curr Opin Cell Biol 10: 262-267, 1998.
130. Coffer PJ, Jin J and Woodgett JR. Protein kinase B (c-Akt): a
multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J
335 ( Pt 1): 1-13, 1998.
131. Testa JR and Bellacosa A. AKT plays a central role in tumorigenesis.
Proc Natl Acad Sci U S A 98: 10983-10985, 2001.
132. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF,
Stanbridge E, Frisch S and Reed JC. Regulation of cell death protease
caspase-9 by phosphorylation. Science 282: 1318-1321, 1998.
133. Datta SR, Brunet A and Greenberg ME. Cellular survival: a play in three
Akts. Genes Dev 13: 2905-2927, 1999.
134. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ,
Arden KC, Blenis J and Greenberg ME. Akt promotes cell survival by
phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868,
1999.

41

135. Burgering BM and Medema RH. Decisions on life and death: FOXO
Forkhead transcription factors are in command when PKB/Akt is off duty. J
Leukoc Biol 73: 689-701, 2003.
136. Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL and
Burgering BM. Direct control of the Forkhead transcription factor AFX by
protein kinase B. Nature 398: 630-634, 1999.
137. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM and Donner DB.
NF-kappaB activation by tumour necrosis factor requires the Akt serinethreonine kinase. Nature 401: 82-85, 1999.
138. Cross DA, Alessi DR, Cohen P, Andjelkovich M and Hemmings BA.
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase
B. Nature 378: 785-789, 1995.
139. Rayasam GV, Tulasi VK, Sodhi R, Davis JA and Ray A. Glycogen
synthase kinase 3: more than a namesake. Br J Pharmacol 156: 885-898,
2009.
140. Frame S and Cohen P. GSK3 takes centre stage more than 20 years
after its discovery. Biochem J 359: 1-16, 2001.
141. Stambolic V and Woodgett JR. Mitogen inactivation of glycogen
synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J
303 ( Pt 3): 701-704, 1994.
142. Liu F, Liang Z, Shi J, Yin D, El-Akkad E, Grundke-Iqbal I, Iqbal K and
Gong CX. PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of
tau in site- and kinase-specific manners. FEBS Lett 580: 6269-6274, 2006.

42

143. Vilimek D and Duronio V. Cytokine-stimulated phosphorylation of GSK-3
is primarily dependent upon PKCs, not PKB. Biochem Cell Biol 84: 20-29,
2006.
144. Frame S, Cohen P and Biondi RM. A common phosphate binding site
explains the unique substrate specificity of GSK3 and its inactivation by
phosphorylation. Mol Cell 7: 1321-1327, 2001.
145. Meijer L, Flajolet M and Greengard P. Pharmacological inhibitors of
glycogen synthase kinase 3. Trends Pharmacol Sci 25: 471-480, 2004.
146. Klein PS and Melton DA. A molecular mechanism for the effect of lithium
on development. Proc Natl Acad Sci U S A 93: 8455-8459, 1996.
147. Martinez A, Alonso M, Castro A, Perez C and Moreno FJ. First nonATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors:
thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's
disease. J Med Chem 45: 1292-1299, 2002.
148. Beurel E and Jope RS. The paradoxical pro- and anti-apoptotic actions of
GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog
Neurobiol 79: 173-189, 2006.
149. Linseman DA, Butts BD, Precht TA, Phelps RA, Le SS, Laessig TA,
Bouchard RJ, Florez-McClure ML and Heidenreich KA. Glycogen synthase
kinase-3beta phosphorylates Bax and promotes its mitochondrial localization
during neuronal apoptosis. J Neurosci 24: 9993-10002, 2004.
150. Kulikov R, Boehme KA and Blattner C. Glycogen synthase kinase 3dependent phosphorylation of Mdm2 regulates p53 abundance. Mol Cell Biol
25: 7170-7180, 2005.

43

151. Watcharasit P, Bijur GN, Song L, Zhu J, Chen X and Jope RS.
Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the
actions of p53. J Biol Chem 278: 48872-48879, 2003.
152. Bijur GN and Jope RS. Opposing actions of phosphatidylinositol 3-kinase
and glycogen synthase kinase-3beta in the regulation of HSF-1 activity. J
Neurochem 75: 2401-2408, 2000.
153. Chu B, Soncin F, Price BD, Stevenson MA and Calderwood SK.
Sequential phosphorylation by mitogen-activated protein kinase and glycogen
synthase kinase 3 represses transcriptional activation by heat shock factor-1. J
Biol Chem 271: 30847-30857, 1996.
154. Khaleque MA, Bharti A, Sawyer D, Gong J, Benjamin IJ, Stevenson
MA and Calderwood SK. Induction of heat shock proteins by heregulin beta1
leads to protection from apoptosis and anchorage-independent growth.
Oncogene 24: 6564-6573, 2005.
155. Pap M and Cooper GM. Role of glycogen synthase kinase-3 in the
phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 273:
19929-19932, 1998.
156. Hetman M, Cavanaugh JE, Kimelman D and Xia Z. Role of glycogen
synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J
Neurosci 20: 2567-2574, 2000.
157. Hall JL, Chatham JC, Eldar-Finkelman H and Gibbons GH.
Upregulation of glucose metabolism during intimal lesion formation is coupled
to the inhibition of vascular smooth muscle cell apoptosis. Role of GSK3beta.
Diabetes 50: 1171-1179, 2001.

44

158. Kim HS, Skurk C, Thomas SR, Bialik A, Suhara T, Kureishi Y,
Birnbaum M, Keaney JF, Jr. and Walsh K. Regulation of angiogenesis by
glycogen synthase kinase-3beta. J Biol Chem 277: 41888-41896, 2002.
159. Suhara T, Magrane J, Rosen K, Christensen R, Kim HS, Zheng B,
McPhie DL, Walsh K and Querfurth H. Abeta42 generation is toxic to
endothelial cells and inhibits eNOS function through an Akt/GSK-3beta
signaling-dependent mechanism. Neurobiol Aging 24: 437-451, 2003.
160. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O and Woodgett JR.
Requirement for glycogen synthase kinase-3beta in cell survival and NFkappaB activation. Nature 406: 86-90, 2000.
161. Hardt SE and Sadoshima J. Glycogen synthase kinase-3beta: a novel
regulator of cardiac hypertrophy and development. Circ Res 90: 1055-1063,
2002.
162. Miura T and Miki T. GSK-3beta, a therapeutic target for cardiomyocyte
protection. Circ J 73: 1184-1192, 2009.
163. Kinnard RS, Mylabathula DB, Uddemarri S, Rice KM, Wright GL and
Blough ER. Regulation of p70S6k, GSK-3beta, and calcineurin in rat striated
muscle during aging. Biogerontology 6: 173-184, 2005.
164. Fang CH, Li B, James JH, Yahya A, Kadeer N, Guo X, Xiao C, Supp
DM, Kagan RJ, Hasselgren PO and Sheriff S. GSK-3beta activity is
increased in skeletal muscle after burn injury in rats. Am J Physiol Regul Integr
Comp Physiol 293: R1545-R1551, 2007.
165. Vyas DR, Spangenburg EE, Abraha TW, Childs TE and Booth FW.
GSK-3beta negatively regulates skeletal myotube hypertrophy. Am J Physiol
Cell Physiol 283: C545-C551, 2002.
45

166. Evenson AR, Fareed MU, Menconi MJ, Mitchell JC and Hasselgren
PO. GSK-3beta inhibitors reduce protein degradation in muscles from septic
rats and in dexamethasone-treated myotubes. Int J Biochem Cell Biol 37: 22262238, 2005.
167. van der Velden JL, Langen RC, Kelders MC, Wouters EF, JanssenHeininger YM and Schols AM. Inhibition of glycogen synthase kinase-3beta
activity is sufficient to stimulate myogenic differentiation. Am J Physiol Cell
Physiol 290: C453-C462, 2006.
168. van der Velden JL, Langen RC, Kelders MC, Willems J, Wouters EF,
Janssen-Heininger YM and Schols AM. Myogenic differentiation during
regrowth of atrophied skeletal muscle is associated with inactivation of GSK3beta. Am J Physiol Cell Physiol 292: C1636-C1644, 2007.
169. Patel S, Doble BW, MacAulay K, Sinclair EM, Drucker DJ and
Woodgett JR. Tissue-specific role of glycogen synthase kinase 3beta in
glucose homeostasis and insulin action. Mol Cell Biol 28: 6314-6328, 2008.

46

CHAPTER 2:
SUPPRESSION OF GSK-3ß ACTIVATION BY M-CADHERIN PROTECTS
MYOBLASTS AGAINST MITOCHONDRIA-ASSOCIATED APOPTOSIS
DURING MYOGENIC DIFFERENTIATION
As published in J Cell Sci (in press)

Yan Wang, Yanlei Hao and Stephen E. Alway*

Laboratory of Muscle Biology and Sarcopenia, Division of Exercise Physiology, and
Center for Cardiovascular and Respiratory Sciences, Robert C Byrd Health Sciences
Center, West Virginia University School of Medicine, Morgantown, West Virginia 26506

Running title: M-cadherin prevents myoblast apoptosis

Keywords: M-cadherin, Myoblasts, Apoptosis, Myogenesis

*Address correspondence to: Stephen E. Alway, Ph.D., Division of Exercise Physiology,
School of Medicine, Robert C. Byrd Health Sciences Center, West Virginia University,
Morgantown WV 26506-9227, Tel. 304-293-0772; Fax. 304-293-7105; Email:
salway@hsc.wvu.edu

47

ABSTRACT
Apoptosis occurs concurrently with differentiation of muscle progenitor cells (MPCs)
before they fuse to form myotubes. Dysregulated apoptosis in MPCs contributes to the
low regeneration capability in aged muscle and decreases the survival rate of donor
cells in stem cell-based therapies including muscular dystrophies. This study
investigated the role of the M-cadherin/PI3K/Akt/GSK-3β signaling pathway in regulating
apoptosis during differentiation of MPCs. Disruption of M-cadherin-dependent cell-cell
adhesion by M-cadherin RNA interference (RNAi) in confluent C2C12 myoblasts
sensitized the cells to mitochondria-associated intrinsic apoptosis induced by cell
confluence or serum starvation. Further investigation of this pathway revealed that Mcadherin-mediated signaling suppressed GSK-3β activation by enhancing the
PI3K/AKT-dependent inhibitory phosphorylation of GSK-3βser9. Overexpression of wildtype GSK-3β in confluent C2C12 myoblasts exacerbated the apoptosis, while chemical
inhibition of GSK-3β (TDZD-8), or forced expression of constitutively active Akt
(myrAkt), or a kinase-deficient GSK-3β (GSK-3βK85R) mutant, attenuated apoptosis
and rescued the impaired myogenic differentiation that is caused by M-cadherin RNAi.
These data suggest that M-cadherin-mediated signaling prevents acceleration of
mitochondria-associated intrinsic apoptosis in MPCs via suppressing GSK-3β activation
during myogenic differentiation.
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INTRODUCTION
Muscle progenitor cells (MPCs, i.e., satellite cells) remain quiescent both metabolically
and mitotically in adult muscles under normal basal physiological conditions. Once
activated by stimuli such as muscle injury or exercise, they enter the cell cycle,
proliferate, differentiate, and fuse into myotubes for muscle regeneration (1; 2). The
differentiation of MPCs is critical for myotube formation but it also occurs concurrently
with apoptosis (3; 4). Apoptosis is a systematic process of programmed cell death which
is important for normal tissue morphogenesis and development by maintaining the
tissue homeostasis.

The dysregulation of apoptosis contributes to a variety of

pathologies, including cancer, autoimmune diseases, cardiovascular disease and
degenerative neurological diseases (5-7). In skeletal muscle, apoptosis has been linked
to conditions of muscle wasting caused by disuse, denervation, and aging (8-10). In
addition, inappropriate apoptosis of muscle progenitor cells may contribute to the low
regeneration capability of dystrophic muscles and the poor outcomes of stem-cell-based
therapeutic strategies (11-14). Decreased muscle progenitor cells number (15), function
(16; 17), and altered responses to their niche (18; 19) contribute to the impaired
regenerative capability in aging skeletal muscle. In addition, muscle progenitor cells that
are isolated from aged muscle are susceptible to apoptosis and their number declines
as more of them are depleted by apoptosis in aged muscle (20-22).

M-cadherin is a member of the classical cadherin family of transmembrane
glycoproteins mediating calcium-dependent homophilic cell-cell adhesion. M-cadherin is
specifically expressed in skeletal muscle and certain neural tissues. In mature skeletal
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muscle, M-cadherin is only detectable on satellite cells and the underlying sarcolemma
of myofibers (23; 24). The number of M-cadherin-positive satellite cells decreases in
aged muscle (25). Although a mouse knockout model indicated that M-cadherin might
play a dispensable role in myogenesis and muscle regeneration in vivo (26), data from
in vitro studies showed that by interacting with Rac1 and other members of Rho
subfamily, M-cadherin is critical in mediating myoblast alignment and fusion into
myotubes (27-29). However, its role in regulating the survival and death of muscle
progenitor cells/myoblasts has never been addressed.

In the present study, we investigated the role of M-cadherin-dependent cell-cell
adhesion on the survival of mouse C2C12 myoblasts as well as primary muscle
progenitor cells during myogenic differentiation. We were particularly interested in the
potential for M-cadherin to protect against the mitochondria-associated intrinsic
apoptosis that is induced by cell confluence or serum starvation. By disrupting Mcadherin-dependent cell-cell adhesion through knocking down M-cadherin expression
via RNA interference, we demonstrated that M-cadherin-mediated signaling is important
for maintaining mitochondrial integrity. This occurred by suppressing GSK-3β activation
in a PI3K/Akt-dependent manner, and reducing apoptotic signaling through the
mitochondrial pathway, thus promoting the survival of myoblasts during myogenic
differentiation. Moreover, apoptosis and impaired myogenic differentiation that is caused
by M-cadherin RNAi can be rescued by the inhibition of GSK-3β activation. Together,
these results suggest an indispensable role of M-cadherin-mediated signaling in
maintaining the balance between apoptosis and differentiation of muscle progenitor

50

cells during myogenesis and potentially during activation of muscle stem cells such as
that occurring during muscle regeneration.

MATERIALS AND METHODS
For detailed methods see Supplementary information.

Cell Culture
C2C12 myoblasts were purchased from American Type Culture Collection (Manassas,
VA) and maintained in Dulbecco Modified Eagle’s Medium (DMEM) (Invitrogen Life
Technologies, Bethesda, MD) supplemented with 10% fetal bovine serum (FBS) and
1% antibiotic and antimycotic mixture solution (Invitrogen). Primary myoblasts were
isolated from hindlimb muscles of one-week old C57BL/6 mice (30) and purified by
Percoll (Sigma-Aldrich Co., St Louis, MO) gradient centrifugation. The Syndecan-4positive myoblasts were identified by fluorescence activated cell sorting (FACS) using a
Syndecan-4 antibody (BD). The Syndecan-4-positive myoblasts were cultured in Ham’s
F10 supplemented with 20% FBS at 37ºC. Serum starvation was induced by incubating
the cells in serum-free DMEM supplemented with 1% antibiotic and antimycotics.
Myogenic differentiation was induced by culturing the confluent cells in differentiation
medium (DMEM, 2% horse serum, 1% antibiotic and antimycotic).
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Chemical Inhibitors
The cells were treated with a PI3K inhibitor Wortmannin (200 nM, Alexis Biochemicals,
Plymouth Meeting, PA), a GSK-3 inhibitor, TDZD-8 (25 μM, Sigma), or a MEK1 inhibitor
PD98059 (50 μM, Cell Signaling, Danvers, MA).

Inhibition of M-cadherin expression by RNA interference
The myoblasts were seeded at a density of 1.7 × 10 5 per well in a six-well plate, 24
hours before transfection with SMARTpool small interfering RNA (siRNA) targeted to Mcadherin mRNA (Life Thermo). The transfection media included either DharmaFECTTM3 reagent (Life Thermo) (for C2C12 myoblasts) or Lipofectamine 2000 (Invitrogen) (for
primary myoblasts) at a final siRNA duplex concentration of 100nM. The efficacy of Mcadherin protein knockdown by RNA interference (RNAi) was confirmed by
immunoblotting.

Plasmids and Transfection
The full-length mouse wild-type GSK-3β cDNA was generated by RT-PCR. mRNA was
derived from wild C2C12 myoblasts using Trizol reagent (Life Technologies, Inc.) and
reverse-transcribed into cDNA using Superscript II (Life Technologies, Inc.). The PCR
product was cloned into the expression vector pcDNA3.1/myc-His(-) (Invitrogen). The
constitutively active mutant of Akt (myrAkt) and the V5-tagged kinase-deficient GSK-3β
mutant (K85R) carried by vector pcDNA3 were generous gifts from Dr. Jia Luo. The
cells were transfected with the wild-type GSK-3β plasmids using FuGENE 6 (Roche
Diagnostics, Indianapolis, IN). The co-transfection of M-cadherin siRNA with myrAkt or
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GSK-3β (K85R) plasmids was carried out using DharmaFECT Duo transfection reagent
(Dharmacon, Inc., Thermo-Fisher Scientific, Lafayette CO).

Recombinant M-cadherin-Fc treatment
The recombinant M-cadherin-Fc chimera was purchased from R&D Systems
(Minneapolis, MN). 6-well plates were pre-coated with goat anti-Fc antibody (0.5µg/cm2
in PBS/Ca2+; Jackson ImmunoResearch, West Grove, PA) overnight at 4°C followed by
coating with recombinant M-cadherin-Fc chimera at a final concentration of 2µg/cm2 in
0.1%BSA/PBS/Ca2+ for 2 hours at room temperature. The dishes were blocked with 1%
BSA/HBSS/Ca2. Plates coated with solely the anti-Fc antibody were used as vehicle
controls. The cells were seeded at 0.5 x 105 cells per well and grown for 48 hours
before being harvested for further assays.

Subcellular fractionation
The membrane fraction of C2C12 myoblasts was prepared using a commercial reagent
(Thermo Fisher). The nuclear protein fraction was prepared according to methods that
have been previously described (31). The mitochondrial, mitochondria-free and nucleifree cytosolic fractions were prepared using mitochondria/cytosol reagents (BioVision,
Mountain View, CA). The concentration of the protein extracts was quantified in
duplicate by Bio-Rad DC Protein Assay (BioRad, Hercules, CA). The whole cell lysate
was obtained by disrupting the cells with RIPA buffer supplemented with protease and
phosphatase

inhibitor

cocktails

(Sigma-Aldrich,

1:100

dilution)

centrifugation. The supernatant was collected as the whole cell lysate.
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followed

by

Immunoblotting
Antibodies specific to phosphoserine 473 Akt, total Akt, phosphoserine 9 GSK3β, total
GSK3β, cytochrome c, cleaved caspase-9 and cleaved caspase-3, AIF, survivin
(1:1000) and cyclin D1 (1:2000 dilution) were purchased from Cell Signaling Technology
(Danvers, MA). The anti-M-cadherin antibody (1:200) was obtained from Calbiochem
(La Jolla, CA). The anti-caspase-8 antibody (1:250) was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Anti-histone H2B (1:5000), -β-tubulin (1:500) and GAPDH (1:5000) antibodies were obtained from Abcam (Cambridge, MA). The
antibodies to manganese superoxide dismutase (MnSOD) and copper-zinc superoxide
dismutase (Cu-ZnSOD) (1:1000) were purchased from Millipore (Billerica, MA). The
secondary antibodies for immunoblotting including goat anti-rabbit or goat anti-mouse
IgG conjugated with horseradish peroxidase (HRP) were obtained from Jackson
ImmunoResearch Laboratories (West Grove, PA). The proteins were separated on a 412% gradient polyacrylamide gel (Invitrogen), and transferred to a nitrocellulose
membrane (Bio-Rad, Hercules, CA). The membranes were probed with primary
antibodies overnight at 4°C, followed by incubation of the appropriate secondary
antibody for 1 hour at room temperature. The resulting signals were developed using an
enhanced chemiluminescence lighting (ECL) Western blotting detection reagent kit (GE
Health Care, Piscataway, NJ). Digital records were obtained from each blot and the
protein bands of interest were quantified using 1-D analysis software (Eastman Kodak).
The membranes were stripped and reprobed for β-tubulin, GAPDH, or Histone H2B as
loading controls.
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Immunoprecipitation
The cells were washed in ice-cold PBS and lysed in ice-cold buffer (150 mM NaCl, 50
mM Tris, pH 7.5, 0.25% SDS, 0.1% Nonidet P-40). Non-soluble materials were removed
by centrifugation at 12,000 g. The lysate was incubated with anti-PI3K-p85α (Abcam),
anti-M-cadherin (Santa Cruz) or IgG (Millipore) overnight at 4°C. The sample was then
incubated with Protein A/G PLUS-agarose beads (Santa Cruz) and the beads were then
collected by centrifugation. The bound proteins were eluted from the agarose beads in
Laemmli sample buffer (5X) at 95-100°C. The samples were clarified by centrifugation
and the supernatants were separated by SDS-PAGE and immunoblotted against Mcadherin or PI3K-p85α.

Cell imaging
Phase contrast images of live C2C12 and primary myoblast cells were obtained by a
Nikon eclipse TS100 phase-contrast microscope. The digital images were obtained with
a SPOT RT camera and analyzed with SPOT RT software (Diagnostic Instruments Inc.,
Sterling Heights, MI). Immunocytochemical assays were conducted on fixed cells after
they had been grown coverslips. After fixation in 4% paraformaldehyde, the cells were
incubated at 4°C with antibodies against anti-M-cadherin (1:20, Calbiochem) or antimyosin heavy chain (MyHC) (1:500, Developmental Studies Hybridoma Bank, Iowa
City, IA). The cells were incubated with the Alexa Fluor 546 IgG (H+L) (Invitrogen) and
counter-stained with 4,6-diamidino-2-phenylindole (DAPI). The cells were imaged with a
Zeiss LSM510 confocal laser scanning microscope using AIM software (Carl Zeiss
MicroImaging).
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Myoblast fusion index. The myoblast fusion index was calculated as the ratio of the
number of DAPI-positive nuclei located in the MyHC-positive myotubes (i.e., fused
myoblasts) divided by the total number of nuclei in the same field. This fusion index was
used as a read-out of myogenic differentiation. The fusion index was obtained from 10
non-overlapping areas of each coverslip.

Apoptosis assays
DNA fragmentation. DNA fragmentation was used to assess the level of apoptosis in
muscle cells using an ELISA (Roche) with measurements for DNA fragmentation that
were made at an absorbance of 405nm (31; 32). The data were normalized to the
protein concentration of the sample.

Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL). A TUNEL
assay (Roche) was used to identify the extent of apoptotic nuclei in adherent myoblasts
as reported previously (33). The nuclei of all cells were counter-stained with DAPI. The
number of TUNEL- and DAPI-positive nuclei was counted in ten images from nonoverlapping areas of each group of cells. The data were presented as the apoptosis
index, which was determined by the ratio of TUNEL-positive nuclei to the total number
of DAPI-positive nuclei. To identify the full extent of apoptosis, and determine if Mcadherin-RNAi treatment increased the sensitivity of C2C12 myoblasts to serum
starvation-induced apoptosis, we assessed apoptosis by a TUNEL assay in both
adherent and floating cells in each well using a published method (4). The total percent
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of apoptotic cells for each well was calculated as: (the total number of TUNEL-positive
attached cells + the total number of TUNEL-positive floating cells) /(total attached cells
+ total floating cells).

Cardiolipin content and mitochondrial membrane potential measurement
Nonyl acridine orange (NAO, Invitrogen) was used to determine the cardiolipin content
in the inner mitochondrial membrane as an indicator of mitochondrial integrity. C2C12
myoblasts were transfected with M-cadherin-targeted (M-) or scrambled siRNA (siCON)
with NAO (250nM) at 37ºC. Fluorescence was visualized with a Nikon eclipse E800
fluorescence microscope and digital images were captured using a SPOT RT camera
(Diagnostic Instruments, Inc). The fluorescence intensity was analyzed and quantified
using the ImageJ software (NIH).

To measure changes in the mitochondrial membrane potential, mitochondria were
isolated from M-cadherin RNAi or control cells. The purity of mitochondria was verified
by staining with MitoTracker Deep Red 633 (Molecular Probes, Carlsbad, CA), a
mitochondria-specific marker and analyzed by flow cytometry. This fluorescent dye
diffuses passively into intact and respiring mitochondria. The mitochondrial membrane
potential (Δψmt) was estimated by staining the mitochondria with 5,5',6,6'-tetrachloro1,1',3,3'-tetraethylbenzimidazolyl carbocyanine iodide (JC-1) (Molecular Probes). The
staining results of JC-1 orange/green were analyzed using a FACSCalibur system (BD
Bioscience) using Cell Quest Pro. 4.0 Software. 100,000 gated events were collected
for each sample.
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Statistical analyses
The results are presented as mean ± standard error of mean (SE). Statistical analyses
were performed using the SPSS 13.0 software package. A one-way analysis of variance
(ANOVA) was used to compare differences in all measured variables. P < 0.05 was
considered statistical significant.

RESULTS
M-cadherin RNA interference exacerbates mitochondria-associated apoptosis in
confluent C2C12 myoblasts. To evaluate the apoptotic propensity to low and high cell
densities, C2C12 myoblasts were seeded in 6-well plates at either 2.0 x103/cm2 to
obtain a low density (~ 20-30% confluent) or 2.1x104/cm2 to reach a high cell density
(~100% confluent) within 48 hours. The phase-contrast images in the top panel of
Figure 4A show typical morphology of C2C12 myoblasts at low or high cell densities.
The middle panel of Figure 4A shows that the protein abundance of cleaved caspase-3
and Poly (ADP-ribose) polymerase (PARP) was markedly increased in fully confluent
cells as compared with cells that were plated at a low density. The cleavage of PARP by
caspases leads to nuclear DNA fragmentation. Furthermore, a cell death ELISA assay
showed an elevation of cytosolic nucleosomes at full cell confluence (bottom panel,
Figure 4A). This provided additional evidence for an increase in apoptotic DNA
fragmentation in confluent cells compared with non-confluent cells. We next explored
the expression pattern and level of M-cadherin at different cell densities. As shown in
the top panel of Figure 4B, M-cadherin was located diffusely throughout the cells that
were plated at a low density. In contrast, M-cadherin relocated to cell-cell contacts at
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the periphery of the cells when they were confluent. The protein abundance of Mcadherin increased in confluent C2C12 myoblasts compared with the non-confluent
cells (bottom panel, Figure 4B). To investigate the role of M-cadherin in regulating
myoblast survival and apoptosis, we inhibited M-cadherin expression in confluent
C2C12 myoblasts via transient transfection with M-cadherin-targeted small interfering
RNA (siRNA). Figure 4C shows that the knockdown of M-cadherin expression in
confluent C2C12 myoblasts causes a disruption in the cell-cell contacts and this
increased the separation between the cells. Cells in the control group adhered tightly to
each other as the cells became confluent (Figure 4C). The knockdown of M-cadherin
was verified by immunoblotting (Figure 4D). In control groups, the M-cadherin signals
were detected in a multi-band pattern because most cadherins undergo various
posttranslational modifications and truncation to get to their mature form (34). The
protein abundance of N-cadherin in C2C12 cells was not affected by M-cadherin RNAi
treatment (Figure 4D). M-cadherin RNAi exacerbated cell confluence-induced apoptosis
in C2C12 cells as determined by the increased protein abundance of cleaved caspase-3
and cleaved PARP (Figure 4D). An increase in DNA fragmentation as measured by a
cell death ELISA assay (Figure 4E) confirmed that M-cadherin RNAi increased the level
of cell confluence-induced apoptosis.

Apoptosis is initiated in muscle by three pathways. These include the extrinsic death
receptor-mediated, the intrinsic mitochondrial-dysfunction associated and the intrinsic
endoplasmic reticulum-dysfunction associated pathways (10; 35; 36). To further clarify
which apoptotic pathway was most likely involved in cell death caused by M-cadherin
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RNAi, we examined the activation status of caspase-9 and caspase-8, which are
representative initiation caspases for the intrinsic or the extrinsic apoptotic pathway,
respectively. The protein abundance of cleaved caspase-9 but not caspase-8 was
markedly increased in response to M-cadherin RNAi (Figure 4F). In addition, the protein
abundance of cytosolic cytochrome c and nuclear apoptosis inducing factor (AIF) were
also increased upon M-cadherin RNAi. This suggests that the apoptosis that was
induced by M-cadherin RNAi was mediated via the intrinsic mitochondria-associated
pathway. To further investigate the impact of M-cadherin RNAi on mitochondria as a
mediator of apoptosis, we examined the cardiolipin content of the inner mitochondrial
membrane of live cells using nonyl acridine orange (NAO) staining. NAO is a
metachromatic dye that binds specifically to the mitochondrial cardiolipin and its
fluorescence intensity is an indicator of mitochondrial integrity (37; 38). The median
fluorescence intensity of NAO staining in M-cadherin-RNAi treated cells was
significantly lower than that in control cells (Figure 4G). This indicates that the integrity
of mitochondria in C2C12 cells was disrupted after M-cadherin RNAi treatment.
Furthermore, the mitochondria membrane potential (Δψmt) was also disrupted by
reducing M-cadherin in confluent cells, as shown by a decrease in the orange/green
signals from M-cadherin RNAi treated mitochondria compared with the control
mitochondria after incubation with the fluorescent probe JC-1 (Figure 4H). JC-1 is a
mitochondria permeable lipophilic cation that changes its color from orange to green as
the Δψmt decreases. A reduced Δψmt leads to a shift of the emitted light from 590nm
(orange) to 530nm (green) (39).
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M-cadherin RNAi sensitizes C2C12 myoblasts to serum-starvation-induced
apoptosis. To further explore M-cadherin’s role in regulating mitochondrial integrity and
cell survival/apoptosis during myogenic differentiation, M-cadherin-RNAi-treated or
control C2C12 myoblasts were cultured in serum-free medium. Mitochondria were
isolated and Δψmt was assessed by JC-1 staining after 0, 6, 12, 24 or 48 hr of serum
starvation. There was a transient decrease in the ratio of JC-1 orange/green staining of
isolated mitochondria from all groups of cells in response to serum starvation, but the
M-cadherin-RNAi-treated group had the lowest Δψmt at all time points compared with
the control cells (Figure 5A). These results show that knocking down M-cadherin by
RNAi reduced Δψmt during serum starvation. The level of apoptotic DNA fragmentation
was significantly increased in M-cadherin RNAi-treated cells that were still attached to
the plates at all time points of serum starvation compared with the control groups
(Figure

5B). Furthermore, quantification of apoptotic cells from both attached and

floating cell populations by TUNEL staining, demonstrated that there was a significant
increase in the number of cells undergoing apoptosis during serum starvation in Mcadherin RNAi-treated cells as compared with the control groups (Figure 5C). In
addition, there are fewer cells that remained attached to the plates in the M-cadherin
RNAi-treated group as compared with control groups when serum starvation progressed
to longer time periods (Figure 12). Serum starvation caused an acute activation of
cleaved caspase-9 in C2C12 myoblasts, which is indicative of activation of the
mitochondrial-associated apoptotic pathway. The protein abundance of cleaved
caspase-9 was significantly higher in M-cadherin RNAi treated cells at all time points of
serum starvation as compared with control cells (Figure 13). This suggests that
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knockdown of M-cadherin expression sensitizes C2C12 myoblasts to serum-starvationinduced apoptosis.

M-cadherin-mediated

signaling

enhances

PI3K/Akt-dependent

inhibitory

phosphorylation of GSK-3βser9. Akt is a key mediator of survival signaling pathways,
and it is associated with cadherin signaling in various cells (40; 41). Since GSK-3β,
another key regulator of cell fate and a phosphorylation target of Akt, is associated with
muscle wasting, we also examined the change in GSK-3β phosphorylation in response
to M-cadherin RNAi treatment in confluent cells. As a functional read-out for GSK-3β
activation, the protein abundance of two targets for GSK-3β, cyclin D1 (42) and survivin
(43) were measured. M-cadherin RNAi significantly reduced the activation of Akt in
confluent C2C12 cells as determined by the expression of phospho-Aktser473 (Figure
6A). Consequently, the inhibitory phosphorylation of GSK-3βser9 was decreased in cells
that were treated with M-cadherin RNAi. Quantification of the immunoblot signals from
four independent experiments showed a statistically significant and a reproducible
(bottom panel of Figure 6A and Figure 15A-D) reduction in phospho-Aktser473, GSK-3β
phosphorylation, survivin and cyclin D1 in C2C12 cells after M-cadherin RNAi treatment.
Conversely, the activation of M-cadherin-mediated signaling via a recombinant Mcadherin-Fc chimera treatment induced a significant increase in phosphorylation of Akt
and GSK-3β at the corresponding residues (Figure 6B and Figure 16A, 16B). The
protein abundance of survivin and cyclin D1, were increased in response to
recombinant M-cadherin-Fc chimera treatment (Figure 6B; Figure 16C, 16D).
Immunoprecipitation data show that the binding between the p85α subunit of PI3K and
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M-cadherin was increased in response to recombinant M-cadherin-Fc chimera
treatment (Figure 6C). The protein abundance of PI3K-p85α in the membrane fraction
was markedly increased in M-cadherin-Fc-treated cells compared with the control cells
(Figure 6D). Treatment with the PI3K inhibitor, Wortmannin, but not the MEK-1 inhibitor,
PD9805, during the last 6 hours of M-cadherin-Fc treatment, completely prevented the
increase in phospho-Aktser473 and phospho-GSK-3βser9. This shows that the increased
inhibitory phosphorylation of GSK-3β that is induced by M-cadherin-mediated signaling,
is PI3K dependent (Figure 6E).

GSK-3β

overexpression

exacerbates,

whereas

M-cadherin-Fc

treatment

attenuates apoptosis induced by cell confluence or serum starvation. To further
characterize the role of GSK-3β in regulating apoptosis, C2C12 myoblasts that were
80% confluent were transiently transfected with a wild-type GSK-3β plasmid and
allowed to grow for 48 hours until they reached overconfluence. The transfection
efficiency of the GSK-3β plasmid by FuGENE 6 in C2C12 cells was estimated to be
~20-30% (Figure 14A). Immunoblot analysis confirmed that transfection with GSK-3β
increased the protein abundance of GSK-3β and decreased the protein level of cyclin
D1 (Figure 7A), a target of GSK-3β phosphorylation that induces its degradation.
Overexpression of wild-type GSK-3β in confluent C2C12 myoblasts increased the
protein abundance of cleaved caspase-9, caspase-3, and PARP. This effect was
reversed by co-treating the cells with recombinant M-cadherin-Fc (Figure 7B and 7C). In
addition, Δψmt was decreased in mitochondria from C2C12 cells upon overexpression of
wild-type GSK-3β, which was rescued by recombinant M-cadherin-Fc co-treatment
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(Figure 7D). Together these data indicate that overexpression of wild-type GSK-3β
alone is sufficient to exacerbate the mitochondria-associated apoptosis induced by cell
confluence and this effect can be reversed by enhancement of M-cadherin-mediated
signaling via M-cadherin-Fc treatment. Furthermore, in response to serum starvation,
the wild-type GSK-3β plasmid-transfected cells had significantly higher cell death than
the control cells at all time points, suggesting that overexpression of wild-type GSK-3β
sensitized the cells to serum starvation-induced apoptosis (Figure 7E). In contrast, cotreatment of C2C12 cells with M-cadherin-Fc and wild-type GSK-3β overexpression
after 48 hours of serum starvation significantly attenuated cell death, as compared to
GSK-3β overexpression alone (Figure 7F).

GSK-3β inhibition attenuates the apoptosis exacerbated by M-cadherin RNAi. The
role of GSK-3β inhibition on M-cadherin’s role in regulating apoptosis was examined
using a myristoylated Akt mutant (myrAkt) which functions as a constitutively active form
of Akt (44), to inhibit GSK-3β activity, and a V5-tagged kinase-deficient mutant GSK3β(K85R), which functions as a dominant negative GSK-3β (45). The transfection
efficiency of these plasmids using DharmaFECT Duo in C2C12 myoblasts was
estimated to be 25-35% as determined from transfecting studies using the pEGFP-C3
vector and DharmaFECT DUO as the transfection agent (Figure 14B).
To evaluate the effects of GSK-3β inhibition on apoptotic signaling, C2C12 cells that
were 80% confluent were transfected with M-cadherin-targeted siRNA, plus either the
myrAkt or the GSK-3β(K85R) plasmid, or an empty vector. The cells were allowed to
grow for 48 hours at which time they had reached overconfluency. As expected, there
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was a significant increase in both phospho-Akt and total-Akt abundance in the cells
transfected with the myrAkt plasmid (Figure 8A, right panel). In addition, there was an
increase in total GSK-3β and cyclin D1 protein abundance in the cells that were
transfected with GSK-3βK85R plasmids (Figure 8A, left panel). Forced expression of
myrAkt or GSK-3βK85R plasmids significantly attenuated apoptosis as seen by lower
levels of cleaved-caspase-9, cleaved-caspase-3, and cleaved-PARP (Figure 8B and
8C) after M-cadherin RNAi treatment or overconfluency. Furthermore, co-transfection of
myrAkt or GSK-3βK85R plasmid with M-cadherin-targeted siRNA significantly reduced
DNA fragmentation that was caused by 48-hours serum starvation alone or exacerbated
by M-cadherin RNAi treatment (Figure 9A). To further confirm the impact of GSK-3β
inhibition on M-cadherin’s regulatory effect on apoptosis, we transfected the cells with
M-cadherin-targeted siRNA for 36 hours followed by treatment with TDZD-8 (20µM) for
12 hours. TDZD-8 is an established non-ATP competitive inhibitor for GSK-3β (46).
TDZD-8 treatment abrogated apoptosis and reversed the loss of Δψmt that was caused
by M-cadherin RNAi following a period of 48-hours of serum starvation (Figure 9B, 9C).

GSK-3β inhibition partially restores the myogenic differentiation impaired by Mcadherin RNAi. Lastly, we sought to investigate the impact of M-cadherin RNAi and
GSK-3β inhibition on the outcome of myogenic differentiation. M-cadherin-RNAi C2C12
myoblasts treated with or without TDZD-8 were cultured in differentiation medium for 48
hours to induce myogenic differentiation. Immunofluorescent staining of myosin heavy
chain (MyHC) was used as a terminal myogenic marker. A TUNEL assay was
performed to determine the level of in situ apoptotic DNA fragmentation. Knockdown of
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M-cadherin by RNAi significantly impaired myogenic differentiation, as many cells died
and detached from the plates. In contrast, TDZD-8 treatment partially restored the
myogenic differentiation that was blocked by M-cadherin RNAi. This was determined by
the myoblast fusion index, which represented the percentage of myoblasts that matured
into myotubes (Figure 10A, 10B). Calculation of the apoptotic index from TUNEL
labeling showed that TDZD-8 treatment significantly attenuated the number of apoptotic
nuclei that was caused by M-cadherin RNAi over 48-hours of myogenic differentiation
(Figure 10A, 10C).

These findings were further verified in mouse primary myoblasts. Syndecan-4-positive
primary myoblasts were isolated by fluorescence activated cell sorting (FACS) as
representative muscle progenitor cells (18; 47). ~20% of the adult muscle stem cells
were Syndecan-4 positive (Figure 11A). Knockdown of M-cadherin by RNAi significantly
impaired myotube formation from Syndecan-4-positive primary myoblasts, which was
partially rescued by TDZD-8 treatment as shown from MyHC staining and a greater
fusion index (Figure 11B and 11C) in the TDZD-8 treated cells.

Furthermore, M-

cadherin RNAi exacerbated apoptosis in Syndecan-4-positive primary myoblasts after
48-hours of myogenic differentiation. Apoptosis could be abrogated by TDZD-8
treatment, as shown by a lower TUNEL staining (Figure 11B) and an apoptotic index
(Figure 11D) after TDZD-8 treatment.
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DISCUSSION
This is the first report to show that M-cadherin-mediated signaling protects myoblasts
against apoptosis during myogenic differentiation. In vitro culture of myoblasts at high
cell density has been shown to yield not only a better myogenic differentiation outcome,
but also an increased incidence of apoptosis, as compared to culturing the cells at a low
density (4). This observation is consistent with the suggestion that apoptosis and
differentiation are tightly regulated in a coordinate pattern in myoblasts (3). In the
current study we show that M-cadherin protein abundance is increased and M-cadherin
engagement at cell-cell contacts is induced when myoblasts become confluent. While
confluence triggers apoptosis during differentiation, other cells survive, differentiate and
fuse into myotubes (3; 4; 48-50).

In this study we show that the disruption of M-cadherin signaling by M-cadherin RNAi,
sensitized C2C12 myoblasts to apoptosis that was induced by either cell confluence or
serum starvation. Apoptosis in C2C12 cells is accompanied by decreased Δψmt,
increased mitochondrial release of cytochrome c and AIF, and consequently an
increased cleavage of caspase-9 but not caspase-8. Together these data indicate Mcadherin RNAi–induced apoptosis is mediated by the intrinsic mitochondria-associated
pathway and M-cadherin-mediated signaling plays an important role in maintaining the
mitochondrial integrity of differentiating myoblasts and suppressing apoptosis during
myogenic differentiation. Our findings are consistent with data showing that Δψmt is
compromised in myoblasts undergoing apoptosis but not those that successfully
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differentiate (51). Furthermore, proper mitochondria function is critical for successful
myogenic differentiation (37; 52; 53).

Previous findings have shown that in aged muscle, the number of M-cadherin-positive
satellite cells is decreased (25) but the apoptotic propensity of satellite cells is increased
compared with those in young animals (20; 21). This suggests that there may be a
negative relationship between the expression level of M-cadherin and the apoptosis
susceptibility of muscle progenitor cells. In the current study, we show that M-cadherin
has a protective role against apoptosis during myogenic differentiation since inhibition of
M-cadherin expression by RNAi, sensitized both C2C12 and Syndecan-4-positive
primary myoblasts to apoptosis, which resulted in an increase in pro-apoptotic markers,
and resulted in an impaired myotube formation as compared to control cells. We
speculate that reduced M-cadherin might be a contributing mechanism that would
explain, at least in part, an increased susceptibility of muscle progenitor cells to
increased apoptotic signaling and elimination of nuclei in aged muscles (10; 20; 21; 36).

GSK-3β is a serine/threonine kinase that is constitutively active in resting cells and
plays a key role in regulating glucose homeostasis (54). GSK-3β is also important in
regulating apoptosis. However, it has a paradoxical effect on apoptosis from different
pathways by promoting mitochondrial-dysfunction-associated apoptosis signaling, but
also inhibiting death-receptor-mediated apoptosis signaling (55). Dysregulation of GSK3β has been reported to be involved in several pathologies including neurodegenerative
diseases, mood disorders, cancer, and diabetes (55). Studies in skeletal muscles have
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linked GSK-3β to muscle wasting conditions. GSK-3β activity has been shown to
increase in aged (56) and burn-injured skeletal muscles (57). Inhibition of GSK-3β is
required for IGF-1-induced myogenic differentiation (58).

Furthermore, GSK-3β

inhibition reduces protein degradation in conditions of muscle wasting and may also
promote re-growth of atrophic muscle (59-61). Although a conditional skeletal muscle
knockout of GSK-3β has been reported to manifest a phenotype with an improved
insulin tolerance and glucose metabolism in muscle tissues (62), currently, there are no
data that evaluate a direct role of GSK-3β in regulating the muscle progenitor cell
survival and apoptosis during myogenic differentiation. In this study we show for the first
time that overexpression of wild-type GSK-3β is sufficient to induce apoptosis in
confluent C2C12 myoblasts and to sensitize the cells to serum-starvation-induced
apoptosis. This effect can be attenuated by increasing M-cadherin-mediated signaling
via recombinant M-cadherin-Fc treatment. We also show that the activation of Mcadherin-mediated signaling recruits PI3K and activates Akt, which in turn
phosphorylates GSK-3β at the serine 9 residue, resulting in its suppression. Conversely,
inhibition of GSK-3β activation attenuates apoptosis that is induced by knockdown of Mcadherin expression. This suggests that GSK-3β plays a critical role in mediating Mcadherin’s protective effect against apoptosis during myogenic differentiation. Our
findings are consistent with data from Robakis and colleagues (63) who showed that the
expression of presenilin-1 in fibroblasts promotes the association of PI3K with E- and Ncadherins and activates Akt, leading to the inhibition of GSK-3β activity. Skeletal muscle
is the largest consumer of glucose and GSK-3β plays an important role in regulating
glucose metabolism and insulin sensitivity in muscle (62; 64). Thus we speculate that
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manipulation of M-cadherin-mediated cell-cell adhesion may have a profound impact on
glucose metabolism and insulin tolerance of muscle tissue through regulating the
activation status of GSK-3β. Interestingly, a type 2 diabetic phenotypic KK/Ta mouse,
has been shown to have an ectopic expression of M-cadherin in liver with three
missense mutations (65). Further statistical analysis revealed a correlation between Mcadherin

expression

and

the

hypertriglyceridemia,

glucose

intolerance

and

hyperinsulinemia in the KK/Ta mouse. This suggests that disrupted M-cadherin
signaling may have a role in the pathology of type 2 diabetes (65).

GSK-3β may regulate mitochondrial outer membrane permeabilization by targeting
multiple substrates. The Bcl-2 family of proteins represents one target of GSK-3β. GSK3β directly phosphorylates the pro-apoptotic Bax protein at serine 163, leading to its
activation (66). GSK-3β activation also induces the expression of the pro-apoptotic Bim
protein (67). On the other hand, GSK-3β phosphorylation of MCL-1, an anti-apoptotic
member of Bcl-2 family protein, facilitates its degradation (68). Another class of GSK-3β
substrates in regulating apoptosis is a group of transcription factors that include p53, βcatenin, and Myc. p53 plays a crucial role in regulating cell cycle arrest, senescence
and apoptosis. GSK-3β can form a complex with nuclear p53 and this promotes p53induced apoptosis (69). β-catenin is a key mediator for the canonical Wnt signaling
pathway, which plays an important role in promoting cell growth and survival. β-catenin
also connects cadherins to the actin cytoskeleton. Together with adenomatous
polyposis coli (APC) and axin, GSK-3β forms the “destruction complex” that
phosphorylates β-catenin and promotes its ubiquitination and degradation (70).
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Cadherins control both the turnover rate and the subcellular distribution of β-catenin. As
a result, β-catenin could be the nexus for the convergence of cadherin and GSK-3βmediated signaling in skeletal muscle. Additional studies are required to identify the
important upstream mediators and downstream targets for M-cadherin/Akt/GSK-3β
signaling that are responsible for maintaining mitochondrial integrity and suppressing
apoptosis in myoblasts; however, this is beyond the scope of the current investigation.

In conclusion, the data in the current study show that M-cadherin plays a critical role in
regulating survival versus death via apoptosis of myoblasts during myogenic
differentiation in vitro. M-cadherin-mediated signaling maintains the inhibitory tone from
PI3K/Akt upon GSK-3β by activating PI3K/Akt. M-cadherin signaling appears to help
maintain a balance between apoptosis and differentiation and prevents the acceleration
of mitochondrial-associated apoptotic signaling in muscle cells.
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Figure 4. Effect of M-cadherin RNAi on apoptosis in confluent C2C12 myoblasts.
A. Top panel: Representative phase-contrast images of C2C12 myoblasts that were
obtained 48 hours after seeding them at a low density (2.0 x103/cm2), or a high density
(2.1x104/cm2). The objective magnification = 10x. The scale bar = 200 μm. Middle
panel: Immunoblots of cleaved caspase-3 and PARP obtained 48 hr post plating.
Bottom panel: Cytosolic nucleosomes of low or high-density cells were measured an
indication of apoptotic DNA fragmentation. Each data point represents the mean ± SEM
of the mean of three independent experiments. *, P<0.05 vs. the low-density group.
B. The expression pattern and protein abundance of M-cadherin at low and high cell
densities. Top panel: Representative confocal images of M-cadherin (red) and DAPI
(blue) staining in C2C12 myoblasts at low or high cell density as described in Figure 1A.
The objective magnification = 63x. The scale bar = 10 μm. Bottom panel:
Immunoblotting analysis of protein abundance of M- cadherin. β-tubulin was probed as
a loading control.
C-H, 80% confluent C2C12 myoblasts were transfected with M-cadherin-targeted siRNA
(M-) or non-targeted scramble siRNA (SiCON) as a control. Non-transfected cells with
identical culture conditions were used as a normal control (NC) cells. The cells were
harvested 48hr post-transfection. Each data point (mean ± SEM) is the mean of three
independent experiments. * , P<0.05 vs. the control groups.
C. Phase-contrast images of transfected cells that were acquired at an objective
magnification = 20x. The scale bar = 100.
D. Immunoblot analysis of transfected cells.
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E. The apoptotic DNA fragmentation of transfected cells is shown as mean± SEM of
three independent experiments. *, P<0.05 vs. both NC and SiCON control groups.
F. Left panel: Proteins associated with apoptotic signaling (and the relevant control
proteins) were measured in transfected and control cells. Right panel: The integrity and
purity of protein subcellular fractions was verified by immunoblotting with appropriate
control antibodies.
G. TOP panel: Digital images were obtained (objective=100x; scale bar = 20 μm) from
control or transfected C2C12 cells that were stained with NAO. Bottom panel: The
median fluorescence intensity of NAO per cell was determined. The data are mean±
SEM of three experiments.
H. Mitochondria were isolated from control and transfected cells and stained with JC-1.
The data represent FACS analyses of the ratio of orange (intact mitochondria) to green
(compromised Δψm) mitochondria.

92

Figure 5

93

Figure 5

94

Figure 5. Effect of M-cadherin RNAi on serum starvation-induced apoptosis. Mcadherin-RNAi (M-), non-targeted scrambled siRNA-transfected (SiCON) or normal
control (NC) C2C12 myoblasts were serum starved from zero to 48 hours before being
harvested. *, P<0.05 vs. both SiCON and NC control groups. The data are shown as the
mean± SEM for three independent experiments.
A. Mitochondria were isolated from attached cells after serum starvation for 0 hours
(SS-0h), 6 hours (SS-6h), 12 hours (SS-12h), 24 hours (SS-24h) or 48 hours (SS-48h).
The mitochondria Δψm (orange/green ratio) was evaluated by FACS analysis JC-1
staining.
B. DNA fragmentation in attached cells was measured by a cell death ELISA at the
same time points as described in A.
C. The percentage of cells undergoing apoptosis in both attached and floating cells
were defined as: total TUNEL-positive attached cells + total TUNEL-positive floating
cells) divided by (total attached cells + total floating cells.
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Figure 6. M-cadherin-mediated signaling effect on the PI3K/Akt/GSK-3β pathway.
A-E. The data are shown as the mean± SEM for three independent experiments.
A-B *, P<0.05 vs. the control groups.
A. Top panel: Representative immunoblots of M-cadherin-RNAi (M-) treated, nontargeted scrambled siRNA-transfected (SiCON) treated or normal control (NC) C2C12
cells. Survivin and cyclin D1 were measured as a functional read-out for GSK-3β
activation. GAPDH was used as a loading control. Bottom Panel: Densitometric
analyses of Akt, GSK-3β, survivin and cyclin D1 normalized to their loading controls.
B. Top panel: C2C12 myoblasts were grown in normal control (NC), vehicle control
(Vehicle) or recombinant M-cadherin-Fc-coated (M-cad-Fc) dishes for 48 hours. The
cells were lysed and subjected to immunoblotting analysis of the same proteins as
measured in Fig. 3A. Bottom Panel: Densitometric analyses of immunoblot band
intensities of phosphorylated and total Akt and GSK-3β, as well as survivin and cyclin
D1 in response to recombinant M-cadherin-Fc treatment. The band intensities of the
above proteins were normalized by corresponding control proteins.
C. Immunoprecipitation assays of untreated C2C12 myoblasts (NC) or myoblasts
treated with either the vehicle (Veh) or with recombinant M-cadherin-Fc (rMFc) were
conducted 48 hr after treatment with either a mouse anti-PI3K-p85α or a rabbit anti-Mcadherin antibody respectively. Western blots of the protein abundance of M-cadherin
or PI3K-p85α were conducted in the precipitated proteins.
D. Cell membrane fractions were prepared from cells that had been treated as
described in Fig. 3C and blotted to detect the protein abundance of PI3K-p85α.
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E. C2C12 myoblasts were treated as described in Fig. 3C. The cells were then treated
for a subsequent 12 hours with no vehicle added (-), Wortmannin (WM, 200nM),
PD98059 (PD, 50µM), Wormannin plus PD98059 (WM+PD), or DMSO.

Untreated

normal control cells (NC) did not receive either the recombinant M-cadherin-Fc or the
vehicle treatments. The cells were harvested for immunoblotting analysis.
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Figure 7. Effect of wild-type GSK-3β overexpression and recombinant M-cadherinFc treatment on apoptosis that was induced by cell confluence or serum
starvation.
A. A wild-type GSK-3β plasmid (GSK-3βWT) or an empty vector (EV) were transiently
transfected into C2C12 myoblasts that were 80% confluent. 48 hours after transfection,
the cells were harvested in RIPA buffer and processed for immunoblotting for GSK-3β
and cyclin D1 protein abundance. The experiment was repeated three times under each
experimental condition.
B. Wild-type GSK-3β plasmids (GSK-3βWT) or empty vectors (EV) were transiently
transfected into C2C12 myoblasts growing in recombinant M-cadherin-Fc-coated (Mcad-Fc) or vehicle-coated (Vehicle) dishes. 48 hours later, the cells were harvested in
RIPA buffer and immunoblotted against pro-apoptotic proteins. GAPDH was probed as
a loading control.
C. Analyses of immunoblot bands described in 4B. The data were normalized to
GAPDH and expressed as the mean ± SEM from three independent experiments.
*, P<0.05 vs. EV/Vehicle or EV/M-cad-Fc; †, P<0.05 vs. GSK-3βWT/Vehicle.
D. Mitochondria were isolated from C2C12 myoblasts that had undergone the same
treatments as described in Fig. 4B. The mitochondria were stained with JC-1. A
FACSCalibur system was used to measure the change in mitochondrial membrane
potential (Δψm). The data are expressed as the ratio of orange/green JC-1 staining. The
data are reported as the mean ± SEM from three independent experiments. *, P<0.05
vs. EV/Vehicle or EV/M-cad-Fc; †, P<0.05 vs. GSK-3βWT/Vehicle.
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E. C2C12 myoblasts transfected with the wild-type-GSK-3β plasmid (GSK3βWT) or the
empty vector (EV) and the non-transfected normal control (NC) cells were serumstarved for 0 hours (SS-0h), 6 hours (SS-6h), 12 hours (SS-12h), 24 hours (SS-24h) or
48 hours (SS-48h). At the end of each time point, the attached cells were harvested and
DNA fragmentation was measured by a cell death ELISA assay. The data represent the
mean ± SEM from three independent experiments. *, P<0.05, vs. NC or EV.
F. The wild-type GSK-3β plasmid (GSK3βWT) or the empty vector (EV) was transiently
transfected into C2C12 myoblasts growing in recombinant M-cadherin-Fc-coated (Mcad-Fc) or vehicle-coated (Vehicle) dishes. 48 hours later, the cells were treated with
serum starvation for another 48 hours before being harvested. A cell death ELISA assay
was used to measure the DNA fragmentation in the harvested cells. The data represent
the mean ± SEM from three independent experiments. *, P<0.05 vs. EV/Vehicle or
EV/M-cad-Fc; †, P<0.05 vs. GSK-3βWT/Vehicle.
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Figure 8. Effect of GSK-3β inhibition on cell-confluence-induced apoptosis.
A. C2C12 myoblasts were grown to 80% confluency then transfected with an empty
vector (EV) or GSK-3βK85R, which contained a V5 tag (left panel), or constitutively
active Akt (myrAkt), (right panel) for 48h. Non-transfected cells normal control cells (NC)
were cultured under identical conditions. The protein abundances of V5 tag, GSK-3β,
and cyclinD1 were examined in GSK-3βK85R plasmid-transfected cells (left panel) and
those of serine-437-phosphorylated and total Akt were examined in myrAkt plasmidtransfected cells (right panel) by immunoblotting.
B. C2C12 myoblasts were grown to 80% confluent then co-transfected with the Mcadherin-targeted-siRNA (M-) plus myrAkt (M-/ myrAkt) or the GSK-3βK85R plasmid
(M-/ GSK-3βK85R) or an empty vector (M-/EV).

Similar co-transfections were

completed with the non-targeted scramble siRNA (SiCON) with myrAkt (SiCON/
myrAkt), GSK-3βK85R (SiCON/ GSK-3βK85R) or the empty vector (SiCON/EV). Fortyeight hours after transfection, the cells were harvested and processed for
immunoblotting of cleaved caspase-9, cleaved caspase-3, and cleaved PARP. GAPDH
was used as a loading control. Each experiment was repeated three times.
C. Densitometric analyses of immunoblots were obtained from C2C12 cells with
identical treatments as described in Figure 5B. The data represent the mean ± SEM
from three independent experiments. *, P<0.05, vs. SiCON/EV; †, P<0.05, vs. M-/EV.
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Figure 9. Effect of GSK-3β inhibition on serum-starvation-induced apoptosis.
A-C. Each experiment was repeated three times. *, P<0.05, vs. NC or SiCON.
A. C2C12 cells were co-transfected with M-cadherin-targeted siRNA and one of the
plasmids (myrAkt/GSK-3βK85R/empty vector) for 48 hours, then serum-starved for 48
hours. DNA fragmentation was measured by an ELISA. †, P<0.05 vs. M-/EV.
B. C2C12 cells were transiently transfected with M-cadherin-RNAi (M-), or a nontargeted scrambled siRNA (SiCON). These were compared to normal non-transfected
C2C12 cells (NC). The cells were treated with 20 µM TDZD-8 or DMSO for the last 12
hours of siRNA transfection. Forty-eight hours after transfection, the treated and control
cells were serum starved for 48 hours. The cells were harvested and DNA
fragmentation was assessed by cell death ELISA. Each experiment was repeated three
times. †, P<0.05 vs. SiCON/TDZD8 and the M-/DMSO.
C. Mitochondria were isolated from each experimental group and stained with JC-1. The
ratio of JC-1 orange/green staining was analyzed using a FACSCalibur system to
measure the mitochondrial membrane potential. †, P<0.05 vs. M-/DMSO.
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Figure 10. Effect of M-cadherin RNAi and GSK-3β inhibition on myogenic
differentiation of C2C12 myoblasts. C2C12 cells were grown on coverslips,
transfected with M-cadherin-targeted (M-) or non-targeted scrambled siRNA (SiCON)
for 36 hours then incubated with or without TDZD-8 for 12 hours. The cells were then
cultured in differentiation medium for 48 hours.
A. Representative confocal images of C2C12 myoblasts after treatment with a
combination of M-cadherin RNAi (M-) or non-targeted scrambled siRNA transfection
(SiCON) and TDZD-8 or DMSO as a vehicle control. The cells were incubated in
differentiation medium for 48 hours after the co-treatments. MyHC: red; DAPI: blue;
TUNEL: green. Images were acquired at 20x. The scale bar = 100 μm.
B-C. The data from three independent experiments were given as mean ± SEM. *, P<
0.05 vs. SiCON/DMSO; †, P< 0.05 vs. M-/DMSO.
B. The myoblast fusion index was calculated for cells after each treatment described in
Fig. 7A, as the ratio of the number of DAPI-positive nuclei located in the MyHC-positive
myotubes (i.e., fused myoblasts) divided by the total number of nuclei in the same field.
C. The apoptotic index was calculated as the percent of total nuclei that were TUNEL
positive.
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Figure 11. Effect of M-cadherin RNAi and GSK-3β inhibition on apoptosis and
myogenic differentiation of primary Syndecan-4-positive myoblasts. Primary
myoblasts were isolated from hindlimb muscles of 1-week old C57BL/6 mice and
Syndecan-4-positive myoblasts were purified from isolated cells by fluorescence
activated cell sorting (FACS).
A. Approximately 20.2% cells of adult stem cells that were isolated from hindlimb
skeletal muscles were Syndecan-4 positive (Top panel). The post-sort verification of
FACS sorted cells indicated that the purity of Syndecan-4-positive cells was 97%
(Bottom panel).
B. Syndecan-4-positive myoblasts were grown on coverslips and treated as described
in Fig. 7. The imaging of the cells was the same as in Fig. 7A.
C-D. The data from three independent experiments were given as mean ± SEM. *, P<
0.05 vs. SiCON/DMSO. †, P< 0.05 vs. M-/DMSO.
C. The myoblast fusion index was calculated as described in Fig. 7B.
D. The apoptotic index was calculated as described in Fig. 7C.
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Figure 12. M-cadherin knockdown reduces cell survival. C2C12 myoblasts were
plated in 6 well plates at a density of 1.7x10 5 per well. 24 hours later, the cells were
transfected with M-cadherin-targeted siRNA (M-) or non-targeted scrambled siRNA
(SiCON). A group of non-transfected cells with identical culture condition was used as a
normal control (NC). 48 hours after transfection, the cells were treated with serum
starvation for 0 (SS-0h), 6 (SS-6h), 12 (SS-12h), 24 (SS-24h), or 48 hours (SS-48h).
Phase contrast images were taken at the end of each time point prior to harvesting the
cells for additional analyses. The magnification of the microscope objective was 20x.
The scale bar = 100 μm.
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Figure 13. Immunoblotting analysis of cleaved caspases-9 in response to Mcadherin RNAi plus serum starvation. The C2C12 cells were treated as described in
Figure S1. The cells were harvested in RIPA buffer at the end of each time point and
processed for immunoblotting.
Top panel: Representative immunoblots are shown of cleaved caspase-9 in C2C12
myoblasts after transfections with M-cadherin-targeted siRNA (M-), non-targeted
scrambled siRNA (SiCON) or in non-transfected normal control cells (NC) after 0 (SS0h), 6 (SS-6h), 12 (SS-12h), 24 (SS-24h), or 48 hours (SS-48h) of serum starvation.
GAPDH was probed as a loading control. Protein abundance of M-cadherin was
detected to confirm the efficiency of M-cadherin knock-down by siRNA.
Bottom panel: Densitometric quantification of immunoblots from cleaved caspase-9
protein abundance normalized to GAPDH. Each data point (mean ± SEM) is the mean
of three independent experiments. *, a significant difference (p<0.05) from the NC and
SiCON control groups.
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Figure 14. Determination of transient transfection efficiency in C2C12 myoblasts.
The transfection efficiency of the GSK-3β plasmid by FuGENE 6 in was estimated to be
~20-30%. This was estimated by transfecting a pEGFP-C3 vector into C2C12 cells and
counting the eGFP-positive cells in the fields 6-well plates of proliferating myoblasts with
cell density ~ 70%~80% confluency were transfected with an EGFP-C3 vector (3ug per
well) using either FuGENE 6 (Roche) (A) or DharmaFECT Duo (Thermo Scientific) (B).
48 hours after transfection, eGFP-positive cells were visualized under a Nikon Eclipse
TS100 microscope connecting to an X-Cite 120 fluorescence illumination system
(Lumen Dynamics). Fluorescent images as well as phase-contrast images of the same
field were captured using a SPOT RT camera (Diagnostic Instruments, Inc). The
magnification of objective lens was 10x. The scale bar = 200 μm.
The transfection efficiency was estimated by counting eGFP-positive cells and total
cells from ten random fields for either condition. The transfection rate was defined as
number of eGFP-positive cells divided by the total number of cells within the same field.
The transfection efficiency achieved by using FuGENE 6 in our experiments was 25.3%
± 4.8%. The transfection efficiency using DharmaFECT Duo was 29.7% ± 5.4%.
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Figure

15.

Densitometric

analyses

of

immunoblot

band

intensities

of

phosphorylated and total Akt and GSK-3β, survivin, and cyclin D1 in response to
M-cadherin RNAi. C2C12 were transfected with M-cadherin-targeted siRNA (M-), nontargeted scrambled siRNA (SiCON) or in non-transfected normal control cells (NC) and
harvested 48 hours after transfection. Phosphorylated protein band intensities were
normalized by those of corresponding total proteins (A, phospho-Akt/Akt; B, phosphoGSK-3β/GSK-3β). The band intensities of survivin and cyclin D1 were normalized to
GAPDH (C, Survivin/GAPDH; D, Cyclin D1/GAPDH). The data represent four separate
experiments and show that the data are highly reproducible.
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Figure

16.

Densitometric

analysis

of

immunoblot

band

intensities

of

phosphorylated and total Akt and GSK-3β, survivin, and cyclin D1 in response to
recombinant M-cadherin-Fc treatment.

C2C12 myoblasts were grown in normal

control (NC), vehicle control (Vehicle) or recombinant M-cadherin-Fc-coated (M-cad-Fc)
dishes for 48 hours. The cells were lysed and subjected to immunoblotting analysis.
Phosphorylated protein band intensities were normalized by those of corresponding
total proteins (A, phospho-Akt/Akt; B, phospho-GSK-3β/GSK-3β). The band intensities
of survivin and cyclin D1 were normalized to GAPDH. (C, Survivin/GAPDH; D, Cyclin
D1/GAPDH). The data are shown from 3 separate experiments, and indicated that the
results are repeatable.
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Supplementary Detailed Materials and Methods

Cell Culture
C2C12 myoblasts were purchased from American Type Culture Collection (Manassas,
VA) and maintained in Dulbecco Modified Eagle’s Medium (DMEM) (Invitrogen Life
Technologies, Bethesda, MD) supplemented with 10% fetal bovine serum (FBS) and
1% antibiotic and antimycotic mixture solution (Invitrogen), in a humidified incubator
under an atmosphere of 5% CO2 at 37ºC. Serum starvation was carried out by culturing
the cells in serum-free DMEM supplemented with 1% antibiotic and antimycotic mixture.

Primary myoblasts were isolated from hind limb muscles of one-week old C57BL/6 mice
using a modified protocol from Dr. Margaret Goodell’s lab (30). Briefly, the hindlimb
muscles were minced and digested by 0.2% type II collagenase/HBSS at 37ºC. The
minced muscle slurry was filtered with 40 µM cell strainers and myoblasts were
separated from fibroblasts and other cell components by percoll (Sigma-Aldrich Co., St
Louis, MO) gradient centrifugation. The Syndecan-4-positive myoblasts were further
purified from isolated cells by fluorescence activated cell sorting (FACS) using a BD
FACSAria (Benton Dickson Biosciences, San Jose CA) and anti-Syndecan-4 antibody
(BD) with the program of BD FACS DIVA version 6.2. The Syndecan-4-positive primary
myoblasts were cultured in Ham’s F10 supplemented with 20% FBS and 1% antibiotic
and antimycotic mixture solution in a humidified incubator under an atmosphere of 5%
CO2 at 37ºC.
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Myogenic differentiation was induced by culturing the confluent C2C12 or primary
myoblasts in differentiation medium composed of DMEM supplemented with 2% horse
serum and 1% antibiotic and antimycotic mixture (Sigma-Aldrich).

Chemical Inhibitors
The PI3K inhibitor Wortmannin (working concentration: 200 nM) was obtained from
Alexis Biochemicals (Plymouth Meeting, PA). GSK-3 inhibitor TDZD-8 (working
concentration: 25 μM) was purchased from Sigma (St. Louis, Missouri). MEK1 inhibitor
PD98059 (working concentration: 50 μM) was from Cell Signaling Technology (Danvers,
MA).

Inhibition of M-cadherin expression by RNA interference
SMARTpool small interfering RNA (siRNA) targeted to M-cadherin mRNA (Life Thermo)
consisted of duplex 1: sense: 5’-CGACACAGCUCUCAUCUAUUU-3’, antisense: 5’-PAU
AGA UGA GAG CUG UGU CGU U-3’; duplex 2: sense: 5’-UAG AUG AUA UCA ACG
ACA AUU-3’, antisense: 5’-PUU GUC GUU GAU AUC AUC UAU U-3’; duplex 3: sense:
5’-GAA GGA CGG CUG GUA CAG AUU-3’, antisense: 5’-PUC UGU ACC AGC CGU
CCU UCU U-3’; duplex 4: sense: 5’-CAG GAU GCA UAC GAC AUA AUU-3’, antisense:
5’-PUU AUG UCG UAU GCA UCC UGU U-3’. The myoblasts were seeded in six-well
plates 24 hours before transfection at a density of 1.7 × 10 5 per well. The transfection of
siRNA was performed using either DharmaFECTTM-3 reagent (Life Thermo) (for C2C12
myoblasts) or Lipofectamine 2000 (Invitrogen) (for primary myoblasts) according to the
manufacturer’s instructions at a final siRNA duplex concentration of 100nM. The
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efficacy of M-cadherin protein knockdown by RNA interference (RNAi) was confirmed
by immunoblotting.

Plasmids and Transfection
The full-length mouse wild-type GSK-3β cDNA was generated by RT-PCR. mRNA was
derived from wild C2C12 myoblasts using Trizol reagent (Life Technologies, Inc.) and
reverse-transcribed into cDNA using Superscript II (Life Technologies, Inc.). The
forward primer was 5’-TTC CCG CGG CCG CCG CCA TGT CGG GGC GAC CGA GAA
C-3’, and the reverse primer was 5’-TTC CCT CTA GAT CAG GTG GAG TTG GAA
GCT GA-3’, with recognition sites for restriction endonucleases NotI and EcoRI
included. The PCR product was cloned into the expression vector pcDNA3.1/myc-His(-)
(Invitrogen). The inserted region was verified by DNA sequencing (SeqWright, Inc.,
Houston, TX). The constitutively active mutant of Akt (myrAkt) and the V5-tagged
kinase-deficient GSK-3β mutant (K85R) carried by vector pcDNA3 were generous gifts
from Dr. Jia Luo (University of Kentucky). The wild-type GSK-3β plasmids were
transfected into the cells using FuGENE 6 reagent (Roche Diagnostics, Indianapolis, IN)
according to the manufacturer’s instructions. The co-transfection of M-cadherin siRNA
with myrAkt or GSK-3β (K85R) plasmids was carried out using DharmaFECT Duo
transfection reagent (Dharmacon, Inc., Thermo-Fisher Scientific, Lafayette CO)
according to the manufacturer’s instructions.
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Recombinant M-cadherin-Fc treatment
The recombinant M-cadherin-Fc chimera was purchased from R&D Systems. 6-well
cell culture plates were pre-coated with goat anti-Fc antibody (0.5µg/cm2 in PBS/Ca2+;
Jackson ImmunoResearch, West Grove, PA) overnight at 4°C followed by coating with
recombinant

M-cadherin-Fc chimera at a final concentration

of

2µg/cm2 in

0.1%BSA/PBS/Ca2+ for 2 hours at room temperature. The dishes were washed with
PBS/Ca2+ and blocked with 1% BSA/HBSS/Ca2 for 1 hour. Plates coated with anti-Fc
antibody only were used as vehicle control. A number of 0.5 x 105 per well cells were
plated and allowed to grow for 48 hours before being harvested for further assays.

Subcellular fractionation
The membrane fraction of C2C12 myoblasts was prepared using the Mem-PER
eukaryotic membrane protein extraction reagent kit (Thermo Fisher Scientific, Rockford,
IL) according to according to the manufacturer’s instruction. The nuclear protein fraction
was prepared according to methods that have been previously described in our lab (31)
with minor modifications. Briefly, the cells were harvested by trypsinization and
incubated in lysis buffer (10mM NaCl, 1.5mM MgCl2, 20mM HEPES, pH 7.4, 20%
glycerol, 0.1% Triton X-100, and 1mM dithiothreitol (DTT)) supplemented with protease
and phosphatase inhibitor cocktails (Sigma-Aldrich, 1:100 dilution) with rotation at 4°C
for 2 hours. The lysates were centrifuged at 2,500 rpm for 5 minutes at 4°C. The pellet
containing nuclei portion was washed three times with lysis buffer and resuspended in
nuclear lysis buffer containing 0.6M NaCl and incubated for another 2 hours at 4°C and
centrifuged at 15,000 x g for 15 minutes. The supernatants contain the nuclear fraction.
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The mitochondrial and mitochondria-free and nuclei-free cytosolic fractions were
prepared using mitochondria/cytosol reagents (BioVision, Mountain View, CA)
according to the manufacturer’s instruction. The concentration of the protein extracts
was quantified in duplicate by Bio-Rad Dc Protein Assay (BioRad, Hercules, CA). The
whole cell lysate was obtained by disrupting the cells with RIPA buffer (mM NaCl, 1.0%
IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0)
supplemented with protease and phosphatase inhibitor cocktails (Sigma-Aldrich, 1:100
dilution) followed by centrifugation at 10,000 rpm for 5 minutes at 4°C. The supernatant
was collected as the whole cell lysate.

Antibodies and immunoblotting
Antibodies specific to phosphoserine 473 Akt, total Akt, phosphoserine 9 GSK3β, total
GSK3β, cytochrome c, cleaved caspase-9 and cleaved caspase-3, AIF, survivin (all the
above antibodies were diluted by 1:1000) and cyclin D1 (1:2000 dilution) were
purchased from Cell Signaling Technology (Danvers, MA). The anti-M-cadherin
antibody (1:200 dilution) was obtained from Calbiochem (La Jolla, CA). The anticaspase-8 antibody (1:250 dilution) was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). The antibodies to histone H2B (1:5000 dilution), β-tubulin (1:500
dilution) and GAPDH (1:5000 dilution) were obtained from Abcam (Cambridge, MA).
The antibodies to Manganese superoxide dismutase (MnSOD) and Copper-Zinc
superoxide dismutase (Cu-ZnSOD) (both diluted at 1:1000) were purchased from
Millipore (Billerica, MA). The secondary antibodies for immunoblotting including goat
anti-rabbit or goat anti-mouse IgG conjugated with horseradish peroxidase (HRP) were
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obtained from Jackson ImmunoResearch Laboratories (West Grove, PA). The
secondary antibodies were used at dilution ranges between 1:30000 and 1:100000.
Immunoblotting of the cell fractions were conducted by diluting the cell lysates in 4X
NuPAGE LDS sample buffer (Invitrogen) then heating them at 70°C for 10 min. Equal
amount of proteins were loaded on to a 4-12% gradient polyacrylamide gel (Invitrogen)
and separated by routine get electrophoresis. The proteins were transferred to a
nitrocellulose membrane (Bio-Rad, Hercules, CA) and the membranes were blocked in
5% non-fat milk or 5% bovine serum albumin dissolved in Tris buffered saline with
0.05% Tween-20 (TBS-T) for 1 hour at room temperature. The membranes were probed
with primary antibodies overnight at 4°C. The appropriate secondary antibody was
applied to the membrane for 1 hour at room temperature. The resulting signals were
developed using an enhanced chemiluminescence lighting (ECL) Western blotting
detection reagent kit (GE Health Care, Piscataway, NJ). The resulting signals were
visualized by exposing the membranes to X-ray films (BioMax MS-1; Eastman Kodak,
Rochester, NY). Digital records were obtained from each blot and the protein bands of
interest were quantified using 1-D analysis software (Eastman Kodak).

The

nitrocellulose membranes were stripped in a commercially available buffer (Millpore,
Billerica, MA) and reprobed for β-tubulin, GAPDH, or Histone H2B as loading controls.

Immunoprecipitation
The cells were washed three times with ice-cold PBS and lysed in ice-cold buffer (150
mM NaCl, 50 mM Tris, pH 7.5, 0.25% SDS, 0.1% Nonidet P-40) containing protease
and phosphatase inhibitor cocktails, and centrifuged at 10,000 rpm for 5 minutes at 4°C.
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The supernatants were collected and the protein concentration of each sample was
determined by protein assay. 500 µg of each lysate was incubated with 10μg of mouse
anti-PI3K-p85α (Abcam) or 2μg of rabbit anti-M-cadherin antibody (Santa Cruz) or
mouse or rabbit IgG (Millipore) overnight at 4°C with rotation. The sample was then
incubated with 20µl of Protein A/G PLUS-agarose beads (Santa Cruz) for 1 hour at
room temperature with rotation. The beads were then collected by centrifugation at
3,000 rpm for 1 minute and washed three times with ice-cold lysis buffer. The bound
proteins were eluted from the agarose beads in 30ul of Laemmli sample buffer (5X) at
95-100°C. The samples were centrifuged at 10,000rpm for 30 seconds and the
supernatants were collected. The proteins were separated by SDS-PAGE and
immunoblotted with antibodies against M-cadherin or PI3K-p85α.

Microscopy, cell morphology and the myoblast fusion index
Phase contrast microscopy. Phase contrast images of C2C12 and primary myoblast
cells were captured using a Nikon Eclipse TS100 phase-contrast microscope (Nikon
Instruments, Melville, NY) equipped with 10x/0.25 and 20x/0.40 phase contrast
objectives and a SPOT RT camera, and analyzed with SPOT RT software (Diagnostic
Instruments Inc., Sterling Heights, MI).

Immunocytochemistry and Fluorescence microscopy. Immunocytochemical assays
were conducted on cells that were grown on coverslips coated with 1% gelatin. The
cells were fixed with fresh 4% paraformaldehyde/PBS, permeabilized with 0.5% Triton
X-100/PBS, and then blocked with 1% BSA/PBS. The coverslips were then incubated at
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4°C overnight

with

antibodies against mouse anti-M-cadherin

(1:20 dilution,

Calbiochem) or mouse anti-myosin heavy chain (MyHC) (1:500 dilution, Developmental
Studies Hybridoma Bank, Iowa City, IA). The primary antibodies were diluted with 1%
BSA/PBS. After washing in PBS, the coverslips were incubated with the Alexa Fluor
546 goat anti-mouse IgG (H+L) (Invitrogen) at 37°C for 1 hour. The nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI) and the cells were mounted in
VECTASHIELD mounting medium (Vector Labs) and imaged with a Zeiss LSM510
confocal on an AxioImager Z1 microscope using the Zeiss AIM software (Carl Zeiss
MicroImaging, Thornwood, NY) and either a Plan-Apochromat 20x/0.8 objective or a
Plan-Apochromat 63x/1.40 Oil objective, as indicated in the figure legends. The scan
speed was 8 seconds and pinhole size was set at 1 Airy unit for each channel. 8-bit
images (1024x1024) were sequentially acquired with equivalent settings (gain, offset,
laser power, etc) for comparable intensity analysis. Tiff images (raw data) were
exported and opened in Photoshop where the levels were adjusted equivalently across
images.

Myoblast fusion index. The myoblast fusion index was calculated as the ratio of the
number of DAPI-positive nuclei located in the MyHC-positive myotubes (i.e., fused
myoblasts) divided by the total number of nuclei in the same field. This fusion index was
used as a read-out of myogenic differentiation. The fusion index was obtained from 10
non-overlapping areas of each coverslip.
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Apoptosis assays
DNA fragmentation. DNA fragmentation was used to assess the level of apoptosis in
muscle cells using an ELISA (Roche) which assessed cytosolic nucleosomes in
attached cells. Measurements for DNA fragmentation were made at an absorbance of
405nm. These methods have been described previously for our laboratory (31; 32). The
data were normalized to the protein concentration of the sample.

Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL). A TUNEL
assay (In Situ Cell Death Detection Kit; Roche) was used to identify the extent of
apoptotic nuclei in adherent myoblasts as reported previously (33). The nuclei of all
cells were counter-stained with DAPI. The number of TUNEL- and DAPI-positive nuclei
was counted in ten images that were chosen randomly from non-overlapping areas of
each group. The data were presented as the apoptosis index, which was determined by
dividing total number of TUNEL-positive nuclei by the total number of DAPI-positive
nuclei.

As treatment with serum starvation and M-cadherin-siRNA resulted in apoptosis and cell
death, some cells detached from the plates. To identify the full extent of apoptosis, and
determine if M-cadherin-RNAi treatment increased the sensitivity of C2C12 myoblasts to
serum starvation-induced apoptosis, we assessed apoptosis by a TUNEL assay in both
adherent and floating cells in each well. The methods from Weyman’s group (4) were
adapted as a third approach to quantify the apoptotic cells in both attached and floating
cells. Briefly, floating cells were collected by centrifugation at 500x g for 5 minutes,
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washed, and fixed in 4% paraformaldehyde for 20 minutes. Thereafter, the cells were
permeabilized in 0.1% Triton X-100 for 2 minutes then incubated with TUNEL reagents
using the In Situ Cell Death Detection Kit (Roche). Apoptotic cells in attached cells were
labeled by TUNEL staining in a similar fashion. The total percent of apoptotic cells for
each well was calculated as: (the total number of TUNEL-positive attached cells + the
total number of TUNEL-positive floating cells) /(total attached cells + total floating cells).

Cardiolipin content and mitochondrial membrane potential measurement
Nonyl acridine orange (NAO, Invitrogen) was used to determine the cardiolipin content
in the inner mitochondrial membrane as an indicator of mitochondrial integrity. C2C12
myoblasts cultured on coverslips and transfected with M-cadherin-targeted or
scrambled siRNA were incubated with NAO (250nM) at 37ºC for 20 minutes.
Fluorescence was visualized with a Nikon Eclipse E800 fluorescence microscope
equipped with a Plan Fluor 100x/1.30 Oil objective and images were captured using a
SPOT RT camera (Diagnostic Instruments, Inc). The exposure time was constant for all
images. The fluorescence intensity was analyzed and quantified using ImageJ
(Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA,
http://imagej.nih.gov/ij/, 1997-2011.). To measure changes in the mitochondrial
membrane potential, mitochondria were isolated from M-cadherin RNAi or control cells
and suspended in sucrose buffer (sucrose 220mM, mannitol 70mM, Tris HCl 10mM,
EDTA 1mM, pH 7.4). The purity of mitochondria was verified by staining the
mitochondria suspension with MitoTracker Deep Red 633 (Molecular Probes, Carlsbad,
CA) at a final concentration of 100nM and analyzed by flow cytometry. This fluorescent
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dye diffuses passively into intact and respiring mitochondria. Debris was excluded by
appropriate gating strategies during flow cytometry analysis. The mitochondrial
membrane potential (Δψmt) was measured by staining the mitochondria with 5,5',6,6'tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine

iodide

(JC-1)

(Molecular

Probes) at a final concentration of 10ug/ml. The staining results of JC-1 orange/green
were analyzed using a FACSCalibur system (BD Bioscience) using Cell Quest Pro. 4.0
Software. 100,000 gated events were collected for each sample.
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ABSTRACT
β-catenin is an essential molecule in both cadherin-mediated cell-cell adhesion and
canonical Wnt signaling. The phosphorylation of β-catenin by GSK-3β at residues
serine31/37/threonine41 of N-terminus regulates its stability and its role in canonical
Wnt signaling. Recent work from our lab found that M-cadherin-mediated signaling
protects myoblasts against apoptosis and promotes myogenic differentiation by
suppressing GSK-3β activation. In this study, we further investigated the possibility that
the N-terminal phosphorylation of β-catenin was regulated by M-cadherin and that this
regulation mediates M-cadherin’s role in promoting myogenic differentiation. We
demonstrated that knockdown of M-cadherin expression by RNA interference (RNAi) in
C2C12 myoblasts significantly enhances the phosphorylation of β-catenin at
ser33/37/thr41 and decreased the protein abundance of ser37/thr41-unphosphorylated
active β-catenin. This effect can be relieved by LiCl treatment. Furthermore, M-cadherin
RNAi promotes LiCl or Wnt-3a-induced TCF/LEF transcription activity but significantly
blunts the myogenic induction by LiCl or Wnt-3a treatment. Knockdown of β-catenin
expression by RNAi in C2C12 myoblasts also significantly decreased myogenic
induction by LiCl treatment. Forced expression of phosphorylation-resistant mutated βcatenin (S33Y-β-catenin) failed to enhance myogenic differentiation but partially
rescued the myogenic and apoptotic phenotype caused by M-cadherin RNAi. These
data show that M-cadherin-mediated signaling attenuates β-catenin phosphorylation at
Ser31/37/Thr41 by GSK-3β and this regulation has a positive effect on myogenic
differentiation induced by canonical Wnt signaling independent of TCF/LEF transcription
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activity. Our findings provide a novel mechanism by which M-cadherin mediates
myogenic differentiation.
INTRODUCTION
β-catenin is a key transcription cofactor within the T cell factor/lymphoid
enhancer factor (TCF/LEF) family of DNA binding proteins in the Wnt signaling pathway.
It is also a central structural adaptor protein linking cadherins to the actin cytoskeleton in
intercellular adherens junctions

(1; 2). Without Wnt signaling, a sequential

phosphorylation of β-catenin by serine/threonine kinases casein kinase Iα (CKIα) at
serine45 and glycogen synthase kinase-3β (GSK-3β) at serine 33/37/threonine 41
results in ubiquitination and degradation of cytoplasmic β-catenin. Activation of Wnt
signaling leads to inactivation of GSK-3β, resulting in accumulation of cytoplasmic βcatenin, which translocates to nucleus and binds to the TCF/LEF transcription factors to
induce target gene expression. As a result, the key factors in β-catenin signaling include
its stabilization and accumulation in the cytoplasm (3-5). β-catenin-mediated canonical
Wnt signaling is crucial to muscle development (6; 7). One of the key mechanisms by
which the β-catenin/Wnt pathway regulates myogenesis, is to induce the expression of
basic helix-loop-helix (bHLH) myogenic regulatory factors (MRFs) such as Myf5 and
MyoD (8; 9). The β-catenin/Wnt pathway is also essential for the myogenic specification
of muscle-derived CD45-positive stem cells after injury (10) and differentiation of
multipotent cells into myogenic cells (11; 12).
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It is well established that a key role of the cadherins is to inhibit βcatenin/canonical Wnt signaling (13-17). In addition to its direct binding and mechanical
sequestering effect (18; 19), reports from several labs show that cadherins may also
modulate β-catenin signaling via an adhesion-independent mechanism (13; 16; 17).
Recent data from Gorttadi and colleagues suggest that E-cadherin directly promotes βcatenin phosphorylation at N-terminus by GSK-3β in S2480 colon carcinoma cell lines
(20), which in turn has an inhibitory effect on Wnt signaling. This provides a potential
mechanism to explain how cadherins regulate β-catenin signaling function at least in
cancer cells, although it is not know if this signaling would be similar in muscle cell lines.
As a member of the classical cadherin family of transmembrane glycoproteins
that mediates calcium-dependent homophilic cell-cell adhesion, M-cadherin has been
shown to be crucial in mediating myoblast alignment and fusion (21; 22), and it is
required for myogenic differentiation (23). We have recently reported that M-cadherinmediated signaling suppresses GSK-3β activation and protects myoblasts against
intrinsic mitochondrial-dysfunction associated apoptosis during myogenic differentiation
(24). However, the role for M-cadherin to regulate β-catenin phosphorylation at Nterminus by GSK-3β in myoblasts and the potential impact that this regulation might
confer to myogenic differentiation is unknown.
In the present study, we investigated the regulatory effect of M-cadherin signaling
on β-catenin N-terminal phosphorylation by GSK-3β and the impact of this regulation on
myogenic differentiation. We show that knockdown of M-cadherin expression promotes
TCF/LEF

transcription

activity

but

decreases

the

availability

of

N-terminal

unphosphorylated signaling-active β-catenin in confluent C2C12 myoblasts. This effect
146

can be reversed by LiCl treatment. Furthermore, both M-cadherin and β-catenin RNAi
abrogated the myogenic and fibrotic induction by LiCl treatment. Forced expression of a
phosphorylation-resistant mutated β-catenin induces a dramatic increase in TCF/LEF
transcription activity but failed to induce myogenic differentiation by itself. However, it
partially rescued the myogenic and apoptotic phenotype caused by M-cadherin RNAi.
Together, these results suggest that M-cadherin signaling suppresses GSK-3βdependent β-catenin N-terminal phosphorylation and promotes myogenic differentiation
in a TCF/LEF-independent manner.
MATERIALS AND METHODS
Cell Culture
C2C12 myoblasts were purchased from American Type Culture Collection
(ATCC) and maintained in Dulbecco Modified Eagle’s Medium (DMEM) (Invitrogen)
supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic and antimycotic
mixture solution (Invitrogen), in a humidified incubator under an atmosphere of 5% CO 2
at 37ºC. Myogenic differentiation was induced by culturing the myoblasts in
differentiation medium composed of DMEM, 2% horse serum and 1% antibiotic and
antimycotic mixture. Recombinant Wnt-3a (working concentration: 50ng/ml) and
recombinant Dickkopf-related protein (DKK-1, working concentration: 200ng/ml) were
purchased from R&D Systems (Minneapolis, MN) for cell treatment. Lithium chloride
(LiCl; working concentration: 20mM) was purchased from Sigma-Aldrich (St. Louis,
MO).
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Inhibition of M-cadherin and β-catenin expression by RNA interference
SMARTpool small interfering RNA (siRNA) targeted to M-cadherin and β-catenin
mRNAs were purchased from Dharmacon/Thermo Scientific (Lafayette, CO). The Mcadherin-targeted siRNA consisted of duplexes targeting the following sequences: 5’CGACACAGCUCUCAUCUAU-3’;

5’-GAAGGACGGCUGGUACAGA-3’;

5’-

GAGCAAACGCUGAACGUCA-3’; 5’-UCGACGAGCACACGGGAGA-3’. The β-catenintargeted siRNA consisted of duplexes targeting the following sequences: 5’GAACGCAGCAGCAGUUUGU-3’;

5’-CAGCUGGCCUGGUUUGAUA-3’;

5’-

GCAAGUAGCUGAUAUUGAC-3’; 5’-GAUCUUAGCUUAUGGCAAU-3’. The myoblasts
were seeded in six-well plates 24 hours before transfection at a density of 1.7 × 10 5 per
well. The transfection of siRNA was performed using either DharmaFECTTM-3 reagent
(when transfected alone) or DharmaFECTTM-Duo reagent (when co-transfected with
plasmids) (Thermo Scientific) according to the manufacturer’s instructions at a final
siRNA duplex concentration of 100nM.
Plasmids and Transfection
The phosphorylation-resistant mutated β-catenin plasmid (pcDNA3-S33Y-βcatenin), β-catenin/Wnt reporter plasmid super 8x TOPFlash, and its mutated control
plasmid, super 8x FOPFlash, were purchased from Addgene (Cambridge, MA). The
plasmids were extracted from bacteria and purified using EndoFree plasmid Maxi Kit
(Qiagen). The plasmids were transfected into the cells using either FuGENE 6 reagent
(Roche) (when transfected alone) or DharmaFECTTM-Duo (Thermo Scientific) (when cotransfected with other plasmids or with siRNA) according to the manufacturer’s
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instructions.
Luciferase reporter assay
Cells were transfected with 2µg of super 8xTOPFlash or FOPFlash reporter
plasmid and allowed to grow for 24-36 hours before further treatment. And at the end of
treatment, the cells were harvested in lysis buffer and 20 µl of each lysates was
monitored for luciferase activity using a Luciferase Reporter Assay System (Promega,
Madison, WI) according to the manufacturer’s instructions. Light units were measured
using Berthold Autolumat Plus tube luminometer (Berthold Technology, Germany). The
TCF/LEF transcription activity was determined as ratios of TOPFlash to FOPFlash
luciferase activity from triplicate experiment.
Cell surface biotinylation assay
A cell surface biotinylation assay was used to quantify the subcellular
(membrane-bound vs. membrane-free) protein abundance of β-catenin at different cell
densities according to published protocols (25) with minor modifications. Briefly, the
cells were washed three times with ice-cold PBS/Ca-Mg (138mM NaCl, 2.7 mM KCl, 1.5
mM KH2PO4, 9.6 mM Na2HPO4, 1mM MaCl2, 0.1 mM CaCl2) and incubated with EZ
link Sulfo-NHS-SS-biotin (1mg/ml, Pierce) in PBS/Ca-Mg for 30 min at 4°C. The
reaction was quenched by two washes with ice-cold 100 mM glycine in PBS/Ca-Mg for
10 min each and three times washes with ice-cold PBS/Ca-Mg. The cells was scraped
from the dishes and lysed in ice-cold RIPA buffer containing protease inhibitor cocktail
(Sigma, 1:100 dilution). The cell lysates were centrifuged at 15,000rpm for 30 min at 4
°C, and aliquots of supernatants were incubated with streptavidin beads (Sigma, 25 µl
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of beads for 500ug/500µl of aliquot) for 1 hour at 4°C with rotation. The beads were
washed three times with ice-cold RIPA buffer. The bound proteins were eluted with 30ul
of Laemmli sample buffer (5X) for 5 min at 95-100°C. The whole cell lysates and the
unbound fractions were processed through the routine sample preparation procedure
for immunoblotting.
Antibodies and immunoblotting
Antibodies

that

were

specific

to

phosphorylated

β-catenin

(serine31/37/threonine41) and cyclin D1 were purchased from Cell Signaling
Technology (Danvers, MA). An antibody to M-cadherin was from Calbiochem (La Jolla,
CA). The antibody to the serine37/threonine41-unphosphorylated active β-catenin was
purchased from Millipore (Billerica, MA). The antibody to total β-catenin was purchased
from Sigma (St. Louis, MO). Antibodies to Axin2, Troponin T, and GAPDH were
obtained from Abcam (Cambridge, MA). All the secondary antibodies for immunoblotting
including goat anti-rabbit or goat anti-mouse IgG conjugated with horseradish
peroxidase (HRP) were obtained from Jackson ImmunoResearch Laboratories (West
Grove, PA). Immunoblotting of cell lysates were conducted according to established
protocols in our lab (24). Briefly, the cell lysates were diluted in 4X NuPAGE LDS
sample buffer (Invitrogen) and boiled at 70°C for 10 min. Equal amount of proteins were
loaded in a 4-12% gradient polyacrylamide gel (Invitrogen) and separated by
electrophoresis. The proteins were transferred to a nitrocellulose membrane (Bio-Rad)
and the membranes were blocked in 5% non-fat milk dissolved in Tris buffered saline
with 0.05% Tween-20 (TBS-T) for 1 hour at room temperature and then probed with
primary antibodies overnight at 4°C. This was followed by incubation with secondary
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antibodies for 1 hour at room temperature. The resulting signals were developed using
Amersham enhanced chemiluminescence lighting (ECL) western blotting detection
reagent kit (GE Health Care) and exposed to films. The protein signals were captured
with a digital camera (Kodak 290) with the KODAK 1D molecular imaging software.
Densitometric analysis of immunoblot intensities was done using KODAK 1D molecular
imaging software.
Cell Imaging
For immunocytochemistry, cells were grown on coverslips coated with 1%
gelatin. Cells ready for immunocytochemical staining were fixed with fresh 4%
paraformaldehyde/PBS, permeabilized with 0.5% Triton X-100/PBS, blocked with 1%
BSA/PBS. Primary antibodies were diluted with 1% BSA/PBS. The antibodies that were
used for cell imaging were: mouse anti-β-catenin antibody (Sigma-Aldrich), rabbit anti-βcatenin antibody (Cell Signaling), mouse anti-serine37/threonine41-unphosphorylated
active β-catenin antibody (Millipore), mouse anti-myosin heavy chain (MyHC) antibody
(Developmental Studies Hybridoma Bank), and rat anti-ER-TR7 antibody (Santa Cruz
Biotechnology). The coverslips were incubated with the appropriate primary antibody at
4°C overnight followed by incubation with the corresponding Alexa Fluor 546 or 488
goat anti-mouse, anti-rabbit, or anti-rat IgG (H+L) (Molecular Probes) secondary
antibody at 37°C for 1 hour. The nuclei were counter-stained with 4,6-diamidino-2phenylindole (DAPI) and the cells were mounted in VECTASHIELD mounting medium
(Vector) and imaged with a Zeiss LSM510 confocal laser scanning microscope using
AIM software (Carl Zeiss MicroImaging). The exposure time was 8 seconds and the
hole size was set as 1.
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Differentiation Index and Fusion Index
After 48-hours in differentiation the cells underwent the immunofluorescent
staining of MyHC and nuclei as described above. The numbers of DAPI-positive nuclei
were counted from 10 non-overlapping areas of each coverslip. The differentiation index
was determined by calculating the ratio of the number of nuclei in MyHC-positive cells
divided by the total number of nuclei in the same field. The fusion index was calculated
as the ratio of the number of nuclei located in myotubes divided by the total number of
nuclei in the same field (24; 26).
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
A TUNEL assay (In Situ Cell Death Detection Kit; Roche) was used to identify the
extent of apoptotic nuclei in adherent myoblasts as reported previously (27; 28). The
nuclei of all cells were counter-stained with DAPI. The number of TUNEL- and DAPIpositive nuclei was counted in ten images that were chosen randomly from nonoverlapping areas of each group. The data were presented as the apoptotic index,
which was determined by dividing total number of TUNEL-positive nuclei by the total
number of DAPI-positive nuclei.
Statistical analyses
The results are given as means ± standard error of mean (SE). Statistical analyses
were performed using the SPSS 13.0 software package. A one-way analysis of variance
(ANOVA) was used to compare differences in all measured variables. P < 0.05 was
considered statistical significant.
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RESULTS
GSK-3β-dependent phosphorylation of β-catenin N-terminus is reduced but
TCF/LEF transcription activity is also down-regulated in C2C12 myoblasts at high
cell density. β-catenin signaling and Wnt activity are regulated by cell confluence in
various types of cells (29; 30). The expression level and pattern of cadherin proteins
vary as the cell density changes. Cadherin is central partner that binds to β-catenin and
in turn, regulates both the subcellular distribution and transcription activity of β-catenin.
Thus to examine the phosphorylation status of β-catenin N-terminus by GSK-3β, mouse
C2C12 mouse myoblasts were seeded at either 2.0 x103/cm2 to obtain a low density (~
20-30% confluent) or 2.1x104/cm2 to reach a high cell density (~100% confluent) within
48 hours. Immunoblot analyses showed that the protein abundance of phosphorylated
β-catenin at residues serine33/37/threonine41 of N-terminus decreased, and those of
“active” serine37/threonine41-unphosphorylated β-catenin and total β-catenin increased
when cells were confluent (Figure 17A). In addition, the protein abundance of two target
proteins for canonical Wnt signaling, Axin2 and cyclin D1, were decreased. We next
examined the subcellular expression pattern of β-catenin at different cell densities. As
shown in left panel of Figure 17B, β-catenin was located in both the nuclei and the cell
cytoplasm, especially in perinuclear regions in cells at a low density. In contrast, βcatenin was detected in the cytoplasm and also more prominently in adjacent cell-cell
contacting regions when the cells were confluent (Figure 17B, right panel). The protein
abundance of membrane-bound versus membrane-free β-catenin was then evaluated
via a cell surface biotinylation assay. As shown in Figure 17C, the ratio of membranebound/membrane-free β-catenin was significantly higher in cells that were grown at a
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high cell density as compared with cells grown at a low density. This finding is
consistent with the data showing that a large portion of β-catenin translocates to cell-cell
adhesive membrane regions in confluent cells (Figure 17B). To examine the difference
in canonical Wnt signal activity in cells at different densities, we plated and grew cells
transfected with either the TOPFlash reporter vector or its mutant control FOPFlash
vector, in either low or high cell densities as described in Materials and Methods. As
shown in Figure 17D, TCF/LEF transcription activity, as determined from the ratio of
luciferase activity in TOPFlash vector-transfected cells normalized by that of FOPFlash
vector-transfected cells, was significantly less in cells that were grown at high density,
as compared with cells that were grown at a low density. However, in spite of the
decreased TCF/LEF transcription activity, myogenic differentiation, as shown by
immunofluorescent staining of myosin heavy chain (MyHC)-positive myotubes, was
clearly enhanced in confluent C2C12 myoblasts as compared with cells that were grown
at a low cell density in differentiation medium for 48 hours (Figure 17E). These data
suggest that phosphorylation of β-catenin N-terminus by GSK-3β is suppressed, and
TCF/LEF transcription is also down-regulated when C2C12 myoblasts become
confluent. The high myogenic outcome of confluent myoblasts is independent of
TCF/LEF transcription activity.
M-cadherin RNAi increases phosphorylation of β-catenin N-terminus but has
positive effect on TCF/LEF transcription activity. We have reported previously that
M-cadherin-mediated signaling suppresses GSK-β activation in confluent myoblasts
(24). To further investigate if M-cadherin-mediated signaling modulates GSK-3βdependent N-terminal phosphorylation of β-catenin, and the impact of this potential
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modulation on TCF/LEF transcription activity in confluent C2C12 myoblasts, we
inhibited M-cadherin expression in confluent C2C12 myoblasts via M-cadherin RNA
interference (RNAi) and subsequently treated the cells with lithium chloride (LiCl), an
established GSK-3β inhibitor and Wnt activator. LiCl inhibits GSK-3β activity by
competing with ATP in the ATP-binding site of the kinase via directly competing with
magnesium and by increasing the inhibitory phosphorylation of Serine 9 residue of
GSK-3β (31). The protein abundance of phospho- and total β-catenin as well as the
unphosphorylated active β-catenin (ABC) were analyzed by immunoblotting. As shown
in Figures 18A and 18B, as the protein abundances of both total β-catenin and
unphosphorylated active β-catenin were significantly increased in LiCl-treated cells, Mcadherin RNAi aborted this effect (Figure 18B, middle and bottom panels). In addition,
M-cadherin RNAi alone significantly increased the phosphorylation of β-catenin Nterminus and LiCl treatment effectively reversed this induction (Figure 18B, top panel).
Furthermore, compared with the scrambled siRNA-transfected group, M-cadherin RNAi
alone did not alter the protein abundance of total β-catenin (Figure 18B, bottom panel)
but decreased the abundance of unphosphorylated active β-catenin. This effect could
be rescued by LiCl treatment (Figure 18B, middle panel). These results suggest that Mcadherin-mediated signaling attenuates phosphorylation of β-catenin at N-terminus and
maintains unphosphorylated active β-catenin in a GSK-3β-dependent manner. We
further investigated the subcellular expression pattern of the unphosphorylated active βcatenin in confluent myoblasts and the effect of M-cadherin RNAi and/or LiCl treatment
on β-catenin via an immunofluorescence assay. Figure 18C shows that without LiCl
treatment, β-catenin was localized primarily to cell-cell contact regions and in the cell’s
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cytoplasm.

Staining

patterns

with

the

anti-ABC

antibody

demonstrated

that

unphosphorylated active β-catenin mainly resides in the cytoplasmic space, but not at
cell-cell

contacting

membrane

regions.

In

addition,

upon

LiCl

treatment,

unphosphorylated active β-catenin but not total β-catenin translocates into nuclei
(Figure 18C, (i) and (ii)). These results suggest that the unphosphorylated active form of
β-catenin is most responsive to LiCl-induced Wnt activation.

However, M-cadherin

RNAi did not alter the expression pattern of ABC and total β-catenin with or without LiCl
treatment (Figure 18C, (iii) and (iv)). We further examined the change in TCF/LEF
transcription activity in response to M-cadherin RNAi. As shown in Figure 18D, in spite
of the decreased protein abundance of ABC, luciferase activity increased indicating that
TCF/LEF transcription activity was increased in cells transfected with M-cadherintargeted siRNA compared with that in control groups. To further verify M-cadherin’s role
in regulating TCF/LEF transcription activity, we co-transfected the cells with M-cadherintargeted siRNA and TOPFlash/FOPFlash-reporter plasmids and then treated the cells
with either LiCl or recombinant Wnt-3a for 12 hours. The luciferase activity was
measured in cells at the end of treatments. As shown in Figure 18E, both LiCl and Wnt3a treatment induced a significant increase in TCF/LEF transcription activity and both
inductions were significantly enhanced in cells transfected with M-cadherin-targeted
siRNA.
M-cadherin RNAi blunts myogenic and fibrotic induction by LiCl treatment. To
further examine the effect of M-cadherin RNAi on the phenotype of myoblasts induced
by LiCl treatment, C2C12 myoblasts transfected with either an M-cadherin-targeted or a
scrambled non-targeted siRNA then treated with LiCl or recombinant Wnt-3a for 12
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hours. This was followed by culture in differentiation medium for 48 hours to induce
myogenic differentiation. The cells were then harvested for immunoblotting analysis. As
shown in Figure 19A, the protein abundance of Troponin T, an established marker for
terminal myogenic differentiation (32; 33), was significantly increased in LiCl or Wnt-3atreated cells compared with vehicle control cells. However, M-cadherin RNAi
significantly attenuated the induction of Troponin T expression in both vehicle and
LiCl/Wnt-3a-treated cells. Further morphological examination via immunofluorescent
staining of MyHC-positive myotubes and nuclei (Figure 19B, top panel) showed that LiCl
treatment induced a significant increase in both myogenic differentiation and fusion as
determined by calculating the differentiation and fusion indexes. The myogenic
differentiation and fusion inductions were both significantly blunted by M-cadherin RNAi
(Figure 19B, middle and bottom panels). Since disregulated increases in Wnt signal
could potentially skew the myogenic progenitor cells into fibrotic lineages (34; 35), we
further examined the expression of a fibroblast marker, ER-TR7 (34; 36) in cells after
the various treatments. As shown in Figure 19C, LiCl treatment induced a substantial
increase in the expression of ER-TR7 in C2C12 myoblasts while M-cadherin RNAi
effectively abrogated this induction. These results suggest that M-cadherin plays a
positive role in mediating myogenic and fibrotic induction by Wnt signal activation
caused by LiCl treatment.
β-catenin RNAi and DKK-1 treatment reverses myogenic and fibrotic induction by
LiCl treatment. To further verify the role of β-catenin/Wnt signaling in mediating
myoblast phenotype induced by LiCl treatment, we treated the cells either with β-catenin
RNAi to inhibit β-catenin expression, or with DKK-1, an established antagonist of
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canonical Wnt signaling, followed by treating the cells with LiCl for 12 hours and culture
in differentiation medium for 48 hours to induce myogenic differentiation. The cell
morphology was examined by immunofluorescent staining of MyHC-positive myotubes
and nuclei. The differentiation and fusion indices were determined and compared
among cells after the appropriate treatments. As shown in Figure 20A, the increased
myotube formation in LiCl-treated cells was largely prevented in β-catenin RNAi treated
cells as both differentiation and fusion of myoblasts were significantly abrogated
compared with LiCl treatment alone group. DKK-1 treatment has the similar antagonistic
effect on LiCl treatment as β-catenin RNAi, although to lesser extent as compared with
the change that was caused by β-catenin RNAi. Furthermore, both β-catenin RNAi and
DKK-1 treatment significantly blocked the expression of the fibrotic marker, ER-TR7,
which was induced by LiCl treatment (Figure 20B). These results provide convincing
evidence that the myogenic and fibrotic induction by LiCl treatment is mediated by βcatenin/Wnt signaling.
Forced expression of phosphorylation-resistant mutated β-catenin partially
rescued the blunting effect of M-cadherin RNAi on the LiCl-induced myogenic
phenotype. To further clarify the role of the phosphorylation status of β-catenin Nterminus in regulating myogenesis, we transfected a phosphorylation-resistant mutated
β-catenin (S33Y-β-catenin) plasmid in C2C12 myoblasts and induced the myogenic
differentiation for 48 hours after the transfection. Forced expression of S33Y-β-catenin
in C2C12 myoblasts induced a significant increase in TCF/LEF transcription activity
(Figure 21A) but failed to increase the protein abundance of Troponin T as determined
by immunoblotting (Figure 21B), indicating that the expression of the phosphorylation158

resistant mutant form of β-catenin alone has no effect on myogenic differentiation of
C2C12 cells. In contrast, LiCl treatment in cells that were co-transfected with both
S33Y-β-catenin plasmid and M-cadherin siRNA, yielded an increased protein
abundance of Troponin T compared with cells that were transfected with M-cadherin
siRNA alone (Figure 21C). This suggests that the phosphorylation-resistant mutant form
of β-catenin attenuates the blunting effect of M-cadherin RNAi on myogenic induction by
LiCl treatment.
Forced expression of phosphorylation-resistant (mutated) β-catenin partially
attenuated apoptosis exacerbated by M-cadherin RNAi during myogenic
differentiation. We have shown previously that M-cadherin RNAi exacerbated
apoptosis in myoblasts during myogenic differentiation (24). We examined this further in
an attempt to determine if the phosphorylation status of β-catenin N-terminus plays a
role in regulating the apoptotic phenotype caused by M-cadherin RNAi. M-cadherintargeted siRNA and S33Y-β-catenin plasmids were either transfected alone or cotransfected into C2C12 myoblasts followed by culturing the cells in differentiation
medium for 48 hours to induce myogenic differentiation. At the end of treatments, the
cells were fixed and stained with an anti-MyHC antibody. In situ apoptotic DNA
fragmentation was examined after staining the cells with terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL), and the nuclei were counter-stained with
4',6-diamidino-2-phenylindole (DAPI) (Figure 22A). The indices for differentiation and
apoptosis were calculated and compared among cells with different treatments. As
shown in Figure 22, forced expression of S33Y-β-catenin alone did not alter the
myogenic or the apoptotic outcomes in C2C12 cells at the end of 48-hour myogenic
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differentiation. However, co-transfection of S33Y-β-catenin with M-cadherin siRNA
partially rescued the impaired myogenic differentiation (Figure 22B) and attenuated the
exacerbated apoptosis caused by M-cadherin RNAi alone (Figure 22C). These results
suggest that alteration of the phosphorylation status of β-catenin N-terminus may
mediate the apoptotic phenotype induced by disruption of M-cadherin-mediated
signaling.
DISCUSSION

This is the first study to show that by modulating N-terminal phosphorylation
status of β-catenin, M-cadherin-mediated signaling regulates β-catenin/Wnt signaling
and promotes myogenic differentiation in a TCF/LEF transcription-independent manner.
In this study we report that M-cadherin RNAi increased GSK-3β-dependent
phosphorylation of β-catenin N-terminus, decreased the protein abundance of
unphosphorylated signaling-active β-catenin, and blunted myogenic induction caused by
LiCl or Wnt-3a treatment. Forced expression of phosphorylation-resistant mutated βcatenin alone failed to enhance myogenic differentiation but partially rescued the
myogenic and apoptotic phenotype caused by M-cadherin RNAi. Interestingly, these
effects are independent of changes in TCF/LEF transcription activity.
The paired phosphorylation of β-catenin at NH2 terminus by CK1a and GSK-3β
plays a crucial role in regulating β-catenin stability and signaling. β-catenin that is
phosphorylated at residues 33 and 37 is recognized by the β-TrCP E3-ligase complex,
resulting in its ubiquitylation and rapid degradation by the 26S proteasome (37). This is
an important mechanism to turn off Wnt signaling. An accumulated body of evidence
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suggests that N-terminus phosphorylation may directly modulate β-catenin-mediated
signaling. It has been demonstrated that Wnt signaling is specifically mediated by Nterminal unphosphorylated β-catenin (38) and these N-terminal unphosphorylated βcatenin

more readily accumulates in nuclei (39; 40). Thus the GSK-3β-dependent

phosphorylation of β-catenin at N-Terminus may not only induce degradation as
suggested by the classical view, but may also directly impact β-catenin transcriptional
activity. Thus it is possible that the phosphorylation status alone may regulate β-cateninmediated Wnt signaling without affecting its stability. Indeed, we demonstrated in this
study that the unphosphorylated active β-catenin (ABC) mainly accumulates in
cytoplasm regions and not at cell-cell contacts in confluent myoblasts. In response to
LiCl treatment, ABC but not total β-catenin translocates into nuclei, indicating that ABC
is more responsive to Wnt stimulation.
It is clear that cadherin proteins modulate β-catenin transcription activity in a
variety of cells. For example, binding of β-catenin to the cadherin cytoplasmic tail has
been shown to inhibit β-catenin degradation and efficiently block its transactivation in
Chinese hamster ovary and SW480 colon carcinoma cell lines (41). In addition,
transient expression of exogenous E-cadherin in both epithelial and fibroblastoid cells
has been reported to arrest cell growth via inhibiting β-catenin transcriptional activity
(42). Furthermore, knockdown of E-cadherin in DLD-1 colorectal cancer cells, which
have constitutive activation of Wnt signaling and exhibit E-cadherin-mediated cell
adhesion, resulted in translocation of β-catenin to the nucleus and an enhancement of
β-catenin/TCF-dependent reporter activity (43). In L929 fibroblasts, which are deficient
in Wnt signaling and E-cadherin-based cell contacts, ectopic expression of E-cadherin
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induced the stabilization of β-catenin at the cell junctions and caused marked alterations
in cellular morphology and phenotype but no significant change in the transcriptional
program of these cells in the absence of Wnt signaling. Furthermore, expression of wildtype E-cadherin significantly inhibits the growth of SW480 colon carcinoma cells via
inhibiting β-catenin/TCF gene promoter activity in an adhesion-independent manner
(44), whereas, that restoration of E-cadherin expression in these cells enhances the
phosphorylation status of β-catenin N-terminus and suppresses the Wnt signaling in the
cells. Similar to our observation in myoblasts, several other labs have demonstrated
that β-catenin translocates to cell-cell junctions and this increase occurs during the
initiation of myogenic differentiation (45). In addition, expression of a short 23-aminoacid segment of the cadherin cytoplasmic tail in mammalian cells does not affect cellcell junctions but effectively inhibits β-catenin-mediated signaling (46). As RhoA activity
is required for β-catenin recruitment to intercellular adhesions sites (47), it is important
to note that N-cadherin-dependent cell-cell contact activates muscle-specific promoters
and RhoA in C2C12 cells. To this point, no study has evaluated how M-cadherin
regulates the phosphorylation status of the N-terminus of β-catenin, nor examined the
impact of this regulation on myogenic differentiation. Our results in the current study
show that inhibition of M-cadherin expression by RNAi increases phosphorylation of the
N-terminus of β-catenin, decreases the protein abundance of unphosphorylated active
β-catenin, and impairs the myogenic induction that is caused by either LiCl or Wnt-3a
treatment. Together these results indicate that M-cadherin-mediated signaling
attenuates GSK-3β-dependent phosphorylation of the β-catenin N-terminus and helps in
maintaining a cytosolic pool of unphosphorylated signaling-active β-catenin, which plays
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a critical role in myogenic induction by Wnt stimulation. Interestingly, the positive role of
M-cadherin on N-terminal unphosphorylated active β-catenin and Wnt signaling in
myoblasts that is demonstrated in our study is different from the findings from another
study that reported a negative regulatory role of restored E-cadherin expression on ABC
and Wnt signals in colon carcinoma cells. A possible explanation for this discrepancy is
that the regulatory role of cadherin on β-catenin phosphorylation is cadherin-type and
cell-context dependent. The exact mechanism by which M-cadherin-mediated signaling
attenuates phosphorylation of β-catenin at the N-terminus remains to be elucidated. We
have shown previously that M-cadherin suppresses GSK-3β activity in confluent
myoblasts (24). In the present study we further demonstrate that while a large portion of
β-catenin is detected at cell-cell contact membrane regions, in confluent myoblasts,
unphosphorylated active β-catenin is located mainly in cytoplasmic regions of the cell
rather than at cell-cell contacts. This observation suggests that the phosphorylation
regulatory effect by M-cadherin is not simply a result of direct binding to
unphosphorylated active β-catenin, but rather in an adhesion-independent manner.
Furthermore, M-cadherin RNAi increases phosphorylation of the β-catenin N-terminus
and decreases the protein abundance of unphosphorylated active β-catenin. Inhibition
of GSK-3β by LiCl treatment significantly reverses this effect. These results indicate that
M-cadherin-mediated signaling attenuates phosphorylation of β-catenin N-terminus
through suppressing GSK-3β activity.
Our results show that the myogenic potential is much higher in confluent
myoblasts as compared with cells with a low density, but the TCF/LEF transcription
activities change in the opposite way. In addition, although knockdown of M-cadherin by
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RNAi promotes TCF/LEF transcription activity at both steady state and LiCl/Wnt-3atreatment conditions, it blunts the myogenic differentiation under those conditions. While
forced expression of the phosphorylation-resistant mutant form of β-catenin induced a
substantial increase in TCF/LEF transcription activity, it failed to induce a similar
increase in myogenic differentiation by itself. These results show that there is a
disconnection between the level of TCF/LEF transcription activity and the outcome of
myogenic differentiation in myoblasts, suggesting that β-catenin may mediate Wnt
signaling and promote myogenic differentiation independent of its role in enhancing
TCF/LEF transcription activity.

These findings are however, consistent with reports

from treated LIM2537 cells, a poorly-differentiated colon cancer cell line, which when
they are treated with the potent differentiating agent sodium butyrate, reduces GSK-3β
activity by 34%, stabilizes the level of cytoplasmic β-catenin but there is no increase in
β-catenin/TCF target genes c-myc and cyclin D1 (48). Previous work has shown that βcatenin interacts with I-mfa (an inhibitor of the MyoD family of muscle regulatory
transcription factors (MRFs)) and this interaction relieved the transcription activity
suppression and cytosolic sequestration of MRFs by I-mfa (11). This observation
suggests that a β-catenin-dependent but TCF/LEF-independent regulatory mechanism
impacts MRFs during myogenesis. Similarly, Kim and colleagues (49) reported that
TCF/LEF activity is dispensable for β-catenin’s role in promoting myogenic
differentiation. Instead, β-catenin directly interacts with MyoD and enhances its
transcriptional activity that is necessary for myogenic differentiation (49). Interestingly,
the results in our present study show that TCF/LEF transcription activity is increased in
response to M-cadherin RNAi in spite of the decreased availability of unphosphorylated
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active β-catenin, suggesting that TCF/LEF transcription activity might be more
responsive to the relief of mechanical sequestration of β-catenin by M-cadherin caused
by M-cadherin knockdown and less dependent on the change in phosphorylation status
of β-catenin N-terminus, at least in C2C12 myoblasts.
Along with Notch signaling, the β-catenin/Wnt signaling pathway plays a critical
role in regulating myogenic differentiation (34; 35; 50; 51). Although skeletal muscle
progenitor cells are committed to be myogenic lineages and do not spontaneously
adopt non-myogenic fates (52), it has been reported that hyper-activation of Wnt
signaling may induce the premature termination of the expansion of myogenic
progenitor cells and push the myogenic progenitor cells towards fibroblast lineages,
resulting in the increased fibrosis in muscle tissues (34; 35). Indeed, we demonstrated
that treating C2C12 myoblasts with LiCl before culturing them in differentiation medium
gave rise to the expression of a fibroblast marker, ER-TR7. The fibrotic induction
caused by Wnt stimulation via LiCl treatment could be effectively reversed by inhibition
of the expression of either M-cadherin or β-catenin.
We have shown previously that knockdown of M-cadherin expression via RNAi in
both C2C12 myoblasts and primary muscle progenitor cells exacerbates apoptosis
during myogenic differentiation. This increase in apoptotic signaling was partially
rescued by inhibition of GSK-3β activity (24). In the current study, we further
demonstrated that M-cadherin RNAi increased phosphorylation of β-catenin N-terminus
and forced expression of the phosphorylation-resistant mutated β-catenin partially
rescued the apoptosis induced by M-cadherin RNAi. These observations suggest that
alteration in the phosphorylation levels of β-catenin N-terminus and β-catenin/Wnt
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signaling might be at least partially responsible for mediating M-cadherin RNAi-induced
apoptosis during myogenic differentiation. Our findings here are consistent with reports
from other groups that show that β-catenin/Wnt signaling plays an important role in
promoting survival of either skeletal or cardiac myoblasts under various conditions (5356).
In conclusion, the data in the present study show that M-cadherin-mediated
signaling attenuates phosphorylation of β-catenin N-terminus and helps in maintaining a
cytosolic pool of N-terminal unphosphorylated signaling-active β-catenin which plays a
key role in mediating canonical Wnt signaling to promote myogenic differentiation in a
TCF/LEF-independent manner.
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Figure 17. Phosphorylation and subcellular distribution of β-catenin, TCF/LEF
transcription activity, and myogenic differentiation in C2C12 myoblasts at
different cell densities.
A. C2C12 myoblasts were plated at either a low density (2.0 x103/cm2), or a high
density (2.1x104/cm2). 48 hours after plating, the cells were harvested in lysis buffer for
immunoblotting analysis of the protein abundance of phosphorylated (Ser33/37/Thr41),
Ser37/Thr41-unphosphorylated active β-catenin (ABC) and total β-catenin. Protein
abundance of Axin2 and cyclin D1 were also examined. GAPDH was used as a loading
control.
B. Representative confocal images of β-catenin staining in C2C12 myoblasts at low or
high cell density as described in Figure 1A. The objective magnification is 63x. The
length of scale bar is 10μm.
C. Top panel: Representative immunoblots of protein abundance of β-catenin in
subcellular fractions (membrane-bound versus membrane-free) of cells at low or high
density as determined by cell surface biotinylation assay. Bottom panel: determination
and comparison of ratios of β-catenin in membrane-bound fraction to that in membranefree fraction in cells of different densities. Each data point (mean ± SEM) is the mean of
three independent experiments. *, P< 0.05 vs. the low density group.
D. C2C12 myoblasts transfected with either a TOPFlash or a FOPFlash plasmid. The
cells were then plated at low or high cell density. 48 hours later the cells were harvested
for luciferase activity measurement to determine the TCF/LEF transcription activity.
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Each data point (mean ± SEM) is the mean of three independent experiments. *, P<
0.05 vs. the low density group.
E. Representative images of MyHC-positive myotubes in cells at low or high density
after culture in differentiation medium for 48 hours. MyHC: red; DAPI: blue. Images
were acquired at 20x. The scale bar = 100 μm.
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Figure 18.

Effect of M-cadherin RNAi and LiCl treatment on β-catenin

phosphorylation and subcellular distribution, and TCF/LEF transcription activity.
A. Representative immunoblots of protein abundance of phospho-, unphosphorylated
active β-catenin (ABC) and total β-catenin in C2C12 myoblasts in either M-cadherin
siRNA-transfected (M-) or non-targeted scrambled siRNA-transfected (SiCON) cells
treated with LiCl (20mM) or PBS as a vehicle control for 12 hours. Non-treated cells with
same culture condition were used as a normal control (NC). GAPDH was probed as a
loading control.
B. Top panel: Densitometric analyses of immunoblots of phospho-β-catenin normalized
to GAPDH. *, P< 0.05 vs. the SiCON plus Vehicle group. †, P< 0.05 vs. M- plus vehicle
group. Middle panel: Densitometric analyses of immunoblots of ABC normalized to
GAPDH. *, P< 0.05 vs. the SiCON plus Vehicle group. †, P< 0.05 vs. M- plus vehicle
group. Bottom panel: Densitometric analyses of immunoblots of total β-catenin
normalized to GAPDH. *, P< 0.05 vs. the SiCON plus Vehicle group. †, P< 0.05 vs.
SiCON plus LiCl group.
C. Representative confocal images of immunofluorescent staining of ABC and total βcatenin in M-cadherin-RNAi-treated (M-) or non-targeted scrambled siRNA-transfected
(SiCON) cells that were treated with PBS or LiCl for 12 hours. ABC: green; β-catenin:
red; DAPI: blue. Images were acquired at 63x. The length of scale bar is 10μm.
D. TCF/LEF transcription activity in M-cadherin-RNAi (M-), non-targeted scrambled
siRNA-transfected (SiCON) or normal control (NC) C2C12 myoblasts as determined by
TOPFLASH/FOPFLASH luciferase activity. *, P< 0.05 vs. the control groups.
185

E. TCF/LEF transcription activity in M-cadherin-RNAi (M-), non-targeted scrambled
siRNA-transfected (SiCON) or normal control (NC) C2C12 myoblasts that were treated
with LiCl (20mM) or recombinant Wnt-3a (50ng/ml) for 12 hours as determined by
TOPFLASH/FOPFLASH luciferase activity. *, P< 0.05 vs. the normal control (NC)
group. **, P< 0.01 vs. NC group. †, P< 0.05 vs. the SiCON plus LiCl treatment group. #,
P< 0.05 vs. the SiCON plus Wnt-3a treatment group.
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Figure 19
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Figure 19
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Figure 19
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Figure 19. Effect of M-cadherin RNAi and LiCl treatment on myogenic and fibrotic
outcome in C2C12 myoblasts.
A, Top panel: Representative immunoblots of protein abundance of Troponin T, an
established marker for terminal myogenic differentiation, in M-cadherin-RNAi-treated
(M-) or non-targeted scrambled siRNA-transfected (SiCON) cells that were treated with
LiCl (20mM), recombinant Wnt-3a (50ng/ml), or DMSO as a vehicle control for 12 hours,
followed by culture in differentiation medium for 48 hours. GAPDH was probed as a
loading control. Bottom panel: Densitometric analysis of immunoblots of Troponin T
normalized to GAPDH. *, P< 0.05 vs. the SiCON plus Vehicle group. #, P< 0.05 vs. Mplus Vehicle group. †, P< 0.05 vs. the correspondent vehicle/LiCl/Wnt-3a-treatment in
SiCON groups.
B, Top panel: Representative confocal images of MyHC-positive C2C12 myotubes after
treatments with PBS, or LiCl, or LiCl plus M-cadherin RNAi (LiCl plus M-), followed by
culture in differentiation medium for 48 hours. MyHC: red; DAPI: blue. Images were
acquired at 20x. The length of scale bar is 100μm. Middle panel: The differentiation
index was determined and compared among cells with above treatments. Bottom panel:
The fusion index was determined and compared among cells with above treatments. *,
P< 0.05 vs. the PBS-treated group. †, P< 0.05 vs. the LiCl-treated group.
C. Top panel: Representative confocal images of immunofluorescent staining of a
fibrotic marker, ER-TR7, in C2C12 myoblasts with treatments as described in figure 3B.
ER-TR7: green; DAPI: blue. Images were acquired at 20x. The length of scale bar is
100μm. Bottom panel: Quantitative analysis of mean fluorescence intensity of ER-TR7
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staining in cells with above treatments. *, P< 0.05 vs. the PBS-treated group. †, P< 0.05
vs. the LiCl-treated group.

191

Figure 20
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Figure 20
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Figure 20. The effect of β-catenin RNAi and DKK-1 treatment on myogenic and
fibrotic induction by LiCl treatment.
A. Top panel: Representative confocal images of MyHC-positive C2C12 myotubes after
treatments of β-catenin RNAi, or SiCON, or DKK-1(200ng/ml), followed by LiCl
treatment for 12 hours and culture in differentiation medium for 48 hours. MyHC: red;
DAPI: blue. Images were acquired at 20x. The length of scale bar is 100 μm. Middle
panel: Differentiation index among cells with above treatments. Bottom panel: Fusion
index among cells with above treatments. *, P< 0.05 vs. the LiCl plus SiCON group.
B. Top panel: Representative confocal images of immunofluorescent staining of ERTR7 in C2C12 myoblasts with treatments as described in Figure 5A. ER-TR7: green;
DAPI: blue. Images were acquired at 20x. The length of scale bar is 100 μm. Bottom
panel: Quantitative analysis of mean fluorescence intensity of ER-TR7 staining in cells
with above treatments. *, P< 0.05 vs. the LiCl plus SiCON group.
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Figure 21
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Figure 21

196

Figure 21. The effect of forced expression of phosphorylation-resistant mutated
S33Y-β-catenin on TCF/LEF transcription activity and myogenic differentiation.
A. TCF/LEF transcription activity in S33Y-β-catenin plasmid-transfected (S33Y-B-CAT),
empty vector-transfected (EV) or untreated normal control (NC) C2C12 myoblasts was
determined by measuring TOPFLASH/FOPFLASH luciferase activity. *, P< 0.01 vs. the
control groups.
B. Representative immunoblots of protein abundance of Troponin T in S33Y-β-catenintransfected (S33Y-B-CAT), empty vector-transfected (EV) or normal control (NC)
C2C12 myoblasts after culture in differentiation medium for 48 hours. GAPDH was
probed as a loading control.
C. Top panel: Representative immunoblots of protein abundance of Troponin T in the
following four groups of cells: normal control (NC), LiCl-treated (LiCl), LiCl plus Mcadherin siRNA-transfected (LiCl/M-), LiCl plus M-cadherin-siRNA and S33Y-β-catenin
plasmid-co-transfected (LiCl/M-/S33Y-B-CAT), and differentiation for 48 hours. Bottom
panel: Densitometric analyses of immunoblots of Troponin T normalized to GAPDH. *,
P< 0.05 vs. NC group. #, P< 0.05 vs. LiCl group. †, P< 0.05 vs. LiCl plus M- group.
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Figure 22
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Figure 22
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Figure 22.

Effect of forced expression of phosphorylation-resistant mutated

S33Y-β-catenin on apoptosis and myogenic differentiation in response to Mcadherin RNAi.
C2C12 cells were grown on coverslips, co-transfected with M-cadherin-targeted (M-) or
non-targeted scrambled siRNA (SiCON) with S33Y-β-catenin plasmid (S33Y-B-CAT) or
an empty vector (EV) for 36 hours. The cells were then cultured in differentiation
medium for 48 hours.
A. Representative confocal images of immunofluorescent staining MyHC-positive
C2C12 myotubes with treatments as described above. In situ DNA fragmentation was
labeled by TUNEL staining. MyHC: red; TUNEL: green; DAPI: blue. Images were
acquired at 20x. The scale bar = 100 μm.
B. The differentiation index of C2C12 cells that were exposed to the above treatments.
*, P< 0.05 vs. SiCON/EV group. †, P< 0.05 vs. M-/EV group.
C. The fusion index of C2C12 cells exposed to the treatments described above. *, P<
0.05 vs. SiCON/EV group. †, P< 0.05 vs. M-/EV group.
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CHAPTER 4:
General discussion, conclusion and future studies
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4.1. General discussion and conclusion. Skeletal muscle comprises about 40% of
human body weight, and plays a key role in various functions including locomotion,
maintenance of posture, respiration (diaphragm and intercostals contractions),
communication (by verbal and facial muscles), thermogenesis and regulation of
metabolism (1). Mammalian skeletal muscle is comprised of multinucleated myofibers
that are formed by fusion of mononucleated myoblasts during embryonic development.
As a contractile tissue that undergoes repeated contraction, damage occurs frequently
to muscles due to the wear and tear during repeated contractions, especially in
response to lengthening contractions. However, adult skeletal muscle is able to
regenerate and repair the injury. Thus muscle regeneration is critical for maintenance of
adult muscle mass, quality and performance.
A population of muscle precursor cells known as satellite cells, function as stem
cells in adult skeletal muscle and are critical for muscle regeneration. In addition,
growth and regeneration of muscle as a postnatal tissue requires additional myonuclei
from outside of myofibers since myonuclei are post-mitotic (2). Satellite cells serve as
the primary source for the addition of new myonuclei to adult muscle tissue (3). The
decrease in both number and function of satellite cells is one of the major cellular
mechanisms for various muscular wasting disorders including sarcopenia. It is one of
the long term research focuses in the Alway lab to get a better understanding on the
mechanism of sarcopenia. Previous findings in the Alway lab have identified an
association between increased apoptotic signaling and the occurrence and progression
of sarcopenia (4-9). The overall purpose of this study is to extend the investigation of
the association between apoptosis regulation and muscle regeneration to a cellular and
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molecular level, and to get further insights in the molecular mechanism of apoptotic
regulation of myoblasts and the effect of this regulation on myogenic differentiation and
adult muscle regeneration. Understanding the regulatory role of M-cadherin in apoptosis
and Wnt signaling was one of the primary goals of this research. Although an in vivo Mcadherin knockout model suggests that M-cadherin is dispensable for myogenesis and
muscle regeneration (10), the extensive potential compensations that occur in a
genetically engineered animal model may not fully represent the consequences caused
by a gene down-regulation that occurs in an adult context. For example, MyoD and
Myf5, are both myogenic regulatory factors (MRFs) that are important in regulating the
behavior of satellite cells. MyoD determines the myogenic capability of myoblasts (11;
12), whereas Myf5 plays a major role in regulating their self-renewal and homeostasis
(13; 14). Interestingly, although either MRF can compensate for the loss of the other
during embryogenesis, they fail to compensate for each other in an adult context. The
same mechanism might also apply to the interpretation of the redundancy among
different types of cadherins. Although the loss of M-cadherin appears to be well
compensated during embryogenesis, the same compensation by other types of
cadherins may not occur as the gene expression of M-cadherin is down-regulated in
adult muscle. This speculation is supported by findings from in vitro studies from
different groups which reported that M-cadherin promotes myoblast fusion (15; 16) and
is indispensable for myogenic differentiation (17). In addition, in spite of the important
role of cadherin in regulating apoptosis and canonical Wnt signaling in other types of
cells and tissues, there is no report that addresses how M-cadherin modulates
apoptosis and Wnt signaling in myoblasts. The study presented in Chapter 2 is the first
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report to show that M-cadherin protects myoblasts against apoptosis during myogenic
differentiation. We demonstrated that M-cadherin-mediated cell-cell adhesion activates
PI3K/Akt and enhances the inhibitory phosphorylation of GSK-3β at serine 9,
suppresses the occurrence of MOMP and protects the cells against mitochondriaassociated intrinsic apoptosis during myogenic differentiation (Figure 4.1). Furthermore,
as the data presented in Chapter 3, this is the first study to show that by modulating the
GSK-3β-dependent phosphorylation of β-catenin at the N-terminus, M-cadherinmediated signaling helps in maintaining a signaling-active N-terminal unphosphorylated
β-catenin, which is critical in mediating the myogenesis-promoting effect of canonical
Wnt signaling in a TCF/LEF-independent manner (Figure 4.1).
Substantial evidence shows that apoptosis is a coincident event that occurs
during cell differentiation in many types of cells including myoblasts (18). Indeed, a
substantial portion of myoblasts die by apoptosis whereas other ones survive by
differentiation and fusion into myotubes (18-22). The underlying mechanism and
signaling pathways controlling the life and death decisions of differentiating cells are
largely unknown and therefore the object of intensive investigation. It is known that
proper mitochondria function is critical in myogenic differentiation (23-25). Furthermore,
there is a difference in mitochondrial membrane potential between myoblasts
undergoing apoptosis and myoblasts that successfully differentiate (26). The current
study demonstrates that M-cadherin-mediated signaling plays an important role in
maintaining the mitochondrial integrity of differentiating myoblasts and regulates
apoptosis during myogenic differentiation. We show that inhibition of M-cadherin
expression by RNAi sensitized C2C12 myoblasts to mitochondria-associated intrinsic
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apoptosis that was triggered by cell confluence and serum starvation. This observation
suggests that M-cadherin-mediated signaling regulates mitochondrial integrity and
function in myoblasts.
Cadherin is an established inhibitor for β-catenin/canonical Wnt signaling in
various types of cell contexts. It inhibits β-catenin activity by three ways: mechanical
sequestration, direct inhibition of its transcription activity, and promoting its N-terminus
phosphorylation by GSK-3β (in colon cancer cells) (27). Interestingly, different from the
finding in a colon cancer cell line, we found in myoblasts that M-cadherin-mediated
signaling attenuates the phosphorylation of β-catenin N-terminus and promotes βcatenin activity in a TCF/LEF-independent manner. This observation adds a novel
mechanism to the regulation of β-catenin by cadherins. In addition, the data in chapter 3
demonstrates that hyperactivation of Wnt signaling caused by LiCl treatment induces
both myogenic differentiation and a conversion from a myogenic lineage to a fibroblastic
one, which is consistent with a study from the Rando group (28). Moreover, inhibition of
M-cadherin expression by RNAi reversed this effect, suggesting that M-cadherinmediated signaling is required by both myogenic differentiation and fibroblastic
conversion induced by the activation of β-catenin/canonical Wnt signaling. This brings
up a question, that is, will overexpression of M-cadherin in skeletal muscle lead to
muscle fibrosis, which remains to be elucidated in a future study. On the other hand,
although it is assumed that muscle fibrosis is a pathological procedure which has
detrimental effects on the muscle quality and function, the mutual effects between
myogenic myoblasts and fibroblasts during the process of myogenesis have drawn
increasing attention and generated interesting observations. Emerging evidence from
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different groups have shown that in addition to its classical role in adult muscle structure
and function, connective tissue is an important component of the niche where muscle
progenitors reside and is a critical regulator of myogenesis (29; 30). The mutual
interactions between fibroblasts and satellite cells promote an efficient, effective
myogenic differentiation (29-31).
In conclusion, the data presented in this dissertation demonstrates that Mcadherin plays a critical role in regulating the fate of myoblasts by promoting their
survival

against

mitochondria-associated

intrinsic

apoptosis

during

myogenic

differentiation via PI3K/Akt/GSK-3β pathway. Furthermore, by modulating the
phosphorylation

status

of

β-catenin

N-terminus,

M-cadherin

regulates

β-

catenin/canonical Wnt signaling in a TCF/LEF-independent manner which is crucial for
myogenic differentiation (Figure 23). These findings identify a novel mechanism
underling the regulation of myoblast’s behavior and fate during muscle regeneration.
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Figure 23. Schematic summary of the regulatory role of M-cadherin in
myoblast’s apoptosis/survival and myogenic differentiation.
“ ” in the figure suggests that certain phosphorylation substrates of GSK-3β
that are involved In the occurrence of MOMP, such as Bax (32), are not
included in this figure since they are beyond the scope of this dissertation.

4.2. Significance of the findings and practical implications for treatment of
human diseases.
Decrease in both number and functionality of satellite cells is among the major
contributing factors to the onset and progress of sarcopenia (33). In aged muscle, the
number of M-cadherin-positive satellite cells is also lower (34).

Prior to the data

presented in this dissertation, it was not known whether there is a correlation between a
decreased M-cadherin expression and the decline in both number and function of
satellite cells in aged muscle. The data in the present study demonstrates that Mcadherin promotes myoblast’s differentiation and reduces apoptotic signaling by
suppressing GSK-3β activity and enhancing β-catenin signaling activity. In contrast to
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cadherin signaling outcomes in many other cell types, this observation supports a novel
hypothesis that the disruption of M-cadherin-mediated cell-cell and cell-niche adhesions
could be a possible mechanism that contributes to the decreased number and function
of satellite cells in aged muscle, which gives rise to the onset and progression of
sarcopenia and other muscle wasting disorders. The implications of the findings in this
study are that gene overexpression of M-cadherin in aged muscle might be used as a
potential therapeutic intervention that could rescue or at least partially attenuate the
decrease in both number and functionality of satellite cells in aged muscle since
enhanced M-cadherin-mediated signaling would provide signals that promote the
survival and myogenic capability of satellite cells in aged muscle.

Cadherins are an important component of the stem cell niche and have been
reported to play a critical role in mediating the recruitment and adhesion of stem cells to
their niche (35-38). A niche to stem cells is an anatomic residence for the cells to stay
in. But more importantly, it is also a functional dimension that enables the cells to
reproduce, self-renew, and survive in a stressful environment (39). Data from the
current project could be eventually used to support therapies for muscular dystrophy.
For example, in current experimental approaches or clinical trials that muscle progenitor
cells or stem cells from other lineages are transplanted into a host with muscular
dystrophic disorders such as Duchene Muscular Dystrophy, the low survival and
engraftment rate of donor progenitor cells after transplantation has been a major barrier
to the full success of this stem-cell-based therapies (40; 41). In addition, the in vitro
handling and expansion of the donor cells before transplantation also decrease the in
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vivo myogenic capability of the cells dramatically after they are injected into the host
muscles (42; 43). Thus, either in vitro culture or injection of the cells into the host sites
as foreign grafts may cause the loss of the original signals from the niche that promote
survival and myogenic capability of the cells because the regular biological niche
becomes temporarily or permanently unavailable to the transplanted cells. This could be
an important contributing factor to the low survival and engraftment rate, as well as the
poor myogenic performance, of the cells after transplantation. The survival- and
myogenic promoting effect of M-cadherin demonstrated in this study provides a
potential novel therapeutic approach. We propose that by increasing the gene
expression of M-cadherin in the donor cells and the niches in host muscles, the survival
and engraftment rate of cells after transplantation in muscle tissue will be improved, and
the myogenic capability of the transplanted cells will also be increased. Thus the
therapeutic outcome of the stem cell-based strategies in treating muscular dystrophies
will be greatly improved. More importantly, this M-cadherin-overexpression hypothesis
demonstrates the crucial role of a healthy niche in maintaining the survival, selfexpansion, and myogenic capability of muscle stem cells, not only for their survival and
engraftment in vivo, but also during the process of expansion in vitro. The cells are
isolated from the donor body and cultured in vitro to expand into enough number before
they are ready to be injected into the host muscles. However, instead of culturing in a
traditional cell culture system, an artificially modified and engineered culture system
which is enriched with M-cadherin and other key adhesion molecules that are found in a
stem cell niche should be used for cell culture. It might be able to help the isolated stem
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cells maintain their myogenic capability before transplantation. The potential to alter the
stem cell niche has attracted much recent attention from stem cell biologists (44; 45).

In the present study, we demonstrate that M-cadherin-mediated signaling
suppresses GSK-3β activation, promotes β-catenin/canonical Wnt signaling, and plays
a positive role in maintaining the mitochondrial integrity in myoblasts during myogenic
differentiation. Since both GSK-3β and mitochondria play a crucial role in glucose
metabolism, the regulation of M-cadherin on both could have profound effects on the
glucose metabolism and insulin sensitivity of muscle tissues. Thus, it is possible that
increased expression of M-cadherin may be a potential therapy to reduce the effects of
metabolic syndrome or diabetes. Our speculation here is in concert with studies from
various groups: Ectopic expression of M-cadherin was found in the liver of KK/Ta
mouse, which is an established animal model for type 2 diabetes (46); E-cadherin may
regulate insulin secretion by modulating the intercellular communication between β-cells
within pancreatic islets (47; 48); In addition, activation of Wnt signaling promotes
mitochondrial biogenesis and regulates insulin sensitivity in C2C12 myoblasts (49).
Although therapeutic applications of the results of this study are likely several years
away, the data we present in this study cast M-cadherin in a new role as a potential
metabolism regulator, and therefore a potential therapy for addressing diabetes and/or
the metabolic syndrome.

4.3. Future studies. Although we demonstrated that M-cadherin-mediated
signaling plays a critical role in regulating myoblast fate and biological behavior in the
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research that we completed in Chapter 2 and 3, there are still many questions that
remain to be elucidated.
Firstly, we showed that M-cadherin promotes β-catenin/canonical Wnt signalingmediated myogenic differentiation in a TCF/LEF-independent manner. Based on the
studies from other groups, MRFs such as MyoD, as well as a MRF-regulatory protein Imfa, could be the candidates that mediate the TCF/LEF-independent myogenic
induction effect by M-cadherin/β-catenin signaling. It has been shown that β-catenin
interacts directly with MyoD and this interaction promotes MyoD transcription activity
(50) and the binding of β-catenin to I-mfa relieves its inhibition to MRFs (51). To further
identify the downstream target for M-cadherin/β-catenin signaling, primary muscle
progenitor cells could be isolated from hind limb muscles of wild-type mice. The change
in gene expression level of MRFs and I-mfa could then be examined in cells treated with
either M-cadherin RNAi or recombinant M-cadherin-Fc, to find out if the gene
expression of any MRF and I-mfa are responsive to the manipulation of M-cadherinmediated signaling. Additionally, the co-immunoprecipitation of β-catenin with MRFs
and I-mfa could be performed to examine the change in interactions between β-catenin
and MRFs and I-mfa in response to the manipulation of M-cadherin–mediated signaling.
Furthermore, the gene expression of MRFs and I-mfa could be manipulated by
overexpression or knockdown techniques to see which one could rescue the myogenic
phenotype caused by M-cadherin RNAi. By doing so, the role of MRFs and I-mfa in
mediating M-cadherin/β-catenin’s myogenesis-inducing effect will be clarified (Figure
24).
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Secondly, one of the ultimate approaches is to establish a muscle-specific Mcadherin overexpression transgenic mouse model. The M-cadherin cDNA could be
cloned into a transgenic vector plasmid driven by a muscle-specific muscle creatine
kinase (MCK) promoter (52). The chimeric transgene should then be purified and used
for generation of muscle-specific transgenic mice. Upon successful generation, the
transgenic mice and the control ones with same genetic background should be used for
following two sets of experiments. First set: cardiotoxin could be injected into the hind
limb muscles of either the young or old, M-cadherin-overexpressing transgenic or wildtype (WT) mice, to cause muscle injury. One to two weeks after cardiotoxin injection,
the injured muscles could then be dissected and markers for muscle regeneration and
fibrosis could be analyzed and compared among young and old, M-cadherinoverexpressing and WT mice (Figure 25). In the second set of experiments, satellite
cells could be isolated from the hind limb muscles of either M-cadherin-overexpressing
or WT 2-week-old mice for in vitro culture. Myogenic differentiation could then be
induced and markers for apoptosis, myogenesis, and fibrosis will be measured and
compared between M-cadherin-overexpressing transgenic and WT cells (Figure 25).
Through these proposed experiments, the findings from in vitro cell culture work that Mcadherin protects myoblasts against apoptosis and promotes myogenic differentiation
will be verified at a gross muscle level in an animal system. These proposed studies
could allow future students to clarify the role of M-cadherin in regulating adult muscle
regeneration.
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Figure 24. Outline of the strategies to clarify the role of MRFs
and I-mfa in mediating M-cadherin/β-catenin’s promoting effect
on myogenic differentiation.
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Figure 25. Outline of the strategies to examine the capability of muscle
regeneration and fibrosis potential of M-cadherin (M-cad)-overexpression
transgenic mouse in response to muscle injury, and the in vitro
myogenic capability of satellite cells isolated from the transgenic mice.
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